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Abstract 
The inflammatory autoimmune diseases rheumatoid arthritis, psoriatic arthritis 
and psoriasis have seen a break through in therapy by targeting cytokines in the 
last decade. Interleukin 17A, a potential new target, is considered as a crucial 
player in rheumatoid arthritis, and has been suggested to be produced by CD4+ T 
cells (Th17 cells). I explored the cellular sources of IL 17A in human established 
RA synovium. Surprisingly, only a small proportion of IL 17 positive cells were T 
cells without expression of a Th17 marker CCR6. Unexpectedly, the majority of 
IL 17A expression colocalized within mast cells. These data do not contradict a 
crucial role for IL 17A in RA pathogenesis, however, suggest that in addition to 
Th17 cells, cells of the innate immune system, particularly mast cells, may be an 
important component of the effector IL 17A response. 
Psoriasis is a common chronic autoimmune disease of the skin characterized by 
hyperplasia of epidermal keratinocytes with associated inflammation. IL 33 is a 
new member of the IL 1 superfamily that signals through the ST2 receptor and 
was originally defined as an inducer of T helper 2 (Th2) cytokines. Recently 
broader immune potential has been discovered for IL 33 particularly via mast 
cell activation. With its expression at body barrier surfaces it is assumed to act 
as an alarmin. In this thesis I demonstrate that IL 33 expression is up regulated 
in the epidermis of psoriatic lesions, compared to healthy skin, thus indicating 
that IL 33 may be a mediator regulating crosstalk between keratinocytes and 
infiltrating immune cells in psoriatic plaques. In a phorbol ester induced model 
of skin inflammation ST2
 /  mice exhibited reduced cutaneous inflammatory 
responses compared to WT mice. Furthermore, consecutive injections of IL 33 
into the ears of mice induced a psoriasis like inflammatory lesion. This was 
partially mast cell dependent and cellular analysis demonstrated recruitment of 
neutrophils to the ear. This concludes that IL 33, via activation of mast cells and 
recruitment of neutrophils, may play a role in psoriasis plaque inflammation. 
In the last part of the thesis I tested if nanoparticles can be utilized to image 
cytokine driven inflammation. Bio linkages with protein nanoparticles have been 
established and in vivo detection of nanoparticles performed. This final 
interdisciplinary outlook demonstrates a still to be established/finalized method 
with great potential. 3 
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Autoimmunity is a process in which the immune system reacts against self 
structures. Thus potent immune cells are implicated in a vicious circle leading to 
damage to self organs. This loss in tolerance against self is a chronic process and 
often only ends after complete destruction of the target. The clinical challenge 
in autoimmunity is to break through this vicious circle, and either reset, re 
programme and/or retrain the immune system. Thus damage can be prevented 
and long term impairment avoided.  
This challenge to stop tissue destruction, deformity and disability but also to 
prevent comorbidities (reduction of cardiovascular risk) is exemplified best in 
rheumatoid arthritis and psoriatic arthritis.  Currently these autoimmune 
diseases are chronic diseases with no cure. Over the last decades more and more 
insights have been gained in regard to the delicate network of the immune 
system and its interactions. Obviously the future goal would be to detect prone 
individuals before failure of the immune system occurs. More insights into 
epigenetics but also metabolomics in autoimmune diseases will lead to future 
improvements in therapeutics. 
Here, I shall give an overview of these autoimmune diseases, describing the 
success of cytokine targeted therapies and will allude to new targets that are 
evolving. Finally, I will provide an outlook as to how future technologies such as 
Nanometrology can help in detecting inflammation earlier with more sensitive 
approaches. 17 
 
1.1 Autoimmune inflammation – rheumatoid arthritis, 
psoriatic arthritis and psoriasis  
I shall first introduce the autoimmune diseases (rheumatoid arthritis, psoriatic 
arthritis and psoriasis) studied in this thesis.  Thereafter I shall introduce the 
relevant cytokine biology focussing mainly on the cytokine TNF α as a core 
example for a successful targeted therapy in autoimmune arthritis. 
1.1.1 The spectrum of clinical presentation of inflammatory 
arthropathies and psoriasis 
Inflammatory arthropathies have multiple causes; but they all share one defining 
feature: namely arthritis predicated on the presence of inflammatory infiltration 
of the synovial membrane and attendant structural damage. On clinical 
presentation patients usually offer the following hallmarks of inflammation: 
calor (heat), rubor (redness), dolor (pain) and tumor (swelling) as described by 
Celsus Aulus (Aurelius) Cornelius (30 B.C. to 45 A.D.). Functio laese (loss of 
function) is another hallmark of arthropathies which has been later added by 
Claudius Galenus (AD 129—ca. 200). However, arthritis does not always present 
itself as described above. I will therefore summarize the clinical commonalities 
and differences across the autoimmune arthropathies “rheumatoid arthritis” 
(RA) and “psoriatic arthritis” (PsA). Further, the connection to autoimmune skin 
diseases will be discussed. 
Clinical diagnosis - Rheumatoid arthritis vs. psoriatic arthritis 
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease of unknown 
aetiology primarily affecting joints. Arthritis occurs symmetrically, and if 
untreated will lead to tissue destruction, deformity and disability. Prevalence of 
RA is about 1% in Caucasians with women being affected 2 3 times more often 
than men. Clinical features of RA are used as tools for diagnosis and serve within 
every classification criteria set thus far prepared. These include arthritis of 
small and large joints, rheumatoid nodules, morning stiffness, erosions on X Rays 
and changes in serum markers such as rheumatoid factor. Table 1.1 summarizes 
the hallmarks used in the American College of Rheumatology (ACR) criteria for 18 
 
diagnosis of RA (1987) (1). These criteria have been updated in 2010 for 
identifying patients with a relatively short duration of symptoms who may 
benefit from early institution of DMARD therapy (2)(Table 1.2).  
Although RA develops its pathology within the synovium many nonarticular 
organs become involved, particularly in patients with severe joint disease. 
Despite the differences between the normal form and function of joints and, for 
example, the bone marrow, it is becoming more clear that the same cytokines 
that drive synovial pathology are also responsible for generating pathology in 
extraarticular tissues (such as skin, eye, lungs, heart, kidney, blood vessels, 
salivary glands, the central and peripheral nervous systems, and bone marrow). 
As examples extraarticular manifestation can involve the lung with pulmonary 
nodules (similar to rheumatoid nodules), but also the heart with pericarditis and 
myocarditis. Hematological disorders such as the Felty’s syndrome manifest with 
seropositive rheumatoid arthritis and neutropenia, often with an associated 
anemia or thrombocytopenia, an enlarged spleen, and (rarely), leg ulcers. 
Recently, antibodies against citrullinated peptides (ACPA) were linked to RA 
and, indeed, ACPA have been identified in up to 90% of patients with RA and 
although they are not specific to RA they correlate with disease severity (3 5). 
Thus a serologic classification of RA is attractive.  However this is not entirely 
clinically useful due to considerable variation in presentation even within this 
group. Therefore, RA patients could be classified per their responsiveness to 
therapies (responders vs. non responders). For example, not all patients with RA 
respond to the standard dosage of anti  Tumour Necrosis Factor α (TNF α) 
agents. In large randomized trials, 28–58% of all patients with RA showed little 
response to these drugs (6, 7), but might respond to different targeted drugs like 
IL 6 inhibitors (tocilizumab) or drugs which block T cell activation (abatacept). 
These responses may reflect either true molecular differences in pathology or 
perhaps distinct phases of disease at which therapeutic resistance may be 
distinct. Genetic or epigenetic distinctions are also possible. With this broad 
clinical spectrum, distinguishing other arthropathies such as PsA from RA can be 
challenging. 
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  Criteria  Comments 
1.  morning stiffness  stiffness of joints lasting at least 1 hr 
2.  arthritis of 3 or more joint areas  Soft tissue joint swelling observed by a physician 
3.  arthritis of hand joints  arthritis in at least one area of hand/wrist 
4.  symmetric arthritis  simultaneous involvement of the same joint 
areas on both sides of the body  
5.  rheumatoid nodules  subcutaneous non tender nodules in 
juxtaarticular regions 
6.  serum rheumatoid factor  presence of autoantibodies which bind Fc 
portion of IgG 
7.  radiographic changes  RA typical changes with erosions or 
decalcifications in hand or wrist 
Table 1.1 criteria 1987 Criteria for the classification of rheumatoid arthritis (1) 
4 of the 7 criteria have to be fulfilled to be classified as suffering from RA. Points 1 through 
4 have to be present for at least 6 weeks. Point 2 and 3 exclude distal interphalangeal joints 
(DIP) (in depth details are published by the ACR, www.rheumatology.org) 
  Classification criteria for RA  
  Patients should have at least 1 joint with definite clinical synovitis (swelling) and with the 
synovitis not better explained by another disease 
A  Joint involvement  points 
  1 large joint  0 
  2 10 large joints  1 
  1 3 small joints  2 
  4 10 small joints  3 
  ≥ 10 joints (at least 1 small joint)  5 
B  Serology   
  Negative RF and negative ACPA  0 
  Low positive RF or low positive ACPA  2 
  High positive RF or high positive ACPA  3 
C  Acute-phase reactants   
  Normal CRP and normal ESR  0 
  Abnormal CRP or abnormal ESR  1 
D  Duration of symptoms   
  < 6 weeks  0 
  ≥ 6 weeks  1 
Table 1.2 The 2010 American College of Rheumatology/European League Against 
Rheumatism classification criteria for rheumatoid arthritis (adapted from (2)). 
Score-based algorithm: add score of categories A–D; a score of ≥6/10 is needed for 
classification of a patient as having definite RA. 20 
 
 
  Inflammatory articular disease (joint, spine or enthesal) with >3 points from the 
following five categories: 
1.  Definite psoriasis (2 points)or a personal history of psoriasis (1 point) or a family history 
of psoriasis (1 point)* 
2.  Typical psoriatic nail dystrophy including onycholysis, pitting and hyperkeratosis on 
current physical examination or documented by a rheumatologist or dermatologist (1 
point). 
3.  A negative test result for the presence of rheumatoid factor (1 point). 
4.  Either current dactylitis, defined as swelling of an entire digit, or a history of dactylitis 
recorded by a rheumatologist (1 point). 
5.  Radiographic evidence of juxta articular new bone formation, appearing as ill defined 
ossification near joint margins (but excluding osteophyte formation) on plain radiographs 
of the hand or foot (1 point). 
Table 1.3 CASPAR criteria for classification of PsA (adapted from (8)). 
*A personal history of psoriasis is only included in the score if definite psoriasis is not 
documented. A family history of psoriasis is only included in the score if neither definite 
psoriasis nor a personal history of psoriasis is present 
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Approximately 6–20% of patients with psoriasis develop a chronic inflammatory 
arthritis or enthesitis. PsA affects approximately 0.1 – 0.5% of the general 
population presenting as peripheral arthritis, axial disease or a combination of 
both (9). In comparison to RA, peripheral PsA evolves with a distinct joint 
pattern, typically asymmetric and potentially involving the distal 
interphalangeal joints. Enthesitis is a characteristic feature of the 
spondyloarthropathies with inflammation at tendon or ligament attachment 
sites. The MRI appearance of enthesitis is quite distinctive characterised by 
marked inflammation in adjacent bone marrow and soft tissues (10). In PsA, MRI 
has detected enthesitis in clinically uninvolved joints suggesting that enthesitis 
may be the primary lesion in PsA. This is supported by the observation that 
enthesial inflammation may extend as far as the synovial cavity. Dactylitis with 
enthesitis involving the complete digit is a characteristic feature which is quite 
distinct from symptoms or signs seen in RA. The peak incidence occurs between 
the age of 20 and 40 years with a slight male bias except in the subset of 
patients with symmetrical polyarthritis in which patients are predominantly 
female (11). For the diagnosis of PsA, several groups have proposed different 
criteria. The criteria defined by Moll and Wright in 1973 were used over the last 
three decades (12). Five groups were defined in regard to the clinical pattern in 
asymmetric oligoarticular, symmetric RA like, distal interphalangeal (DIP) 
predominant, arthritis mutilans and spondylitis. However, considerable overlap 
between groups is now recognized. The definition of “true PsA” is still a topic of 
ongoing discussion and different groups proposed criteria including Bennett (13), 
Gladman et al (14), Vasey and Espinoza (15), the European Spondylarthropathy 
Study Group (ESSG) (16), McGonagle et al (17), and Fournie et al (18). The 
recently developed CASPAR criteria have a specificity of 98.7% and sensitivity of 
91.4% for diagnosing PsA (Table 1.3) (8). The authors of this study suggest that 
due to the high specificity of their criteria they should be used for future clinical 
studies. CASPAR criteria involve arthropathy with the list of criteria shown in 
Table 1.3. 22 
 
Clinical presentation of psoriasis 
Psoriasis is an autoimmune, chronic inflammatory disease targeting primarily the 
skin and nails affecting 2 3% of the Caucasian population (19). It is characterized 
by hyperplasia of the epidermis (acanthosis), infiltration of leukocytes into the 
dermis and epidermis as well as dilatation and proliferation of blood vessels. As 
a common skin disease it appears in different clinical variants. Most frequently, 
psoriasis vulgaris presents with scaly red plaques on predilectionary areas, e.g. 
on scalp, the back, dorsal skin of the elbows and ventral skin of knees. However, 
there is considerable variation concerning the phenotype of psoriasis and the 
disease can present itself as various other clinical variants such as guttate 
psoriasis, palmar pustular psoriasis. This considerable clinical heterogeneity in 
the cutaneous presentation of the disorder indicates a variety of pathogenetic 
processes underlying the different variants which may not be common or 
consistent across each clinical presentation. The skin lesions may be minimal or 
concealed especially in areas such as the scalp, ears, buttocks or umbilicus. 
While severe psoriasis has been associated with a higher prevalence of PsA (20), 
there is no direct temporal relationship between the severity of skin and joint 
inflammation. 
In psoriasis patients, lesions can be triggered by a large number of factors 
including physical trauma to the skin (Koebners phenomenon), rapid withdrawal 
of immunosuppressive medication, drugs like hydroxychloroquine, beta blockers, 
and infections (19). Interestingly, the trigger for PsA is not clear although a 
“deep Koebner phenomenon” has been suggested (21). Hereby it is speculated 
that mechanical damage in the joint (therefore “deep” compared to skin) leads 
to initiation of a repair mechanism and might trigger autoimmune processes 
resulting in arthritis. Mechanical damage is speculated to involve accidents, 
physical stress such as “moving house” or sport injuries. 
Cardiovascular risk and RA, PsA and psoriasis 
Patients with rheumatoid arthritis have an increased risk of premature death 
due to cardiovascular disease (CVD). A meta analysis of observational studies 
performed by Lacaille and colleagues identified 111,758 patients with 22,927 
cardiovascular events. An approximate 50% increased risk of CVD associated 23 
 
death in patients with RA was reported, however, data varied due to different 
study characteristics (22). Further, it has been demonstrated that PsA patients 
are at increased risk of cardiovascular morbidities compared with the general 
population (23). CVD risk in psoriasis is currently debated with studies supporting 
psoriasis as a risk factor and a recent study by Wakkee et al. disproving this (24). 
In this study, the majority of patients had mild psoriasis with only a small 
minority suffering from severe psoriasis (<5%), therefore, selecting for a mild 
disease group. In a cohort study using the General Practice Research Database, 
Gelfand and colleagues demonstrated that patients with severe psoriasis have an 
increased risk of cardiovascular mortality (25). Interestingly, Gladman et al. 
demonstrated severe psoriasis as a risk factor for CVD in patients with PsA (23). 
Thus, severity of psoriasis and therefore the level of inflammation might play a 
role in the development of CVD. Additional studies are needed to determine the 
mechanism of this phenomenon and what impact therapy will have on the 
increased risk of developing cardiovascular complications. 
Bone destruction – RA vs PsA 
Interestingly, pathological signs of disease can be detected at different sites in 
the joint in RA and PsA patients and therefore may allow the differentiation of 
RA from PsA at the radiographic level. As with every characteristic, a certain 
amount of overlap will occur. However, the site and type of bone destruction 
can add important information and thus help in defining the disease clinically. 
Two processes contribute to tissue destruction observed in RA joints. First: 
active invasion of the synovium into the cartilage and second, the activation of 
osteoclasts and chondrocytes and maintenance of an osteoclast favourable 
environment. Erosions occur at juxta articular sites, generally at the point of 
attachment of the synovium. In end stage disease, large cystic erosions of bone 
may be seen. Without treatment to prevent progression, this joint destruction 
will lead to dysfunction of the joints. In hands longstanding disease can advance 
to mechanical dysfunction due to involvement of the wrists with volar deviation 
of the extensor carpi ulnaris as well as ulnar deviation of metacarpophalangeal 
(MCP) joints. Why MCP and wrist joints are favourably involved has not been 
elucidated yet, however, neuronal axis involvement is speculated to play a role. 
Thus, cases of RA are reported in patients previously paralysed by poliomyelitis 24 
 
or stroke, in whom the paralysed limbs have been spared totally or partially by 
the arthritic process, as well as patients with halted progression of arthritis in 
the fingers due to sensory denervation following traumatic nerve dissection (26, 
27) indicate that the nervous system might be involved in the inflammatory 
process seen in RA. 
In comparison to RA, PsA has different features of bone involvement (Table 1.4). 
As described above some subgroups of PsA, which are comparable to RA in 
regard to their clinical presentation, might demonstrate a similar bone 
destruction pattern. However, the major difference to RA is that PsA 
demonstrates a mixture between bone erosion and bone repair mechanisms, 
ranging from periostitis to osteolysis and new bone formation. Furthermore, PsA 
often shows inflammation of the enthesis (tendon bone insertion site). Enthesitis 
can help distinguish PsA from rheumatoid arthritis and osteoarthritis. This is 
evident in plain radiographs and MRI as periostitis, new bone formation and 
erosions (28). Axial disease with sacroileitis can be found in some PsA patients 
and can be used to differentiate it from RA but it also demonstrates the mixed 
clinical pattern overlapping with ankylosing spondylitis. 
  arthritis 
pattern 
axial 
involvement 
RF/ACPA  joint 
erosions 
enthesitis  skin 
involvement 
RA  symmetric     +  +       
PsA  asymmetric  +/      +  +  + 
AS     +        +/     
OA  asymmetric                
Table 1.4 Comparison of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and 
osteoarthritis. 
Demonstrated are the main features of the diseases; it has to be mentioned that in all 
groups overlap occurs, e.g. symmetric variant of PsA, peripheral involvement of AS, etc. -: 
not present; +: present; +/-: present in subgroups. 25 
 
Treatment of RA and PsA 
In recent years, new therapies have evolved for the treatment of RA and PsA. 
The current treatment paradigm for RA emphasizes the sequential use of 
therapeutic agents driven by measurement of disease activity. Thus early start 
of disease modifying anti rheumatic drugs (DMARDs, such as methotrexate and 
sulfasalazine) is considered optimal with possible step up and combinations, 
although this needs to be individualized for each patient. Also the choice of 
DMARD is an individualised decision between the patient and physician. 
Glucocorticoids added at low to moderately high doses to DMARD therapy can 
provide benefit as initial short term treatment; however, glucocorticoids should 
be tapered as rapidly as clinically feasible (29). 
Compared to traditional DMARDs, TNF α blockade represents the first successful 
treatment using cytokine targeted therapy. Infliximab, a chimeric monoclonal 
anti TNF α antibody, adalimumab, a humanized monoclonal anti TNF α antibody 
and etanercept, a soluble TNF α receptor construct are now widely used in 
clinical treatment. By preventing the cytokine to bind to the specific receptor, 
downstream activation signals are blocked and further stimulation of the 
inflammatory processes is thus reduced (Figure 1.1). Interrupting the TNF α 
cascade was found to have beneficial effects on disease outcome, joint damage 
and function, but also on tissue inflammation and cell infiltration measured at 
the histological level in biopsy studies. Anti TNF α therapy was the successful 
proof of concept for cytokine based therapies and hence initiated the 
development of further cytokine/immune targeted drugs.  
The type of cells and mediators involved in the inflammatory processes are very 
similar in PsA and RA joints. Thus, it is not surprising that most of the therapies 
which have been successful in treating RA such as DMARDs like MTX or TNF α 
blockers show similar efficacy in patients with PsA (30, 31). Due to the success 
seen in PsA patients, TNF α blockers were tested in patients with psoriasis and 
found to be effective. These drugs are now approved for patients with severe 
psoriasis. Recent developments of immunotherapies use specific diseases for 
primary proof of concept (e.g. IL 12/23 blockade with ustekinumab in psoriasis 
(32)); however, overlap of treatment between diseases should be expected as 
autoimmune phenomena have common characteristics between diseases. 26 
 
Ustekinumab has also been tested in an phase II trial in PsA with promising 
results (33). Whether this target also works in RA, in which the role of IL 23 
biology in pathogenesis is still not finally solved, needs to be determined. 
Further results of translational trials are awaited. 
Thus more potential therapeutic targets, some of which have been proven to 
play a role in disease as well as others which still need to be analysed further, 
will be discussed below (see 1.1.5). 27 
 
 
 
 
 
Figure 1.1 Cytokine receptor interaction 
Demonstrated is a cytokine (red) binding to possible ligands. Blockade with neutralising 
antibodies prevents further downstream signals (adapted from Hueber, McInnes, 
Rheumatoid Arthritis, Mosby (34)) 
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1.1.2 Pathogenesis of rheumatoid arthritis 
Despite decades of research focused on RA, the pathogenesis of this disease is 
still not fully understood. So far, no single factor has been discovered that can 
account for the initiation of the disease; rather a conglomeration of events and 
factors are thought to drive RA. Recently, many new elements have been 
identified which link genetic associations (e.g. HLA DRB1 and HLA DR4 alleles 
within the MHC class II, polymorphisms in the genes encoding STAT4, TNF α 
receptor and PTPN22) and environmental influences (e.g. smoking) to the 
susceptibility of RA (35, 36) (Table 1.5).  
At the microscopic level, inflammation in RA seems to be maintained by various 
cell types. Figure 1.2 “Picture of synovial joint inflammation” shows a schematic 
illustration of the roles these different cell types play during inflammation in a 
synovial joint. Hereby recruitment of cells, cell cell interaction via cell contact 
or cytokines and matrix changes such as cartilage destruction, tissue invasion by 
fibroblasts and bone erosion due to osteoclasts are linked with each other; all 
playing their parts in the initiation and maintenance of inflammation. Named are 
only some representative cells, however, nearly all immune cells have been at 
some point implicated to play a role in this complex process of autoimmune 
inflammation.  
The trigger to synovitis is still unclear. In an arthritic joint swelling of the 
synovium relates to infiltration by immune cells mediated via 
chemokine/cytokine triggered recruitment of innate and adaptive cells. 
Hypervascularisation and activation of the endothelium supports migration from 
vessels into the tissue. Often tertiary lymphoid follicles are detected containing 
B and T cells and other antigen presenting cells such as macrophages and 
dendritic cells. This over compact gathering of cells provides an environment 
allowing the maintenance of the autoreactive immune response. Further, 
immune cells stimulate stromal cells such as fibroblast like synoviocytes, which 
can produce proinflammatory cytokines and/or proliferate resulting in 
metalloproteinase/aggrecanase dependent cartilage degeneration and bone 
invasion. This cytokine milieu induces maturation of and thereafter, activates 
osteoclasts leading to an imbalance in the osteoclast/osteoblast axis thus 
increasing bone erosion. Therapeutic targeting of the adaptive axis or 
innate/stromal axis are both successful, demonstrating the close 29 
 
interplay/dependence in this cellular network. A more detailed view of 
cytokines as mediators of inflammation will be discussed 1.1.5.  
 
Rheumatoid arthritis                
   
Psoriatic arthritis 
HLA  associated genes 
non-HLA susceptibility genes 
PTPN22 
(intracellular phosphatase) 
  IL 23 receptor 
TRAF1 C5 region  
(TNF receptor associated 
factor 1, C5 (complement)) 
  IL 12p40 
STAT4  
(Signal transducer and 
activator of transcription 4), 
key molecule for interleukin 
(IL) 12 signalling 
  IL 23p19 
6q23 region  
(e.g. TNF α induced protein 
3) 
  5q31 locus (IL 4, IL 5, IL 13) 
PADI4  
(Peptidylarginine deiminases 
citrullinating enzyme 4) 
   
4q27 region  
(incl. IL 2/IL 21 locus) 
  4q27 region 
(incl. IL 2/IL 21 locus) 
CTLA 4 gene 
(cytotoxic lymphocyte 
antigen 4) 
   
     
KIF5A gene     
IL2RB gene     
CD40     
Table 1.5 Susceptibility genes in arthritis.  
Shown are genes/gene regions associated with rheumatoid arthritis and/or psoriatic 
arthritis. Overview from (35, 37, 38)  
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Figure 1.2 Picture of synovial joint inflammation 
This schematic represents a joint which shows different aspects of inflammation. Top left 
corner shows synovial fluid cells (e.g. a macrophage/monocytes or mast cell (MC/MФ), in 
this sketch, MC/MФ could be replaced with mostly every immune cell) producing cytokines 
and chemokines. Closeby fibroblast- like synoviocytes (FLS) can respond to that signal and 
produce inflammatory proteins in turn. Bottom left corner shows a vessel with cells 
migrating from the lumen into the tissue. Top right shows a multinucleated cell (osteoclast, 
OC) invading the bone and leading to erosion. Bottom right is a RA synovial tissue derived 
from arthroplasty (stained with H&E) with infiltrates of inflammatory cells (dark purple 
spots). 31 
 
1.1.3 Pathogenesis of psoriatic arthritis and psoriasis 
Similar to RA, immune cells and the mediators they secrete influence disease 
initiation and progression of PsA. However, different genetic and environmental 
factors play a role in psoriasis and PsA. In psoriasis, micro trauma can lead to 
skin lesions as is reflected by the skin pattern involved in psoriasis. Thus, areas 
exposed to micro trauma or pressure such as the knees and elbows often show 
plaque psoriasis which is frequently most resistant to treatment. Interestingly, in 
PsA, DIP joints are often involved with adjacent psoriasis involvement of the nail 
bed. Inflammation of the nail/skin could be proposed as a possible initiator of 
inflammation in the closest joint causing an arthritic event or involvement of the 
enthesis in the process. With the extensor tendon enthesis linking the joint to 
the nail bed it has been suggested that involvement of the nail bed may be due 
to an extension of the inflammation from the joint (39). However, it is unclear if 
the inflammatory process is initiated in the nail bed and spreads to the DIP joint 
or vice versa.  
Recent genetic analyses have discovered risk factors shared by psoriasis and 
psoriatic arthritis. Most of the genes/loci associated with PsA were initially 
described for psoriasis and then tested for their association with PsA. Genes and 
single nucleotide polymorphisms (SNPs) involved are located in the HLA class I 
region but also cytokine related genes such as the IL 23 pathway (IL 23 receptor, 
IL 12p40, IL 23p19), Th17 cell cytokines such as IL 21, the 5q31 locus (encoding 
for genes like IL 4, IL 5 and IL 13) and others (37). 
The major difference in the pathogenesis of psoriasis as a skin disease compared 
to the inflammation found in the arthritic joint is the involvement of 
keratinocytes rather than fibroblast like synoviocytes. Inflammation of the skin 
as seen in psoriasis causes keratinocytes to be stimulated by cytokines and/or 
inflammatory cells leading to their proliferation and production of 
proinflammatory cytokines (40). For many years there has been debate as to 
whether the onset of psoriasis is due to a fundamental disorder of tissue cells or 
their regulation in the skin or of the immune system a priori. Recently, Wagner 
and colleagues generated a murine model exhibiting psoriasis like skin disease 
with concomitant arthritis by deleting epidermal Jun proteins (JunB and c Jun) 32 
 
normally expressed by keratinocytes. These deletions lead to upregulation of the 
chemotactic proteins S100A8 and S100A9 associated with recruitment of 
inflammatory cells. Furthermore, JunB/c Jun deficient mice crossed on a 
background deficient for Rag2 still developed psoriasis like disease suggesting a 
minor role of T and B cells in the aetiology of this model (41). 
In contrast to this observation, recent data regarding the Th1 Th17–IL 23 axis 
promote the idea of an adaptive influence in psoriasis. This will be further 
discussed below (see subsection 1.2). 
1.1.4 Pathogenic immune cells in inflammatory arthritis 
Chronic inflammatory arthritis mainly targets the synovial membrane, cartilage 
and bone. Hereby a variety of cells play a pathogenic role of disease initiation 
and maintenance of chronic inflammation. The crucial triggers for the onset of 
articular inflammation and subsequent damage are unknown; however, mouse 
data, human genetic associations and targeted therapies consolidate the 
evidence for pathogenic immune cells in inflammatory arthritis. 
T cells are implicated in the pathogenesis of rheumatoid arthritis by genetic 
associations with HLA DR alleles within the MHC class II and lymphoid specific 
PTPN22. Especially disease association with HLA DR4 alleles which contain the 
shared epitope has been well described (42). Further T cells are detected in high 
numbers in inflamed synovial tissue. The notion that T cells take part in the 
pathogenesis of arthritis has been confirmed by various extensively studied 
mouse models of arthritis. These models such as the collagen induced arthritis 
model are clearly T cell dependent. However, the question arises if these data 
are transferable to human disease pathogenesis. T cell modulating therapies 
such as cyclosporine, CD3 or CD4 specific antibodies have been disappointing 
(43). Interestingly, the recently approved drug abatacept, targeting the 
immunological synapsis by binding CD80/CD86 has shown some benefit (44). 
Abatacept, a CTLA 4 immunoglobulin Fc fusion protein interferes with the T cell 
– antigen presenting cell contact and thus prevents T cell activation. This leads 
to the question which T cell subsets are pathogenic. On the on hand increased 
numbers of regulatory T cells in synovial fluid/tissue have been described, 
where it is not clear if these are dysfunctional or try to keep the inflammation 33 
 
at bay. On the other hand, information about subsets such as Th17 cells emerged 
in the literature, with some evidence for its role in arthritis (further information 
see in chapter 1.2). 
Also B cells as part from the adaptive immune system play a pathogenic role in 
chronic inflammatory arthritis due to their regulation in synovitis but also their 
role in preclinical disease. B cell depleting therapeutics, for example rituximab, 
an anti CD20 antibody which is expressed on B cells, but not on plasma cells, was 
initially developed for B cell lymphoma therapy. Interestingly, trials in RA 
demonstrated significant clinical benefit (45). From a standpoint that RA is a T 
cell driven disease, these data demonstrated that a network of pathogenic 
immune cells are responsible for the chronicity of RA. More intriguingly, in 
autoimmunity, production of autoantibodies specific for IgG (rheumatoid factors) 
or recently discovered antibodies against cyclic citrullinated peptides, can occur 
before the onset of clinical symptoms (46). Furthermore, hits in genome wide 
analysis of RA patients showed a susceptibility gene called peptidylarginine 
deiminases citrullinating enzyme 4 (PADI4) in Asian and US cohorts, however, 
could not be verified in UK cohort analysis (47, 48). This gene encodes an 
enzyme responsible for the conversion of arginine to citrulline residues and 
therefore providing a potential substrate for autoantibody production. B cells 
not only contribute to inflammation by autoantibody synthesis but also by the 
production of cytokines and chemokines (e.g. IL 6). Also the data in respect to 
abatacept link B cells as antigen presenting cell to T cell activation and thus 
provide a potential crucial role for antigen specific disease initiation and 
maintenance. Interestingly, autoantibodies such as RF and ACPA are not 
detected in PsA. Nevertheless, B cells accumulate in PsA synovium and thus 
might also play a crucial role.  
Finally potential bystander cells from the innate immune system but also stromal 
cells contribute to the pathogenesis of inflammatory arthritis. Macrophages for 
example are considered as an important source of proinflammatory cytokines in 
the synovium. Macrophages but also mast cells and dendritic cells monitor organ 
integrity and act as sentinels in the tissue. Expression of pattern recognition 
receptors (PRRs) such as Toll like receptors (TLRs) which recognize microbial 
products but also endogenous ligands lead to cytokine production (49). Even 
more, synovial monocytes can be activated by immune complexes. Also 34 
 
neutrophils are present in high numbers in synovial fluid and are detected in the 
inflamed synovium. At last, stromal cells, such as synovial fibroblasts can 
contribute to inflammation. Activation of fibroblasts by TNF and IL 1 stimulate 
the cells to produce TNF, IL 1 and IL 6 but also MMPs. This feedback loop 
prepares the tissue for local migration of T and B cells which further can support 
synovial fibroblast activation. (50) 
 This demonstrates an inflammation loop with cells talking from an adaptive to 
innate to stromal cell system. Disruption of this interaction loop with TNF 
inhibitors finally demonstrated benefit in clinical settings. In the next 
paragraphs cytokine biology with regard to its source will be described (see also 
table 1.6). 
1.1.5 Cytokines in synovitis and dermatitis 
The molecular/cellular pathogenesis of autoimmune diseases can be described in 
two ways. Firstly; to describe the cell as source of pathogenic products (e.g. 
proinflammatory cytokines) in the context of the immune dysfunction. Or 
secondly; to describe the pathogenic products themselves with focus on their 
actions thereafter in immune dysregulation. In general, in disease pathology, 
cells as crucial source for cytokines may be:  
-  Behaving in a dysregulated manner due to some intrinsic aberration – 
there is little evidence for this as a causative feature of RA or PsA beyond 
perhaps the roles of keratinocytes and fibroblasts which exhibit semi 
autonomous behaviours – the latter certainly contribute to perpetuation 
and chronicity. 
-  Operating in the wrong context 
(e.g. T cell help at the wrong time and place; autoreactive) 
-  Attacking structures they should not attack  
(e.g. macrophage/neutrophil activation) 
-  Reorganising tissue in an aberrant way 
(e.g. osteoclast activation, fibroblast/keratinocyte proliferation).  35 
 
Rather than describing the cells’ actions, the following paragraphs will focus on 
the major soluble mediators produced by immune cells: cytokines. Thus, I have 
elected to discuss the important immune cells in the context of the cytokines 
they produce or respond to (summarized in Table 1.6 Selected cytokines 
implicated in pathogenesis of RA, PsA and psoriasis).  
Cytokines are mediators that transmit signals between cells in an autocrine or 
paracrine manner acting either in soluble or membrane bound form. Initially, 
cytokine families were named for their origin—for example, lymphokines, 
monokines, and interleukins. However, as many of these molecules also act on 
and/or are produced by non lymphoid cells, the term cytokine is more 
appropriate. Cytokines are divided into families reflecting either their core 
functional domains and/or their shared structural homology, including, for 
example, hematopoietins, chemokines, interferons, TNF superfamily, IL 6 
superfamily, IL 10 superfamily, and the IL 12 superfamily. Cytokines may exist as 
monomers, homo  or heterodimers, trimers, or tetramers. Receptors mainly 
comprise heterodimers; cytokine receptor families often utilize common 
receptor subunits (e.g. common γ chain receptor, IL 1RAcP, see 1.3.1). 
Receptors, like cytokines, can exist as membrane signaling molecules, or may be 
released as soluble entities as a result of enzymatic cleavage from the cell 
membrane, or through the generation of alternatively spliced mRNA species. 
Soluble cytokine receptors can act as inhibitors of their ligands or act to 
facilitate signaling. Cytokine receptor complexes may thereafter be internalized 
by endocytosis, fused with a lysosome where the cytokine will be destroyed. The 
receptor itself may either shuttle back to the cell surface or undergo 
degradation. 
TNF α is a central cytokine in inflammation and blocking its actions has proven 
to be a successful treatment for some autoimmune diseases. This cytokine will 
hence be discussed in more detail in the following section. Furthermore, IL 17A 
biology will be introduced to prepare a rationale for one aim of this thesis. This 
subchapter is summarized as a table describing cytokines involved in RA, PsA or 
psoriasis. Noteworthy, all the cytokines mentioned in Table 1.6 have been 
chosen as a target for drug development and have been tested in various stages 
of clinical trials including drugs in phase I as well as fully approved drugs 
(source: clinicaltrials.gov). 36 
 
The success story: Tumour Necrosis Factor-α 
TNF α (also termed cachexin or cachectin) plays a central role in inflammatory 
arthritis and has therefore been a perfect target for therapy making it the most 
successful biological innovation in rheumatology so far (51). TNF α is detectable 
in synovial fluid, expressed in synovial tissue and produced by monocytes, 
macrophages, mast cells, fibroblasts, keratinocytes, T cells, B cells and 
neutrophils upon cytokine activation, TLR ligation or cell cell interactions. TNF α 
is synthesized as a 26 kDa, type II transmembrane molecule, which can be 
processed by a TNF α converting enzyme (TACE or ADAM17), to generate 
secreted 17 kDa monomers (52). Monomeric TNF α is a 17350 Da antiparallel β 
sheet sandwich, with ‘jelly roll’ topology interacting with two further monomers 
forming the functional trimeric unit (53). This trimer binds and clusters high 
affinity TNF receptors (TNF R, 55 kDa or 75 kDa) present in great numbers on 
most cells. TNF α exerts its effects by activating NF κB leading to the secretion 
of multiple pro inflammatory cytokines, e.g. IL 1 and IL 6. In vitro, the effects 
of TNF α on synoviocytes (synovium derived fibroblasts) could be blocked by 
addition of anti TNF α antibodies (54). The importance of TNF α in arthritis has 
been confirmed by multiple in vivo studies, such as mice expressing human TNF 
α which spontaneously develop arthritis (55, 56). These studies demonstrated 
that TNF α plays a pivotal role in arthritis and this knowledge was subsequently 
used successfully to develop antibody targeted therapies in RA patients.  
TNF α is expressed in PsA synovial lining and sublining layer as well as in 
psoriatic skin lesions (57). It is therefore not surprising that TNF α was also the 
first successful target of cytokine mediated therapy in psoriasis and PsA. 
Targeting TNF α delivers beneficial effects on joint damage and function as well 
as disease outcome, but also on tissue inflammation and cell infiltration 
measured histologically in biopsies as part of proof of concept studies. 
Treatment with infliximab decreases proinflammatory cytokine expression in 
psoriatic skin and reduces the numbers of infiltrating T cells as well as vessel 
formation in involved skin and synovium. Furthermore, adhesion molecules 
important for cell infiltration have been reported to be decreased upon 
treatment with infliximab and other TNFi (TNF inhibitor) agents (58 60). 37 
 
In summary, the promising experience with anti TNF α therapy has driven the 
search for further potential targets in autoimmune diseases. However, TNF α 
blockade is effective in only approximately 70% of patients receiving treatment, 
thus leaving room for improvement and rendering it necessary to explore the 
therapeutic potential of targeting other inflammatory pathways. 
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Table 1.6 Selected cytokines implicated in pathogenesis of RA, PsA and psoriasis 
DC: Dendritic cell; FLS: Fibroblast-like synoviocyte; KC: Keratinocytes; NK cell: Natural 
killer cell; Pso: Psoriasis; OB: Osteoblasts; OC: Osteoclasts. 
 
Cytokines in RA, PsA and psoriasis 
Cytokine  Cellular 
source 
Receptor  Major 
signalling 
pathway 
Major function  Role in psoriasis / 
PsA / RA 
IL-6  Macrophages, 
T and B cells, 
endothelial 
cells, FLS 
IL-6R/gp130  NFκB  Inflammation, acute 
phase response 
elevated in serum 
and synovial fluid 
IL-12  
(IL12p40/ 
IL-12p35) 
B cells, 
monocytes, 
macrophages, 
DC 
IL-12Rβ1/2  STAT4  Differentiates CD4 T 
cells to Th1 cells. 
Activates NK cells 
Clinical improvement 
of psoriasis in anti 
IL-12p40 treatment 
IL-15  Macrophages, 
FLS, 
endothelial 
cells 
IL-15Rα 
/IL-2/15Rβ, 
common γc 
subunit 
 
JAK1/3, 
STAT3/5 
IL-2 like function, 
inflammation 
Expressed in 
Pso/PsA/RA lesions 
Elevated in synovial 
fluid.  
IL-17A  T cells  IL-17R  TRAF6 
MAPK (?) 
NFκB (?) 
Inflammation,  
neutrophil  
recruitment, cytokine 
secretion, bone 
metabolism 
Elevated in synovial 
fluid 
IL-18  Macrophages, 
DC, FLS, OB, 
KC 
IL-18Rα/Rβ  MyD88, 
IRAK, 
TRAF6, 
NFκB 
Proinflammatory, 
induces IFN 
production by T cells 
Expressed in PsA  
similar to RA 
IL-23  
(IL-12p40/ 
IL-23p19) 
Macrophages, 
DC 
IL-12Rβ1/ 
IL-23R 
Jak2, 
STAT3 
Maintain Th17 cells, 
Induces IL-19 and 
IL-24 
Increased in Pso 
lesions 
Clinical improvement 
of psoriasis in anti 
IL-12p40 treatment 
IL-10 family           
IL-10  T cells, 
monocytes,  
KC 
IL-10Rα/ 
IL-20Rβ 
JAK1, 
STAT1/3, 
SOCS3 
 
Anti-inflammatory / 
regulatory actions, 
induces proliferation 
of B and mast cells 
Decreased in 
Pso/PsA lesions. 
IL-10 improves skin 
disease 
IL-19  Monocytes  IL-20Rα/Rβ  STAT3   Induces IL-6 and 
TNF-α expression 
by monocytes  
Expressed in Pso 
lesions, RA synovial 
cells 
IL-20  Monocytes  IL-20Rα/Rβ 
IL-22R/ 
IL-20Rβ 
STAT3 (?)  Induces keratinocyte 
proliferation and 
proinflammatory 
genes  
Overexpression 
induces psoriasis-
like phenotype 
IL-24  Monocytes,  
T cells 
IL-20Rα/Rβ 
IL-22Rα/ 
IL-20Rβ 
STAT3  Inhibits tumour 
growth 
Expressed in Pso 
lesions 
IL-22  Th17 cells, 
activated T 
cells, NK cells, 
mast cells 
IL-22Rα/ 
IL-10Rβ 
ERK, p38 
MAPK 
Acute phase 
response, 
proinflammatory 
properties 
Induces Pso like 
inflammation, 
expressed in RA 
synovium 
IL-26  memory T 
cells 
IL-20Rα/ 
IL-10Rβ 
?  Unclear role in 
herpes virus saimiri 
transformed T cells 
? 
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Table 1.6 continued: Cytokines in RA, PsA and psoriasis 
Cytokine  Cellular 
source 
Receptor  Major 
signalling 
pathway 
Major function  Role in psoriasis / 
PsA 
OPG  OB, FLS  RANKL  -  Decoy receptor, 
inhibits 
osteoclastogenesis 
Expressed only in 
endothelial cells 
below the synovial 
lining 
RANKL  T cells, OB, 
fibroblasts,  
FLS 
RANK  TRAF6, 
NFκB 
Osteoclastogenesis  Expressed in 
synovial tissue, esp. 
in synovial lining  
layer 
IL-1  Monocytes, 
Macrophages, 
FLS, B cells, 
neutrophils, 
chondrocytes 
Type-1 
(CD121a) or 
Type-2 
(CD121b) 
receptor 
NFκB  proinflammatory, 
cartilage 
degradation,  
expressed in RA 
synovium, limited 
efficacy in clinical 
trials 
April  DC, T cells  BCMA and 
TACI 
NFκB  B cell proliferation  Increased in RA fluid 
and serum. 
BAFF  Macrophages, 
FLS, T cells 
BCMA, TACI 
and BAFF-R 
TRAF2 and 
NFκB2 
(BAFF-R),  
NFκB (TACI, 
BMCA) 
B cell proliferation  Increased in RA fluid 
and serum; elevated 
in Pso serum. 
GM-CSF  T cells, 
macrophages 
GM-CSF-R    proinflammatory, T 
cell modulation 
expressed in RA 
synovium, elevated 
in RA plasma 40 
 
1.1.6 Mouse models of inflammatory skin disease 
Studying psoriasis has advantages compared to other autoimmune diseases. 
Access to the inflamed tissue is far easier and generally presents fewer 
complications when using biopsy approaches. Compared to RA or systemic lupus 
erythematosis (SLE) in which biopsies of joints/kidneys are expensive and 
invasive, punch biopsies of the skin are quick and easily performed rendering 
enough material for mRNA, protein analysis or histology. However, research 
involving human psoriasis material has its disadvantages including; diversity of 
individuals (phenotype and genotype), difficult culture conditions due to 
bacterial and fungal contamination, range in intercurrent therapies, as well as 
limitation in donor numbers. 
To overcome these problems and to study single proteins/genes which might 
influence the pathogenesis of diseases, different mouse models have been 
created in order to study psoriasis. There are currently several different models 
available (reviewed in (61, 62)). Various established rodent models have been 
created by inducing spontaneous mutations, genetic engineering via transgenic 
approaches or immunological strategies. The common approach to elicit the 
overexpression of proteins of interest in the epidermis is to put the gene of 
interest under the transcriptional control of the Keratin 14 (K14) promoter in the 
case of basal keratinocytes or K5 or 10 promoters to express it in differentiating 
keratinocytes. Other approaches have used tissue specific deletion of proteins. 
Expression of inflammatory mediators or keratinocytes growth factors such as 
BMP6, Interferon γ, KGF, TGF α, IL 1 α, TNF α and IL 20 lead to the recreation 
of only partial features of psoriasis (62). Overexpression of TGF β1 or VEGF in 
mouse skin was shown to generate a phenotype more similar to human psoriasis 
with acanthosis, increased vascularization, and leukocyte infiltration (63, 64). In 
both models as well as in the Jun protein deletion model (see 1.1.3 (41)) the 
major mechanism appears to rely on recruitment of immune cells by 
keratinocytes. These models are consistent with the hypothesis that an initial 
defect in the skin environment causes the recruitment of immune cells which 
induce inflammation and tissue damage. Further models which reflect the 
human situation are xenotransplantation models, using e.g. SCID mice. Recently, 
reports demonstrated the growth of reconstructed human epidermis by culturing 41 
 
keratinocytes on inserts with specific differentiation media. After confluency of 
the keratinocytes was achieved on this inert surface, an air liquid interface with 
nutrition from below initiated the creation of a three dimensional structure, 
closely resembling the epidermis (65). This epidermal reconstruction was used in 
subsequent studies to examine the influence of cytokines on the epidermal 
response (66), with results showing that IL 22 upregulates proliferation and 
differentiation of keratinocytes similar to that seen in psoriasis. Other 
psoriasis/skin inflammation models induce psoriasis like inflammation using 
stimuli such as chemicals or cytokines. In this thesis the two following models 
have been used: a TPA skin inflammation model and an intradermal cytokine 
injection model.  
The first model reflects broad inflammation induces by a phorbolester (TPA) on 
the back of the shaved mouse. This has been used to study effects of skin 
inflammation in knock out mice. For example in D6 deficient mice TPA 
treatments lead to inflammation with hallmarks of psoriasis compared to 
wildtype mice. Interestingly, skin inflammation was TNF α and IL 15 dependent 
(67). 
An alternative model of skin inflammation is induced by intradermal injection of 
cytokines. This method was originally established using IL 23. Intradermal 
injections of IL 23 into the dorsal skin induced a psoriasis like phenotype (68). 
The model was subsequently improved by injecting into the ear pinna, hence 
allowing measurements of ear thickness and quantification (69). This has further 
been utilized by other groups using IL 22 and IL 23 (70, 71). Repeated injection 
of IL 22 or IL 23 every alternate day for 2 weeks led to ear as well as epidermal 
thickening with hyperkeratosis. Although these models are not a perfect 
representation of human psoriasis they offer the advantage of daily readout (ear 
thickness) rather than endpoint readouts such as tissue sections and histology, 
allowing the acquisition of data over a time course. Such in vitro models can 
therefore be utilized to identify crucial molecules involved in the pathogenesis 
of psoriasis and test potential targets for future therapies. 
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1.2 Th17 cells and their role in rheumatoid 
arthritis/psoriasis 
The understanding of pathology in regard to its cytokine network has lead to 
new therapies. TNF α has been demonstrated as the first target of many to 
follow. However, it is necessary to find new targets to broaden and specify the 
therapy portfolio and improve current standards. Hence the next subsections 
focus on the cytokine axis IL-17 – IL-23 and the novel cytokine IL-33. 
 
Immunological host defence relies on two parts of the immune system. As a first 
line of defence, the innate immune system responds to danger (e.g. pathogen 
invasion, trauma, physiologic or metabolic dysfunction) in an antigen non 
specific way without inducing classical immunological memory. In a second 
phase, the adaptive antigen specific immunity provides a fine tuned immune 
response including specific antibodies and the advantage of memory for future 
events. As a part of the adaptive immune system, CD4+T helper (Th) cells are 
activated by antigen presenting cells (APC, e.g. dendritic cells, B cells) via MHCII 
(major histocompatibility complex) bound antigenic peptides. This signal 1 is 
supported by further costimulatory signals (signal 2) to fully activate the T cells. 
In the presence of signal 1 and 2 naïve T cells will differentiate into Th effector 
cells. So far, subsets called Th1, Th2, Th9 and Th17 cells have been described, 
in addition to distinct regulatory T cell subsets (Treg) (Figure 1.3). Th1 cells 
produce IL 2 and interferon (IFN) γ and are thought to regulate cellular 
immunity, whereas Th2 cells produce IL 4, IL 5 and IL 13 thus being mainly 
involved in the protection against parasitic helminths (72). IL 4 and IL 13 are the 
major mediator of IgE class switching in B cells. Th2 cells induce IgG1 and IgE 
antibodies in mice and IgM, IgG4 and IgE in humans and thus Th2 cells can 
regulate humoral immunity (73). Th17 cells have been recently described, 
defined by their production of IL 17A. These cells also produce IL 17F, IL 21 and 
IL 22 (72). Th17 cells were initially identified and characterized in the murine 
system but have been since shown to exist in humans. Studies carried out with 
human Th17 cells have shown that there might be some differences between 
murine and human Th17 cells. 43 
 
 
Figure 1.3 T helper cell differentiation (overview). 
Differentiation driven by various cytokines to either proinflammatory cells such as Th1 and 
Th17 (mouse differentiation, see also Figure 1.4), but also regulatory cells (Tregs). 
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Points of discussions are  
-  Differences in Th17 differentiation between human and mice  
and 
Development of TH17 cells in human memory and naïve CD4+ cells 
-  Plasticity of Th17 cells in vivo 
-  Function(s) in disease 
In mice, a series of elegant studies over the last few years have shown that IL 6 
and/or IL 21 and TGF b are in fact the key cytokines in the development of Th17 
cells (74 76). The Th17 lineage defining transcription factor was found to be 
RORγt (77). Interestingly, key cytokines of Th1 and Th2 cells, namely IFN γ and 
IL 4, block Th17 cell differentiation (78). The cytokine IL 23 (compromising 2 
subunits IL 12p40 and IL 23p19) is essential for the maintenance and expansion 
of murine Th17 cells (79). Other factors have been demonstrated to support 
differentiation like TNF α and IL 1b and recently IL 21 in an autocrine manner 
(76) (Figure 1.4). 
Similar to their mouse counterparts, human Th17 cells express RORC2, the 
human orthologs of RORγt (80). Development of human Th17 cells is less straight 
forward and includes more variables. First, Th17 cell development depends on 
the T cell type, differing between naïve T cells and memory T cells. Naïve 
CD45RA
+CD161
+ T cells have been studied derived from umbilical cord blood and 
differentiate to Th17 cells under the influence of IL 1b and IL 23 (81). This 
process is TGF b independent; however, TGF b is speculated to support Th17 
differentiation by inhibiting T bet and hence Th1 development (82). 
In peripheral blood, differentiation of Th17 cells from naïve T cells is not fully 
elucidated as yet. Specifically, the need for TGF b is controversial as serum 
containing media might be contaminated with platelets and TGF b. Serum free 
approaches demonstrated an essential requirement for low dose TGF b in 
conjunction with IL 1b and IL 23. However, the different approaches used in 
many of these studies, such as various purification techniques and culture 
conditions, make direct comparison of results difficult (reviewed in (83)). 45 
 
Interestingly, in human blood serum concentrations are usually higher than the 
concentrations which were used for culturing T cell in vitro in any of the 
described studies, and therefore most likely do not represent the in vivo 
situation. However, TGF b is not the only cytokine involved in the differentiation 
and maintenance of Th17 cells.  Other cytokines such as IL 6, IL 21 and TNF α 
have also been shown to support Th17 polarisation from naïve Th cells (Figure 
1.5). 
More clear is the development of Th17 cells from the memory pool. These 
effector cells can be identified by the combined expression of CCR4 and CCR6 
(84)   another group described a CD4
+CD45RO
+CCR7
 CCR6
+ population which 
produce IL 17 (85). CCR6 is thought to be involved in the recruitment of Th17 
cells to sites of inflammation via the ligand CCL20. IL 1b, IL 23 and IL 6 
promoted production of IL 17; however, TGF b inhibited IL 17 (85, 86). To 
summarize, due to different cell culture and ex vivo approaches including 
various purification techniques ranging from cell sorting to bead purification and 
different cell culture conditions human Th17 biology is still elusive. 46 
 
 
Figure 1.4 Th17 cell differentiation in mice 
APC: antigen presenting cell, Thn: naïve T helper cell, Th17: Th17 cell. RORγT: Th17 cell 
specific transcription factor. 
 
 
Figure 1.5 Th17 polarisation in humans. 
APC: antigen presenting cell, Th0: naïve T helper cell, Th17: Th17 cell. RORC2: Th17 cell 
specific transcription factor in humans. AhR: Aryl hydrocarbon receptor 47 
 
The classification of Th17 cells is further complicated by the plasticity of T cell 
subsets in vivo. T cells expressing both IL 17 and IFN γ have been observed in 
arthritis mouse models (personal communication Dr D Asquith) and have been 
detected in humans (84 86). It is unclear if these cells represent a terminally 
differentiated subset or are precursors which are still able to commit to 
differentiation into Th17 or Th1 cell types. The plasticity of T cells might also 
play a role in the balance between differentiation of Th17 cells and regulatory T 
cells (Tregs) which both depend on the presence of TGF b. Tregs can be induced 
by TGF b and are defined by high expression of forkhead box P3 (FoxP3) in both 
the murine and human systems. These cells are strong immune modulators which 
have the ability to suppress proliferation and cytokine production of effector T 
cells (87). In the murine system a proinflammatory environment, such as the 
presence of IL 6, can lead to a shift from a Treg to a Th17 biased milieu. Due to 
the as of yet still defined role of TGF b in Th17 development in the human 
system, it is unclear if this balance exists in humans as well. However, it has 
been shown in humans that Treg function is adversely affected in 
proinflammatory diseases such as RA and psoriasis (88, 89). Anti TNF α therapy 
reduces IL 6 levels and might therefore shift the balance away from Th17 
development, thereby restoring Treg function (88, 90). There is some evidence 
that TNFi can reset peripheral human T cell responses towards a regulatory 
phenotype (88). What impact this plasticity has in vivo is unclear so far. It is 
noteworthy to particularly consider the situation during recovery from flares or 
periods of relative disease quiescence; eliciting the potential to re balance the 
immune system and to acquire the knowledge of precise triggers that serve to 
initiate disease or flares will be mandatory for future understanding of the 
pathogenesis of autoimmune diseases in general and arthropathies in particular. 
What is the effector role of IL 17? The IL 17 family comprises six cytokines 
termed IL 17A, B, C, D, E (or IL 25) and F. The cDNA of human IL-17 was initially 
cloned from a library of CD4+ T cells and stimulation of peripheral blood T cells 
was shown to induce the production of IL-17 (91). However, only IL 17A and IL 17F 
are produced by Th17 cells. IL 17A was found to be most homologous to IL 17F; T 
cells can produce three different dimeric forms of IL 17: IL 17A/A, A/F and F/F 
(92). The receptor biology of this family remains to be fully elucidated, but it 
appears that IL 17 binds to two subunits of IL17RA and one of IL17RC (93). These 48 
 
receptors are ubiquitously expressed in almost all tissues thus far examined (91). 
Their regulatory elements remain obscure. Therefore, the ability to signal to a 
variety of different cells demonstrates a likely important role this cytokine plays 
in the immune system. IL-17 can stimulate a variety of cells including epithelial, 
endothelial, chondrocyte and fibroblast type cells to produce cytokines such as IL-
6 and IL-8, as well as MMP molecules (94).  
Further IL 17 was found to play a vital role in protection against bacterial, fungal 
and viral pathogens, such as Candida albicans, respiratory Chlamydia and 
Klebsiella pneumoniae (reviewed in (95)). Recent data from IL 17A receptor 
deficient mice suggest that IL 17 is not important for primary Mycobacterium 
tuberculosis infections   Th1 cells seem to be more important (reviewed in (96)). 
IL 17 serving as a mediator in the defence against pathogens, is also produced by 
a number of other cell types such as neutrophils, gd and CD8 T cells, 
macrophages and fibroblasts, although the best characterised cellular source of 
this cytokine is the Th17 cell (97). 
Although IL 17 has evolved to facilitate protection against the infections listed 
above, there has been increasing evidence in the last few years that 
dysregulated expression of cytokines of the IL 17 family might play an important 
role in RA pathogenesis. In 1999, IL 17 was described in RA synovium and 
synovial fluid. IL 17 is expressed at relatively low levels in synovial fluid and 
comparatively few positive cells can be detected in tissues. Nevertheless, 
murine disease models showed interesting results concerning the role of IL 17 in 
autoimmunity (98, 99). For example, IL 17 knock out mice showed suppressed 
induction and ameliorated progression of disease in an collagen induced arthritis 
(CIA) model (100). Studies using mice deficient for the IL 17 receptor or blocking 
IL 17 with anti IL 17 antibodies further confirmed the role IL 17 plays in arthritis 
models (101, 102). A different chronic relapsing arthritis model showed that 
combined blockade of IL 17 with GM CSF also works in a TNF independent model 
(102). More interestingly, TNF α blockade stimulates an increase in circulating 
Th17 and Th1 cells, likely through preventing their accumulation in the joint 
(103). Finally, IL 17 promotes erosions by inducing pro erosive cytokines and by 
upregulation of Receptor Activator of NFκB ligand (RANKL) on osteoblasts and 
promoting the creation of an osteoclast differentiating environment (99). The 49 
 
broad proinflammatory effects of IL 17 in RA make it an interesting target for 
therapeutic blockade. So far blocking anti IL17 antibodies has been shown to be 
an effective treatment of psoriasis, providing an initial proof of the feasibility of 
IL 17 blockade (104). Additionally, two phase I studies have been carried out in 
RA patients demonstrating an improvement in disease activity compared to 
placebo. Finally, ongoing phase II trials across a range of indications should 
render further information on the efficacy of IL 17 targeted therapies (105, 
106). Interestingly, a recent study from Kokkonen et al. found that cytokines 
produced by Th1, Th2 and Treg cell subtypes were upregulated in arthritis 
patients before the onset of disease. Levels of IL 17 did not reach significant 
difference to control subjects, although the concentration of IL 17 in individuals 
before disease onset was significantly higher than that in patients after disease 
onset (107). This indicates that IL 17 may play a role in the initiation rather than 
the maintenance phase of arthritis. However, measurements for this study were 
performed on peripheral blood samples and therefore might not reflect the 
levels of cytokines in tissues such as the joint. 
As noted above, psoriasis is a model disease for cytokine targeting. Recent 
successes targeting TNF α have been extended to other cytokines. Interestingly, 
the Th17 axis raised attention in the field with the discovery of single nucleotide 
polymorphisms of IL12B (the gene for IL 12p40 which is a subunit of IL 12 and IL 
23) and IL23R which are associated with psoriasis (108, 109). Another potential 
gene locus was discovered harboring IL2 and IL21 (110) . In preclinical studies in 
mouse models of psoriasis, injection of IL 23 into mouse skin induces a psoriatic 
like disorder (68). Others showed that this effect is dependent on IL 22 (another 
Th17 cytokine) and CCR6 (a marker for Th17 cells) (69, 70). In addition, high 
amounts of IL 12 p40 and IL 23 p19 as well as IL 17 are detected in psoriatic skin 
from humans (111, 112). Trials using antibodies against IL 12p40 (IL 23p40) 
(ustekinumab and ABT 874) have been successful in moderate to severe chronic 
plaque psoriasis. Currently, trials in psoriasis are ongoing using antibodies 
against IL 17A (AIN457). Initial results are promising but further study results are 
awaited (104). 
The cytokine IL 23 is a heterodimeric cytokine composed of a p40 and a p19 
subunit, the former of which is shared with IL 12 (p35/p40) which drives naïve T 
cells into Th1 cells. IL 23 is produced by activated macrophages and dendritic 50 
 
cells and seems to be important in induction and maintenance of Th17 cells as 
discussed above. Expression in RA synovial fluid is controversial with groups 
reporting low and others very high levels. Interestingly, in synovial tissue 
bioactive IL 23 seems to be present only in low levels despite high expression of 
IL 23p19 shown by histologic analysis.(113, 114)  
Regarding bone homeostasis IL 23 upregulates Receptor Activator of NFκB 
(RANK) on myeloid precursors and induces RANK ligand expression on CD4+ T 
cells (115, 116). This direct effect combined with an indirect effect via IL 17 
strongly support osteoclast differentiation and further erosive disease. Recent 
genetic studies in psoriasis patients provided strong support for association with 
IL 23 related loci with involvement of single nucleotide polymorphism for IL-23A, 
IL-12B and IL-23R (117) (see also table 1.5). In RA so far, these variants could not 
be observed yet, but larger sample sets might uncover this in the future (118, 
119).  
Due to the shared subunits interpretation of mice deficient in p40 is difficult as 
it lacks IL 12 and IL 23. To test the effect of IL 23 in autoimmune disease anti 
IL 23 antibodies were administered to rats with CIA which demonstrated less 
severity of disease (120).  In a different study in mice developing spontaneous 
arthritis (IL1RA
 /  mice) showed worsening of disease after application of IL 23 
(115). To understand the relationship between IL 23p19 and IL12 p40 Murphy 
and colleagues used mice deficient for these subunits (121). Loss of IL 23p19 
protected mice against arthritis were IL 12p40 deficient mice experienced 
exacerbated disease.  
The final proof for the importance of IL 23 in inflammatory diseases such as 
psoriasis was the in a phase III clinical trial with Ustekinumab, a human 
monoclonal antibody against IL 12p40 targeting IL 23 and IL 12. In psoriasis 
Ustekinumab has yielded beneficial effects in >75% of patients (32, 122). Despite 
not distinguishing between the two cytokines IL 12 and IL 23, targeting Th1 and 
Th17 cell differentiation is effective but might have future side effects due to 
inhibition of two T cell subsets. Thus a future more predicatively approach might 
be a blockade of IL 23p19. Trials are running and results are awaited. 51 
 
1.3 The role of the cytokine Interleukin 33 in health and 
disease 
The novel IL 1 family cytokine IL 33 was chosen for study for several reasons, 
including its striking expression pattern in the nucleus, its biology with reference 
to cellular release, functionality particularly its role as a novel alarmin, its 
divergent roles in the intracellular versus the extracellular compartment and 
finally activation versus neutralisation. Furthermore its role in pathogenetic 
processes demonstrating clear Th2 biology linked it originally to allergy and 
asthma; while on the other hand more recent data suggest a capacity for playing 
an important role in Th1/Th17 biology particularly in autoimmune arthritis. This 
thesis directly addresses its role as an alarmin at body barriers focussing on the 
autoimmune disease psoriasis which is thought to be partially regulated on the 
premise of damage and body defence. In this section, this novel cytokine will be 
introduced in the context of the IL 1/TLR cytokine family, its structure, 
expression and biology as well as its potential role in disease thus far elucidated.  
But what is an alarmin? Pathogens can be detected via a set of receptors which 
detect pathogen associated molecular patterns (PAMPs). With this ability the 
immune system can sense danger and respond to the signal to preserve the 
integrity of the body. However, another source of damage (and subsequent 
danger) is tissue and cell damage caused by trauma (e.g. mechanical forces, 
heat, cold chemical insults, radiation, etc.). The term alarmin is proposed to 
define endogenous molecules released during trauma, which signal tissue and 
cell damage. This term “alarmin” was proposed by Joost Oppenheim (EMBO 
Workshop on Innate Danger Signals and HMGB1, Milano, Italy 2006). The two 
groups, alarmins and PAMPs are subgroups of the damage associated molecular 
patterns (DAMPs). (123)  
1.3.1 IL-33 in the context of its IL-1 receptor / Toll like receptor 
family members 
In the 1980s IL 1 was one of the first cytokines described, hence the number 
given. Prior to this, IL 1 was studied for many years under the guise of biologic 
activities (usually named for these e.g. endogenous pyrogen) and found to cause 52 
 
fever, stimulate acute phase proteins, induce lymphocyte responses, increase 
the number of bone marrow cells and cause joint damage (124). Two proteins 
were shown to share these activities, encoded by different genes – IL 1α (IL1F1) 
and IL 1β (IL1F2). Interestingly, despite being distinctive structural entities from 
TNF α and IL 6, they share approximately 95% overlap in their effector function 
with the latter.   
Both can bind to a heterodimeric receptor complex consisting of IL 1 receptor I 
(IL 1R) and IL 1 receptor accessory protein (IL 1RAcP). Binding to IL 1R leads to 
recruitment of IL 1RAcP with subsequent signalling via TIR (Toll/IL 1R) domains. 
These TIR domains are conserved intracellular receptor parts linking the IL 1 
receptor family to the Toll like receptor (TLR) family and signal via MyD88. 
Major differences between these two receptor families are found primarily in 
their extracellular components: IL 1Rs consist of IgG like domains, whereas TLRs 
consist of leucine rich repeats. Interestingly, IL 1α and IL 1β share the same 
effector function, bind the same receptor and are structurally very similar. 
However, primary amino acid homology of mature human IL 1α to mature IL 1β 
is only 22% (124). IL 1R antagonist (IL 1RA), also named IL1F3, is another ligand 
for the IL 1R and competes for binding. This natural antagonist binds IL 1R but 
does not result in recruitment of IL 1RAcP and therefore prevents signalling.  IL 
1 belongs to the IL 1 superfamily family that includes 11 structurally related 
cytokines; family members had different names from Family of IL1 x (FIL1 x), IL 
1 homolog x (IL1Hx) to IL 1 related protein x (IL1RPx) where x stands for 
different cytokine numbers. Finally, all group members have been linked 
together with the common name IL 1 family member x (IL 1Fx) (Table 1.7). 53 
 
 
Interleukin 
(HGNC gene family nomenclature) 
conventional name  receptor 
IL 1F1  IL 1α  IL 1R, IL 1RAcP 
IL 1F2  IL 1β  IL 1R, IL 1RAcP 
IL 1F3  IL 1RA  IL 1 receptor (antagonist) 
IL 1F4  IL 18, IGIF  IL 18R, IL 18RAcPL 
IL 1F5  IL1RP3, IL1 HY1, FIL1 delta   
IL 1F6  FIL1 epsilon  IL 1Rrp2, IL 1RAcP 
IL 1F7  IL1H4 (homolog 4), FIL1 
zeta, IL1RP1 
 
IL 1F8  FIL1 eta, IL1H2  IL 1Rrp2, IL 1RAcP 
IL 1F9  IL1H1, IL1RP2  IL 1Rrp2 
IL 1F10  FIL1 theta, IL1HY2   
IL 1F11  IL 33, NFHEV  ST2, IL 1RAcP 
Table 1.7 IL-1 family – members and nomenclature 
Different names have been assigned over time to the IL-1 family members. This table shows 
the HUGO Gene Nomenclature Committee (HGNC) nomenclature (left column). Middle 
column shows the conventional names. According receptors are shown in the right column. 54 
 
Monocytes are the main source of IL 1, however, multiple cells from 
hematopoietic or stromal origin can secrete IL 1 such as T cells, B cells but also 
epithelial cells. IL 1α and IL 1β are synthesized as precursors. Interestingly, IL 
1α precursor (pro IL 1α) is also active in its precursor form, whereas IL 1β has to 
be cleaved to a mature form to become active. Pro IL 1α remains in the cytosol, 
undergoes myristoylation and translocates to the cell membrane where it can be 
anchored to the cell (125, 126). Calpain is required for the cleavage of pro IL 
1α, whereas Caspase 1 and/or Caspase 8 are important for the cleavage of pro 
IL 1β (127, 128). 
IL 18 (former known as IFN γ inducing factor, IGIF) is synthesised as a 23 kDa 
pro molecule that is cleaved by caspase 1 to an 18 kDa ligand which is then able 
to bind IL 18R (129). Pro IL 18 is expressed in macrophages, dendritic cells, 
Kupffer cells, keratinocytes, chondrocytes, synovial fibroblasts, and osteoblasts 
(127). Upon release, IL 18 binds to IL 18R which forms a comparable complex to 
the IL 1R complex. IL 18Rα binds IL 18, further IL 18Rβ is recruited which does 
not bind IL 18 on its own but initiates intracellular signaling in this 
heterotrimeric complex (Figure 1.6). IL 18Rβ is an accessory like protein and 
similar to IL 1RAcP (127).  
IL 1F5 shares significant amino acid sequence similarity (52 %) with IL 1RA 
(receptor antagonist) and dysregulation may play a role in skin inflammation 
(130, 131). IL 1F5 may function as a specific receptor antagonist of the IL 1 
related receptor protein 2 (IL 1Rrp2) (130). IL 1F6, F8 and F9 bind to IL 1Rrp2, 
requiring IL 1RacP for signaling. IL 1Rrp2 is highly expressed on epithelial cells in 
the skin suggesting a possible role in host defense in these organs. IL 1F10 binds 
to soluble IL 1RI with an unknown effect (127). 
IL 33 (IL 1F11) is the latest of IL 1 family discoveries. Initially described as 
nuclear factor of high endothelial venules (NF HEV) by Girard and colleagues in 
2003, Schmitz et al defined its function and role in the IL 1 family in 2005 (132, 
133). This group described the IL33 gene after searching a computational derived 
database of the IL 1 family members.  
In the following subsections, more detail in regard to the structure, function and 
biological relevance of IL 33 will be given.55 
 
 
 Figure 1.6 IL-18 receptor complex. 
The IL-1 family cytokine binds IL-18Rα (left part), however, the ligand-receptor pair can not 
induce signalling into the cell. This binding leads to recruitment of IL-18Rβ (middle part). 
This heterotrimic receptor-ligand complex now signals via its TIR domains by recruitment of 
MyD88. Similar processes happen with IL-1 (IL-1R/IL-1RAcP) or IL-33 (ST2/IL-1RAcP). For 
further downstream signals see Figure 1.9. 
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1.3.2 Structure of IL-33 
The sequence of IL 33 has been mapped to human chromosome 9 (9p24.1) and 
mouse chromosome 10 (19qC1). The cDNA encodes for 270 and 266 amino acids 
for human and mouse, respectively, and are approximately 55% identical at the 
amino acid level (132). Its molecular weight is ~ 30 kDa. Using sequence and 
secondary structure alignment, Girard and colleagues demonstrated that IL 33 
consists of a homeodomain like helix turn helix motif (HTH) on the amino 
terminal side (133). This is followed by a nuclear localisation signal and further 
12 predicted β strands comprising an IL 1 like cytokine domain with a typical ß 
trefoil structure. The 1 65 amino acid HTH motif of IL 33 has homology with 
drosophila transcription factors showing the best match with Engrailed. These 
HTH motifs are known to be repressors of transcription. Engrailed is a Drosophila 
homeodomain protein required for proper segmentation and maintenance of the 
posterior compartment identity. The repressor activity of Engrailed lies in the 
sequence containing amino acids 1–298 which has been shown
 to confer 
transcriptional repression when fused to heterologous
 DNA binding domains. Use 
of dominant negative transgenes has been successful in analysing certain 
pathways and using this technique to convert transcription factors into dominant 
repressors can be achieved by fusion to repressor domains such as Engrailed 
(134). Accordingly, translational fusions with the Engrailed repressor domain 
have efficiently converted plant transcription factors, b catenin and c myb, into 
dominant negative proteins. Also, in vivo, an airway targeted GATA6 Engrailed 
dominant negative fusion construct was able to alter epithelial differentiation 
(135).  
In the following figure IL 33 HTH is demonstrated (Figure 1.7, 1.6A altered from 
(133)). This part is built with three α helices with the helix number 3 (H3) 
binding the DNA. The dark gray shaded part determines the turn in this sequence 
(Figure 1.7A). For illustration, figure B shows the general binding of HTH 
proteins into the major groove of the DNA with an example how the protein 
would be orientated to the DNA. Normally these proteins form a homodimer (as 
is IL 33) which leads to another binding of a helix most likely increasing the 
effect (Figure 1.7B).  57 
 
Therefore, similar to Engrailed, IL 33 is thought to be a suppressor of 
transcription. Several data support this idea:  
Carriere et al. demonstrated in elegant studies that IL 33, especially the HTH 
like part is located to heterochromatin. By truncation of IL 33 HTH like part this 
heterochromatin association was abolished and IL 33 expression became 
unrelated to the heterochromatin. More interestingly, by fusing IL 33 to the 
Gal4 DNA binding domain in gene reporter assays with a GAL4 responsive 
luciferase reporter, transcriptional activity was reduced illustrated by decreased 
luciferase activity (136). This could be reestablished by mutating the DNA 
binding parts of IL 33 (137). More strikingly, Roussel et al. showed that the 
association of IL 33 to the heterochromatin is conserved in regard to this 
binding. Kaposi sarcoma herpesvirus (KSHV) LANA consists of a MXLRSG motif, 
which also occurs in IL 33 and is crucial for binding to histone H2A H2B (137). 
Binding alters nuclear architecture and leads to chromatin compaction. KSHV 
LANA uses this binding for maintenance of viral genomes in latently infected 
tumor cells. By even mutating three amino acids in this motif chromatin binding 
could be prevented.58 
 
 
Figure 1.7 Structure of IL-33 HTH like motif 
Example of HTH like motif in comparison to other HTH genes. Figure A demonstrates the 
structure of IL-33 HTH like part with three helices where the helix number 3 (arrow) is able to 
bind DNA; this figure has been altered from (133). B demonstrates a schematic picture of a 
HTH in which one α-helix binds DNA in the major groove. Black arrow indicates the turn. 59 
 
Next to the chromatin binding domain in the HTH like motif, IL 33 possesses a 
nuclear localisation signal (NLS), near the N terminal domain (Figure 1.8). 
Truncation of the NLS (e.g. a construct containing only IL 33112 270, see Figure 
1.8) leads to retention of IL 33 in the cytoplasm (136, 138). The HTH like motif 
and NLS (important for nuclear localisation and DNA binding) are linked to the 
IL 1 like cytokine domain consisting of 12 β strands. The latter part has mainly 
been used to study biological effects of IL 33, as it has been assumed that IL 33 
is cleaved by caspase 1 leading to “mature IL 33” (the IL 1 like cytokine domain) 
which is thought to be released in a similar way to IL 1 or IL 18 (132). 
Interestingly, recent studies revealed that IL 33 is not cleaved by caspase 1, but 
instead cleaved by apoptosis associated caspases 3 and 7 as well as calpain and 
as a result is therefore inactivated rather than activated (139 141). In addition, 
caspase 3 treated IL 33 breakdown products are not able to bind ST2 (the IL 33 
receptor), but the N terminal part still translocates to the nucleus (139). 
Moreover, different groups showed that full length IL 33 is bioactive and can be 
released by necrosis classifying IL 33 as an alarmin (140 143).60 
 
 
 
 
 
Figure 1.8 IL-33 structural components and cleavage sites. 
N terminal domain shows HTH like motif including chromatin binding domain (CBM) with 
the specific amino acid motif and the nucleus localisation site (NLS). β1-12 demonstrates 
the IL-1 like cytokine domain with 12 β strands. At localisation amino acid 112 the initial 
described caspase-1 cleavage site from Schmitz et al (132) is shown. Further after the 
residue Asp178 Cayrol et al showed a truncation by caspase 1 and 3 which deactivated IL-
33 signaling through ST2 (142). One month later, Luthi et al published truncation at Asp178 
by caspase 3 and 7, but did not confirm caspase 1 (143). It has to be emphasised that the 
structure in biological assay using recombinant IL-33 is a product reflecting the IL-1 like 
cytokine domain truncated at amino acid 112.61 
 
 
1.3.3 Tissue localisation and cellular expression of IL-33 
So far, most reports visualising IL 33 expression have shown that IL 33 is 
exclusively expressed in the nucleus. Using antibodies against the C terminal 
region (e.g. Nessy 1) most analyses demonstrate in nearly every tissue nuclear 
expression of IL 33 (www.proteinatlas.org, IL 33 expression pattern by IHC). Few 
exceptions exist although cytosolic staining in LPS stimulated THP 1 cells and 
monocytes in vitro (144) and macrophages in peridontal tissue have been 
reported (personal communication, Dr Fukada Glasgow University). The nuclear 
expression pattern mainly occurs in stromal cells such as endothelial cells and 
epithelial cells. It is noteworthy that IL 33 has initially been described as a 
“nuclear factor of high endothelial venules” consistent with this reported 
expression pattern. Schmitz et al reported IL 33 expression in cDNA libraries. 
They show that IL 33 is broadly expressed in different tissues; however, on the 
cellular level differences occur. Mouse organs expressing high levels of IL 33 
cDNA include stomach, lung, spinal cord, brain, and skin. In humans, IL 33 cDNA 
was detected in adherent stromal cells like epithelial/endothelial cells, smooth 
muscle cells, fibroblasts, and keratinocytes where the latter two upregulated IL 
33 after TNF α and IL 1 stimulation (132). Comparing cDNA reports with protein 
level by IHC, endothelial, keratinocyte and bronchial expression can be 
confirmed (www.proteinatlas.org). Staining for IL 33 in arthritic joints is 
reported by 2 different groups (145, 146). They concluded that these positive 
cells are macrophages or fibroblasts. Initial data from our lab demonstrated 
endothelial staining in inflamed synovium, rather than macrophages, thus 
uncertainties remain and this needs more investigation. Expression in lymphoid 
tissues has been shown to relate to endothelial cells but also fibroblastic 
reticular cells (147). Other expression patterns are still to be confirmed.  
1.3.4 Release of IL-33 
Initial studies hypothesized that IL 33 is released in a caspase 1 dependent 
manner. NLRP3 (NLR family, pyrin domain containing 3) inflammasome 
activation by pathogen associated molecular patterns (PAMPs) or damage 
associated molecular patterns (DAMPs) leads to oligomerisation of NLRP3 and 62 
 
clustering of pro caspase 1. This results in caspase 1 auto activation and 
caspase 1 dependent processing of cytoplasmic targets, including the pro 
inflammatory cytokines IL 1β and IL 18, which mediate repair/inflammation 
responses such as angiogenesis and neutrophil influx to remove cellular debris or 
fight pathogens (148). The mature cytokines are released from the cell by an 
secretion pathway that is currently not defined (149) but may include the P2X7 
receptor. Full length IL 33 with ~30 kDa was reported initially to be cleaved to a 
20 22 kDa product in a similar way to IL 1 and IL 18(132). 
Until recently, IL 33 was rarely detected in serum or tissue culture supernatant 
mainly due to lack of good reagents however new data concerning the 
activation/deactivation of IL 33, has provided more clarity about its secretion. 
Weak secretion of full length IL 33 has been reported in a monocyte cell line 
(THP 1 cells) in response to LPS (142). More intriguing, cell death in particular 
necrosis releases IL 33. Different groups established the fact that either 
chemical (H2O2, NaN3, Daunorubicin, TritonX100) or mechanical (scraping, 
scratching, freeze/thaw) necrosis of IL 33 expressing cells release full length IL 
33 into the media (142, 143). Further, in diseases with a high burden of cell 
death serum IL 33 was detectable. Reports state IL 33 in RA synovial fluid, SLE 
serum and serum of sepsis patients (150 152). The mechanism/pathway as to 
how IL 33 is released in such disease states remains ill defined. 
IL 33 seems to play a similar role to other signals released from injured tissues 
that trigger the homeostatic responses that promote repair and activate the 
immune system. These signals, collectively referred to as damage associated 
molecular patterns (DAMPs) or alarmins, possibly comprise quite heterogeneous 
molecules that share some functional characteristics (123). IL 33, exhibiting 
nuclear expression and release during cell death, reflects similar features to 
HMGB 1 (high mobility group box 1). In addition, HMGB1, like IL 33 is highly 
conserved in mammals. Furthermore HMGB1 deficient mice die shortly after 
birth (153) while IL 33 deficiency is embryonically lethal (personal 
communication, Dr D Gilchrist, University Glasgow, Dr A McKenzie, Cambridge 
University). In comparison, HMGB1 plays a different intracellular role as DNA 
chaperones influencing multiple processes in chromatin such as transcription, 
replication, recombination, DNA repair and genomic stability (154). Cellular 
release of HMGB1 can work in several ways. Stimulated cells can actively secrete 63 
 
HMGB1 while cell death, particularly necrosis passively releases these proteins. 
During apoptosis (programmed cell death) HMGB1 binds tightly to chromatin and 
thereby is retained in apoptotic bodies (155).  Extracellular HMGB1 delivers 
multiple signals: it behaves as a trigger of inflammation, attracting inflammatory 
cells while it promotes tissue repair by recruiting stem cells and promoting their 
proliferation. It activates dendritic cells and promotes their function to support 
antigen specific T cells and supports their polarization towards a T helper 1 
phenotype (156). To conclude, HMGB1 and IL 33 are conserved proteins, act as 
alarmins, fulfill different functions in the nucleus while promote diverse 
signaling in inflammatory cells. Nevertheless, both proteins are unquestionably 
mandatory for the function of a mammalian organism. 
1.3.5 IL-33 receptor signalling via ST2 and IL1RacP 
ST2 receptor – discovery 
The IL 33 receptor ST2 (also named T1, IL1RL1, DER4, and FIT 1) was first 
described in 1989 (157). Differential splicing leads to formation of 3 isoforms: 
transmembrane ST2, a soluble form (soluble ST2 or sST2) and a variant ST2. ST2 
is a member of the IL 1 receptor family and has 38% amino acid homology to the 
IL 1 receptor (158). Transmembrane ST2 is membrane bound with 3 extracellular 
immunoglobulin G domains, a single transmembrane domain, and an 
intracellular domain homologous to toll like receptors and other IL 1 receptors. 
Soluble ST2 lacks the transmembrane domain as well as the intracellular 
domains and is thought to act as a decoy receptor for IL 33 signaling. 
ST2 receptor - deficiency 
ST2 deficient mice are healthy and displayed no overt phenotypic abnormalities 
(159). In the initial manuscript describing ST2 deficiency, mice when challenged 
with a pulmonary parasite infection, had severely impaired levels of Th2 
cytokine production. Subsequent studies used ST2 deficient mice for multiple IL 
33 studied pathogenetic models ranging from allergy models to arthritis (more 
information below). 64 
 
ST2 receptor - expression 
ST2 is mainly expressed on mast cells and Th2 cells but not on Th1 cells (159 
161). Further expression has been detected on fibroblasts, dendritic cells and 
other stromal cells but also on endothelial cells (146, 162, 163). Recently, 
basophils have been reported to respond to IL 33 (164 166). The newest subset 
of cells expressing ST2 has been described by 2 groups. Moro et al detected new 
adipose tissue associated c Kit
+ Sca 1
+ lymphoid cells which were an innate 
source of Th2 cytokines (167). These cells express high levels of ST2. McKenzie 
and colleagues defined a new innate effector leukocyte associated with the 
intestine. These cells were lineage marker negative, highly positive for ST2 and 
IL 17B receptor (IL 25 receptor). These cells produced high amounts of IL 13 and 
therefore McKenzie and colleagues named this new entity “nuocytes” owing to 
their high level of IL 13 expression, and nu being the 13th letter of the Greek 
alphabet (168). Furthermore they demonstrated that “nuocytes” are important 
in parasite defense while Moro et al showed that their cell entity is important 
for helminth expulsion. Due to their Th2 type role, with an innate lymphocyte 
signature, Moro proposed to call these cells “natural helper cells”. In both 
papers, cells responded to IL 25 and IL 33 and produced high amount of IL 5, IL 6 
and IL 13. Further characterization of these cells (nuocytes or natural helper 
cells) is awaited. 
ST2 receptor - signalling 
Similar to IL 1 and IL 18 that require a co receptor for intracellular signalling, 
Chackerian et al, and shortly thereafter Palmer et al, identified IL 1RAcP as part 
of the IL 33 receptor complex with ST2 (169, 170). In vivo, IL 1RAcP deficient 
mice did not respond to IL 33 treatment compared to wildtype controls (169). 
Interestingly, soluble IL 1RAcP enhances the ability of sST2 to inhibit IL 33 
signalling (170). Signal transduction in ST2 and IL 1RAcP is mediated via the TIR 
domains. Binding of IL 33 to the IL 33R complex results in recruitment of the 
adaptor proteins myeloid differentiation factor 88 (MyD88) and other numerous 
activation proteins with downstream nuclear factor κB (NF κB) activation; thus 
IL 33 uses the same signaling components as IL 1 (Figure 1.9). Briefly, the 
recruitment of MyD88 leads to the recruitment of IL 1R associated kinase (IRAK) 
1 and IRAK4 and TNFR associated factor 6 (TRAF6) (132, 171). MyD88 is essential 65 
 
for IL 33 signalling as MyD88 deficient mice do not respond to IL 33 
administration (169). IL 33 stimulation also leads to phosphorylation of inhibitor 
of NF κB (IκBα) as well as the kinases Erk1/2, p38, and JNK(132).  
More insights in signalling cascades for MyD88 downstream pathways are 
summarized by Professor Luke O’Neill (172): 
-  MyD88 recruits IRAK1 and IRAK4; IRAK4 phosphorylates IRAK1 
-  IRAK1 phosphorylates Pellino 1 (E3 ligase), this leads to IRAK1 
polyubiquination 
-  further recruitment of NEMO
1/IKK1
2/IKK2 complexes 
-   polyubiquitination of TRAF6 with TAK1
3 recruitment to the NEMO/IKK1/IKK2 
complex 
-  activation of IKK2 by TAK1 
-  TAK1 also couples to the upstream kinases for p38 and JUN N terminal 
kinase 1 (JNK). 
 
This intracellular activation cascade by IL 33 (or IL 1) is likely to be more 
complex, however (172). Furthermore in mast cells, IL 33 triggers Ca
2+
 influx by 
the activation of phospholipase D and sphingosine kinase (173).  
Although ST2 receptor signaling is understood in the broad context, it is not 
clear, why signaling cascades through MyD88 by different receptors lead to 
different cellular responses. Difficulties in determination of all variables still 
hinder these insights. 
                                         
 
1 NEMO: NF-κB essential modulator (a scaffold protein) 
2 IKK: inhibitor of NF-κB (IκB) kinase 
3 TAK1: transforming growth factor β-activated protein kinase 66 
 
 
 
Figure 1.9 IL-33 binding to ST2 and IL1RacP signals via MyD88 
Schematic overview for binding and signalling of IL-33: nuclear IL-33 is released by 
necrosis and binds to ST2 which leads to recruitment of IL-1RAcP, MyD88, IRAK1, IRAK4. 
TRAF6 is necessary for recruitment of IRAK. This signalling complex leads through further 
events to activation of NF-κB and p38 and JNK pathways. These pathways induce gene 
expression leading to cytokine and chemokine synthesis. 67 
 
1.3.6 Cellular biological functions of IL-33 
Initially IL 33 biology has been reported to stimulate Th2 cell and mast cells 
which both highly express ST2. IL 33 drives production of Th2 cytokines in in 
vitro differentiated Th2 cells but not Th1 cells with high levels of IL 5 and IL 13 
expressed, but intriguingly not IL 4 (132). Further it acts as chemoattractant for 
human Th2 cells (174). IL 33 also stimulates NK and NKT cells to produce IFN γ 
(175). DCs express low levels of ST2; however, upon stimulation with IL 33, DC 
can induce Th2 cytokines in CD4 T cells (163). 
Mast cells are by far the most studied and responsive cell to IL 33 stimulation. 
Tissue and mucosa associated mast cells with high levels of ST2 expression fulfill 
the role of tissue guardians with the inherent capacity to respond quickly to IL 
33 expression. Mast cells that are capable of producing multiple cytokines react 
to IL 33 stimulation with production of IL 5 and IL 13, but also IL 1, IL 6, TNF α 
and other chemokines. IL 33 also induces the degranulation of IgE primed mast 
cells in vitro and in vivo and enhances mast cell maturation and survival 
(reviewed in (176)). In co cultures, fibroblast derived IL 33 can also regulate 
tryptase expression on mRNA and protein level (177). Interestingly, IL 33 also 
drives production of IL 17 in these cells (personal communication, Dr A 
Melendez, University of Glasgow). 
Three reports describe basophils and their response to IL 33 (164 166). Schneider 
et al studied murine basophils and found that cells express ST2 and respond in 
an unprimed state with the production of IL 4 and IL 6 (165). In vivo indirect 
increase of GM CSF and IL 5 promoted expansion of basophils. In humans, 
Smithgall et al and Suzukawa et al confirmed ST2 expression in basophils (164, 
166). Stimulated with IL 33, these cells produced IL 4, IL 5, IL 6 and IL 13 and 
increased their adhesive function. 
High endothelial venules express IL 33; however, its biology therein is unclear. 
An elegant study by Kuchler et al demonstrated that IL 33 is globally expressed 
in nuclei of vascular endothelium in normal human tissues staining vessels in 
human skin, small intestine, umbilical cord and lung (178). This group further 
shows in vitro that vascular IL 33 is downregulated by proinflammatory cytokines 
IL 1β, TNF α and VEGF. More surprisingly, IL 33 is strongly down regulated in 68 
 
endothelium undergoing tumor or wound healing angiogenesis. These findings 
stand opposite to fibroblast data, where IL 1 and TNF α upregulated IL 33 (146). 
However, cell type and stromal origin could explain this difference, but also 
culture conditions as Kuchler et al used superconfluent cultures of human 
umbilical vein endothelial cells (HUVECs) and Xu et al used synovial fibroblasts 
with ~80% confluency.  
In contrast to IL 33 expression in endothelial cells, Choi et al studied the 
response of HUVECs to IL 33. They reported that IL 33 has a significant effect on 
angiogenesis and vascular permeability by rapidly increased endothelial nitric 
oxide (NO) production (179). Overall, a more careful dissection of the role of IL 
33 in endothelial cells is required. 
1.3.7 Regulation of IL-33 
Nearly all IL 1 family members are potent cytokines with powerful downstream 
effects. Signalling occurs through a receptor pair sequestering the primary 
receptor. Similar to IL 1 and IL 18 where IL 1RA or IL 18 binding protein can 
block signalling, the soluble form of ST2 (sST2) is thought to act as a decoy 
receptor. Soluble ST2 is increased in multiple inflammatory conditions (151, 180 
182). On a cellular signalling basis, ST2 signalling is counter regulated by TIR8 
also known as single Ig IL 1 receptor related molecule (SIGIRR). This receptor 
belongs to the TLR/IL 1R family, has a single extracellular Ig domain, a long 
cytoplasmic tail and a TIR domain (183). This receptor remains orphan. 
However, it inhibits TLR/IL 1R signalling and NF κB activation (184). SIGIRR 
inhibits direct IL 33 signalling in vitro and IL 33 responses in SIGIRR deficient 
mice are more severe (185).  As mentioned above, depending on the context 
proinflammatory cytokines can downregulate IL 33 in endothelial cells, while on 
the contrary can also upregulate IL 33 in fibroblasts. The mode of action remains 
unclear. 
1.3.8 IL-33 in disease 
Mice treated with IL 33 exhibit splenomegaly, blood eosinophilia and increased 
levels of IgA and IgE. This relates to a Th2 phenotype with increased IL 4, IL 5 
and IL 13 (132). Also anatomical changes of stomach and mucus  and bile filled 69 
 
duodenum as well as lung were observed with recruitment of myeloid cells and 
epithelial reaction with either hyperplasia (esophagus) or massive mucus 
production (lung). In contrast, IL 33 administration was beneficial in a model of 
atherosclerosis (186). In ApoE deficient mice fed on a high fat diet, injection of 
IL 33 significantly reduced atherosclerotic lesions in terms of size and leukocyte 
infiltration. Also serum levels were increased for IL 4, IL 5 (especially) and IL 13 
with decrease of IFN γ suggesting a switch from a Th1 to Th2 phenotype. This 
atheroprotective effect could be blocked with anti IL 5 suggesting rather 
indirect effect whereby IL 33 operated via modulated IL 5 production. IL 33 also 
induced antioxidized low density lipoprotein (ox LDL) antibodies which are 
thought to be atheroprotective. Interestingly, it has also been shown that IL 
33/ST2 signaling is a crucial biomechanically activated system that controlled 
cardiomyocyte hypertrophy and cardiac fibrosis after pressure overload (187). 
Soluble ST2 levels also negatively correlate with survival and directly with 
cardiac injury and microvascular injury post myocardial infarction (188). 
Th2 cells play an important role in allergy but also in allergic asthma. Expressing 
high levels of ST2, IL 33 was speculated to drive allergic airways inflammation. 
Indeed, IL 33 is higher expressed in asthma patients than in controls (189). In 
contrast to the adaptive immune response in asthma, ST2 is also highly 
expressed on mast cells and lead to Th2 cytokine production, which both play a 
crucial role in allergy. This adaptive/innate axis of IL 33/ST2 signalling may 
influence triggering of disease. In support to this sST2 levels are elevated in 
asthma patients with acute exacerbations with the assumption that the decoy 
receptor tries to counter regulate IL 33 pathologic signals (182). Also high levels 
of serum IL 33 were detected in patients with atopic dermatitis during 
anaphylaxis (173). Administration of IL-33 exacerbates experimental asthma and 
induces features of asthma in animals. Furthermore blocking ST2 or IL-33 
attenuates disease in some models (176). More evidence is emerging that 
allergic IL 33/ST2 pathology is antigen mediated with induction of antigen 
specific IL 5 expressing T cells (190). Even more strikingly is the fact, that a SNP 
in a region flanking IL33 is associated as risk factor for asthma in a large scale, 
consortium based genome wide association study (191). 
With expression of IL 33 in the gastrointestinal mucosa Pastorelli et al studied 
the IL 33/ST2 axis in inflammatory bowel disease. In ulcerative colitis (UC) 70 
 
patients they detected higher expression of IL 33 compared to healthy controls 
or patients with Crohn’s disease (CD) (192). Anti TNF therapy downregulated 
serum IL 33 and increased the amount of sST2. High expression in UC patients 
was confirmed by Kobori et al (193). 
In psoriasis IL 33 has also been reported to be upregulated (194). Subcutaneous 
administration of IL 33, however, leads to skin fibrosis with a Th2 fingerprint 
infiltrate (195). Moreover, skin of atopic dermatitis patients have elevated IL 33 
levels compared to controls (173). With psoriasis mainly considered as a 
Th1/Th17 disease, fibrosis and atopic dermatitis as Th2 disease these data have 
confused rather than clarified the role of IL 33 in the epithelium. 
With this paradoxical switch, autoimmune arthritis supports the proinflammatory 
Th1/Th17 supporting role of IL 33. IL 33 and ST2 are expressed in inflamed 
synovium of RA patients (136, 145, 146). Synovial fibroblasts (FLS) in culture do 
not express IL 33, however, when stimulated with IL 1 and TNF α, FLS 
upregulate IL 33 in vitro providing a highly responsive cell in a TNF environment 
like RA. Moreover, Fraser et al demonstrated that autoimmune arthritis patients 
(RA, PsA, gout) have high sST2 levels in the synovial fluid compared to OA (180). 
Also elevated levels of IL 33 have been reported (150). In a mouse model of RA, 
collagen induced arthritis was diminished in ST2 deficient mice (146). In 
addition, CIA mice treated with recombinant IL 33 led to exacerbation of 
disease. This had no effect in ST2 deficient mice. Furthermore, reconstituting 
ST2 deficient mice with mast cells (expressing normal levels of ST2) again led to 
exacerbation of arthritis (146). This supports the important role of mast cells in 
proinflammatory cytokine production. It is interesting, that despite the Th2 
profile of mast cells, secretion of proinflammatory cytokines like IL 1, IL 6 and 
IL 17 can bias the balance to a Th1/Th17 autoimmune phenotype. It is 
noteworthy, that Raza et al and Kokkonen et al detected increased Th2 cytokine 
patterns before onset of RA disease (107, 196). The potency by which IL 33 
increases severity of CIA was confirmed by Palmer et al using anti ST2 antibodies 
(145). Furthermore they showed a decrease in IFN γ as well as IL 17 production 
in the draining lymph nodes. Therefore IL 33 clearly drives Th1/Th17 responses 
in experimental arthritis. This is confirmed by higher levels of IFN γ and IL 17 in 
the IL 33 treated CIA mice (146). Focussing on autoantibody induced arthritis 71 
 
(AIA), IL 33 exacerbated arthritis, where AIA in ST2 deficient mice developed 
attenuated disease (197). 
A proof of how important the IL 33 immune axis has become in terms of future 
therapeutics, is evidenced by the patent application from Medimmune (198). In 
their application, authors patent the invention of IL 33 specific binding 
polypeptides and compositions binding IL 33 such as antibodies. Furthermore 
they state possible treatment options for diseases and disorders such as asthma.  
The cardiology field provides the IL 33/ST2 story from a totally different 
perspective. Sanada et al showed that IL 33/ST2 plays a crucial role in 
cardioprotection (187). With the observation that mice with myocardial 
infarction have increased levels of serum ST2 different groups used sST2 as a 
possible outcome biomarker after myocardial infarction (188, 199). Weir et al 
showed significant correlation with sST2 and left ventricular ejection fraction (a 
measurement for heart function) and also observed a relationship with infarct 
size using cardiac magnetic resonance imaging (MRI). IL 33 and ST2 are 
expressed by vascular endothelial and vascular smooth muscle cells of the heart 
and aorta in mice and humans (186). Therefore, cardiac infarction may lead to 
IL 33 release with subsequent release of sST2 to counteract possible IL 33 
immune mediated effects. In regard to this hypothesis incidences with (IL 33 
containing) cell death would result in release of sST2. Indeed, when focusing on 
sepsis patients cell death can occur on different levels such as organ failure. In 
these patients serum IL 33 is increased but also sST2 (152, 200). Alves Filho et al 
demonstrated that IL 33 reduces mortality in mice with experimental sepsis by 
restoring neutrophil migration abilities (152). Patients who did not recover from 
sepsis had significant higher levels of sST2. Is it possible that sST2 is 
unspecifically released due to severe endothelial stress? A different option would 
be that sST2 is released to limit the alarmin effect and thereby blocks the 
normal protective effect of IL 33. This would allow pathology and comorbidity to 
emerge in patients in whom IL 33 is involved in pathology such as asthma or RA. 
To conclude what role sST2 plays in these life threatening incidences such as 
myocardial infarction or sepsis is still unclear. 
How IL 33/ST2 in epithelial cells might influence inflammation will be addressed 
in this thesis. 72 
 
1.4 Nanoparticles in inflammation 
So far, an introduction to the clinical challenge for treatment of autoimmune 
diseases exemplified on psoriasis, PsA and RA has been given. More insights in 
the immunological network underlying the aberrant functions and subsequent 
causes have been provided. Especially I focused in this network on two cytokines 
(IL 17 and IL 33) for their central role and novelty. While the clinical and 
scientific community focuses on more early detection of  autoimmune diseases 
or even at a stage “pre disease” to prevent initiation of the autoimmune 
response and further long term damage, techniques are lacking in its sensitivity 
and resolution.  
Thus this section introduces how we can utilize nanoparticles as novel 
technical equipment to image on a cellular level to detect subclinical 
inflammation. 
 
Dysregulated inflammation is a feature of a wide variety of human diseases 
including autoimmune, infectious, neurological, cardiovascular and metastatic 
conditions. Detection of such inflammation at an early, subclinical stage is 
critical for informing decisions relating to the necessity and intensity of therapy 
and to subsequent prediction of outcomes. In the above sections cytokines have 
been introduced and context provided how simple triggers can misbalance this 
sensitive system and lead to further consequences such as autoimmune disease. 
To image inflammation and in particular cytokines on a cellular level could be a 
powerful tool to diagnose diseases at early stages at which long term damage to 
the body not happened yet. 
Although a wide range of imaging options exist including X ray, ultrasound, 
magnetic resonance imaging (MRI), computer tomography (CT), positron emission 
tomography (PET), and single photon emission computer tomography (SPECT), all 
of which have led to improvements in sensitivity and specificity, these 
techniques are  expensive and often limited in their ability to detect early 
subclinical inflammation (201). Recent developments in the design and 
application of nanoparticles could offer high resolution information rich imaging 73 
 
(possibly in real time) that can facilitate diagnosis at a pre clinical stage 
previously unachievable with existing technologies. 
1.4.1 What are nanoparticles? 
Nanoparticles (NPs) are often defined as materials with at least one dimension 
of 0.1   100 nm (Figure 1.10). The chemical composition of nanoparticles range 
from coinage metals through chemical polymers such as polyethylene glycol 
(PEG) to inorganic nano dyes such as quantum dots (colloidal semiconductor 
nanocrystals i.e. cadmium selenide, cadmium sulfide and indium phosphide) to 
compounds similar to liposomes (phospholipid bilayers). The important 
properties of NPs including surface charge, size, and solubility have varying 
effects on immune cells (202). Surface charge in particular can affect toxicity, 
binding to plasma proteins, particle clearance and immune cell stimulation. Size 
can play a role with divergent biologic effects mediated upon Th1/Th2 
stimulation, adjuvant properties, phagocytic uptake and particle clearance 
based on size properties alone. 
Different subjects use the term nanoparticle and the paradox between 
nanoparticles termed in toxicology and pharmacology needs to be addressed. In 
the field of toxicology mainly combustion derived nanoparticles are studied in 
regard to their effect on lung inflammation and toxicity (203). 74 
 
 
Figure 1.10 Nanoparticle – size comparison75 
 
Virtually all forms of synthetic nanoparticles are designed to have some kind of 
chemically modifiable surface offering potential for attachment of a wide 
variety of ligands. This has the effect of turning the nanoparticle into a biologic 
nanosensor, a nanoscale fluorescent tag, or a drug delivery vehicle. Modifying 
the surface chemistry of nanoparticles also plays an important role in the organ 
distribution and the half life of nanoparticles in vivo. Unmodified nanoparticles 
are quickly removed from the bloodstream by macrophages. Early studies with 
macrophages suggest that this process may have a preference for larger 
nanoparticles (204). The adsorption of plasma proteins to the surface, largely 
thought to be caused by the surface charge or hydrophobicity, is also thought to 
make the nanoparticles more susceptible to phagocytosis (205). The most 
common method of improving the in vivo characteristics of nanoparticles is to 
‘block’ the surface, commonly by PEGylation. Blocking has been shown to 
increase the half life of nanoparticles in blood, probably by preventing plasma 
protein binding. Conjugation of the PEG with a drug showed in some examples 
increase of half life as well a reduction in toxicity. For example, the half life of 
the recombinant cytokine GCSF, which is given daily for 2 weeks to patients 
after chemotherapy for neutropenia, is increased by PEGylation; only a single 
application was needed compared to the non PEGylated GCSF (206).  
The major advantage in the use of nanoparticles is the almost unlimited array of 
modifications possible. The breadth of NP modifications can facilitate selection 
of particular target cells, act as biosensors, work as drug delivery systems, guide 
surgical procedures and sense/signal molecular responses to therapeutic agents. 
The niche of “nanomedicines” has been elegantly reviewed recently (206).  
Gold nanoparticles bind strongly to thiols and amines. Tsai et al. demonstrated 
that this binding explains observed improvement of arthritis in a rat model. In 
their paper they mainly focused on the binding capacities to VEGF, however, it is 
known that these nanoparticles also bind to other plasma proteins. Interestingly, 
by PEGylation of gold nanoparticles the binding is prevented and the induced 
arthritis not ameliorated (207, 208). 
Depending on the type of nanoparticle used and surface functionalisation 
selection NPs can be traced by a number of different methods that include MRI, 
PET, fluorescent microscopy and, recently surface enhanced Raman 76 
 
spectroscopy (SERS). In the last 10 years imaging in inflammation has advanced 
significantly by utilizing such advances in detection techniques and the next 
major step towards high resolution, molecular imaging is likely to involve 
coupling the existing techniques available with novel nanoparticles techniques 
under development. 
1.4.2 Magnetofluorescent nanoparticles 
Many of the significant advances in imaging with NPs have been achieved by the 
use of magnetic nanoparticles (MNP). The MNPs most commonly used in in vivo 
studies are iron oxide coated NPs whose superparamagnetic core affords the 
ability to easily distinguish between different tissue types using magnetic 
resonance imaging.  Iron oxide nanoparticles have been in use as contrast agents 
in MRI since 1990 and are particular useful owing to their capability for deep 
tissue imaging, their low toxicity and their lack of relevant immunogenic 
properties.  A recent advance has seen MNPs linked to a fluorescent marker 
enabling enhanced ex vivo analysis. Compared to other non nanoparticle based 
techniques of imaging, e.g. PET analysis with radio labelled cells or 
bioluminescence using luciferase, coated cells, MRI has its greatest advantage in 
spatial resolution and non invasiveness.  PET and bioluminescent cell imaging 
are both capable of sensitive in vivo imaging, but present substantial drawbacks. 
PET is not suitable for all studies owing to the opportunity cost of using a radio 
isotope against potential diagnosis and the high cost to produce the necessarily 
short lived radionuclides. Bioluminescent cells require expensive ultrasensitive 
detection systems because the amount of light emitted is typically very small. 
MNP have been used in two ways, namely attached to immune cells actively 
targeting sites of inflammation or passively untargeted by monitoring their 
localisation driven by vascular leakage and / or uptake by phagocytic cells.  
Protocols now exist to facilitate labeling of specific subsets of leukocytes e.g. 
circulating T cells with linked magnetofluorescent nanoparticles (209). How 
inflammation in autoimmune diabetes, atherosclerosis and brain inflammation 
could be monitored using these approaches will now be considered.  77 
 
Imaging autoimmune diabetes 
Type 1 diabetes is an autoimmune disease that includes lymphocytic infiltration 
of pancreatic islets. Autoreactive T lymphocytes target insulin producing β cells 
thereby leading to hyperglycemia and thereafter to diabetes. Extensive tissue 
damage and consequent endocirine deficiency and metabolic compromise is at 
this stage irreversible and therefore immune therapeutic options are distinctly 
limited (210). Thus a major goal is to identify patients with preclinical 
autoimmune diabetes for early initiation of therapy and limit further damage. At 
this stage it is possible that immune tolerance could be reinstated to prevent 
disease forthwith. 
A variety of diabetes models are available including nonobese diabetic mice 
(NOD mice), BDC2.5/NOD mice (BDC2.5 TCR Tg, transgenic TCR which recognizes 
an islet β cell antigen) to study inflammation before and at the onset of disease 
by various non invasive approaches. Weissleder and colleagues injected long 
circulating MNP with a size of ~25nm in NOD mice and were able to show 
microvascular leakage in the inflamed pancreatic tissue over time. MNP leaked 
into the tissue and were longer detectable, most likely phagocytosed by 
macrophages (211). Further, by depleting T cells with anti CD3 antibody the 
observed leakage was reversible in therapy responders (212).  The majority of 
untargeted NPs are taken up by the reticulo endothelial system (RES) of liver 
and spleen; unfortunately in these reports values to document uptake, 
quantities or time course of entry to these organs were not disclosed, or possibly 
measured. Nevertheless, these studies suggest that MNP detection could 
function as an early predictor for monitor treatment response and need of 
intervention. 
In a further significant study, Moore et al. focused on tracking autoreactive 
diabetogenic CD8
+ T cells in vivo.  They used dextran superparamagnetic iron 
oxide nanoparticles and coated these MNP with a high avidity peptide 
recognized by the TCR of diabetogenic T cells. Co incubating T cells and MNP in 
vitro resulted in internalization of MNPs into the T cells. Further, these antigen 
specific trackable T cells were injected into NOD.scid mice and over time, 
labeled cells accumulated in the pancreas. Interestingly, no changes were 
observed in the spleens or livers of the same mice (213). This method nicely 78 
 
demonstrates the ability to track autoimmune cells in vivo. However, it is 
entirely dependent on the knowledge of the islet antigens recognized by 
autoreactive T cells   most such antigens are unknown in the context of human 
autoimmune diseases. Although highly specific therefore this approach can not 
be applied to human diseases as yet although it gives a clue as to the rich 
potential in the technology. Translation of this promising novel tool into humans 
depends on its safety in regard to immune interaction (hemolysis, 
thrombogenicity and complement activation) and trials are awaited. 
Imaging artherosclerosis 
Artherosclerosis comprises a disease of interaction between lipid dysregulation 
and local inflammatory processes in the targeted blood vessel wall. 
Atherocslerotic plaques are characterized by invasion of macrophages into the 
lesion leading to further cytokine secretion, amplification of local inflammation 
and subsequently to destabilisation of the plaque with plaque disruption. 
Magnetofluorescent imaging in arthrosclerosis takes advantage of the property of 
NPs being phagocytosed by macrophages. 
Nahrendorf et al. designed a tri reporter NP for use in fluorescence, MRI and 
PET. Interestingly, these NP accumulated predominantly in the liver, followed by 
intestine, kidney, lung and spleen. However, the striking observation was the 
enhanced accumulation of NPs in atherosclerotic lesions in the apolipoprotein E 
deficient mouse model compared to normal mice. It was also possible to 
colocalize NPs with Mac 3 (a macrophage marker) ex vivo indicating uptake of 
NPs by macrophages (214). Despite the elegant method used in this study, broad 
clinical use is unlikely due to lack of PET access and the relative non specificity 
of the particles employed. In other studies, in the atherosclerotic plaque, 
fluorescent NPs could colocalize macrophages and markers of osteogenesis (see 
below) (215). 
Brain inflammation 
Two models of brain inflammation have been studied, namely experimental 
autoimmune encephalomyelitis (EAE, a model for multiple sclerosis) and acute 
inflammation after cerebral ischemia. Brochet et al used non targeted 79 
 
ultrasmall super paramagnetic iron oxide particles (USPIO) (20 – 40 nm), similar 
to the MNP described above to study a relapsing model of EAE. With the 
assumption that USPIO are taken up by macrophages, lesions were monitored at 
the first clinical phase by MRI. Interestingly, rats with USPIO positive lesions had 
more severe clinical disease in the second phase (216). More specific is the 
approach chosen by McAteer et al (217). In a model of acute brain inflammation 
interleukin 1 (IL 1) was stereotactically injected into the left striatum of the 
brain to induce endothelial activation. After activation, endothelial cells 
upregulate vascular adhesion molecule 1 (VCAM 1) on their luminal cell surface. 
Leukocytes are then recruited via the ligand α4β1 integrin. Microparticles of iron 
oxide linked to antibodies against VCAM 1 bound specifically to activated brain 
endothelium, compared to IgG controls (217). This concept demonstrates 
selective targeting of inflammatory sites within the CNS, typically a challenging 
region in which to define cellular or molecular expression, since relevant tissue 
biopsies are rarely achievable. 
Recently, a new method of fluorine magnetic resonance imaging has been 
described employing biochemically inert nanoemulsions of perfluorocarbons 
(PFCs). The fluorine isotope 
19F is MR active and as sensitive as 
1H MRI. PFC 
nanoemulsions are taken up by phagocytic cells and thus inflammation in brain 
ischemia or cardiac infarction can be demonstrated in mouse models. Cardiac 
infarction was induced by ligation of a coronary artery and infiltration of PFCs 
was monitored 4 days after ligation. Focal brain ischemia by photothrombosis 
leaded to infiltration of PFCs examined 7 days after induction. Ex vivo imaging 
proofed that rhodamine labeled PFCs showed uptake in monocytes, macrophages 
and B cells in vivo. The majority of accumulation occurred in the liver although 
no obvious biologic effects appeared to result (218). 
In summary, MNP or MR active nanoemulsions provide feasible approaches to the 
detection of inflammation in humans with easy applicability to MRI. It should be 
noted that since current research using an untargeted approach, nonspecific 
accumulation of nanoparticles in organs such as the liver, kidney and spleen can 
occur. 80 
 
1.4.3 Fluorescent nanoparticles 
To date, fluorescent imaging is only of use ex vivo or via intravital microscopy 
owing to the limited and therefore superficial penetration of tissue.  Using 
shorter wavelengths of excitation often required tends to promote background 
autofluorescence. In addition increased light scattering limits depth penetration 
making deep tissue imaging problematic. Intravital microscopy is an invasive 
procedure requiring high technical skills and expensive equipment. Furthermore, 
this method only focuses on small areas of interest; however, the sensitivity on a 
cellular level is outstanding compared to the other imaging techniques. An 
example of this method is the 3 dimensional imaging of fluorescent lymphocytes 
trafficking into an atherosclerotic plaque (219). A different approach combines 
two nanoparticles, namely an iron oxide fluorescent nanoparticle (MNP linked to 
a near infrared fluorescent dye), which is taken up by macrophages and a 
bisphosphonate derivatized near infrared fluorescent polymer nanoparticle 
which detects an osteogenesis like pre stage vascular calcification. Reports 
suggest that proatherogenic stimuli promote conversion of vascular 
myofibroblasts into osteoblastic cells which can eventually lead to calcification. 
Using intravital microscopy of the carotid artery in an atherosclerosis prone 
apolipoprotein E deficient mouse, it has been demonstrated that osteogenesis is 
associated with inflammation. Pre stage calcification was detectable with 
fluorescent microscopy compared to a negative micro CT analysis (215). 
Recently, the use of nanosize semiconductor quantum dots (QD) has shown 
benefits compared to conventional organic dyes. QDs are superior in brightness 
due to good quantum yields and often exhibit greater photostability as they do 
not rely on organic conjugated double bond systems that are prone to photo 
initiated degradation. Linked to different target specific antibodies, QD 
conjugates for imaging inflammation have only been tested ex vivo in a model of 
inflammatory colitis (220). However, a liposome QD complex conjugated with a 
tumor detection antibody (HER2) demonstrated the feasibility in a tumor 
xenograft mouse model imaged with a fluorescent camera (221). Still, this 
method is lacking spatial resolution. Zinselmeyer et al report a future possibility 
to track inflammation with QDs. Using 2 photon imaging of a mouse footpad 
demonstrates the feasibility of real time imaging of fluorescent labeled 81 
 
leukocytes. With the footpad being accessible for imaging, this work proves a 
method with excellent spatiotemporal resolution (222). Further studies are 
ongoing in this area to refine technologies and correlation with biologic 
pathways. 
1.4.4 Surface-enhanced Raman spectroscopy (SERS) 
Surface enhanced Raman scattering (SERS) is a highly sensitive spectroscopic 
technique in which narrow vibrational signatures (~0.5 nm) from suitable 
molecules are enhanced enormously (~10
6 to ~10
14) by close proximity to areas 
of high electric field, such as those generated at the surface of metal 
nanoparticles under suitable illumination. At present, this method has only been 
used in imaging of a cancer mouse model (223, 224). SERS active nanoparticles, 
in the study a gold particle linked to a Raman active dye, release a distinct 
signal upon excitation, which in comparison the other fluorescent dyes (e.g. 
QDs) is highly specific and ideally suited for multiplex analysis. In a tumor mouse 
model, where the tumor expressed high amount of EGF receptor, these SERS 
nanoparticles functionalized with EGF receptor antibody were measurable in the 
tumor tissue compared to untargeted particle controls. In common with other 
studies most of the particles accumulated in liver and spleen, interestingly, only 
the tumor targeted conjugates found their way to the tumor (223). This 
approach could be confirmed by Gambhir and colleagues using single walled 
carbon nanotubes (SWNTs) linked with a tumor specific arginine glycine asparate 
(RGD) peptide. This RGD peptide binds to angiogenic overexpression of αvβ3 
integrin in various tumor cells. SERS signals from peptide targeted SERS active 
nanotubes could be detected in subcutaneous tumor cell inoculated mice 
compared to untargeted SWNTs (224). Thus, demonstrating feasibility of SERS 
nanoparticle detection in cancer this approach could represent a future 
application in imaging of inflammation. 
In summary, using the nanoparticle delivery/imaging system provides an 
effective tool to target processes in inflammation, drug target and cytokine cell 
interaction. 82 
 
1.5 Aims of this thesis 
A variety of cells have been described to produce IL 17A. In tissue, the net IL 
17A expression may arise from a broad array of adaptive and innate cells. This 
cytokine plays a vital role in protection against bacterial, fungal and viral 
pathogens. Opposite to this is a novel cytokine named IL 33. Nuclear expressed 
and associated with body barriers it is released due to cell damage and 
biological function composes features of an alarmin. 
In this work I sought to define the role for inflammatory and regulatory cytokines 
in autoimmune disease with a focus on the novel entities IL 17A and IL 33. 
Further I sought to define their effector biology and to thereafter investigate a 
novel bioimaging modality to move the diagnostic and effector biology forward. 
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2  Material and Methods 
2.1 General reagents & buffers 
2.1.1 Materials and reagents 
General chemicals: All chemicals were purchased from Sigma (UK) unless 
otherwise stated. 
Plastics: All plastics used for cell culture were purchased from Corning and 
Gibco unless otherwise indicated. 
2.1.2 Buffers and culture media 
Complete media: Basic media: RPMI1640, DMEM or IMEM 
plus 
10% heat inactivated foetal bovine calf serum, Penicillin (100 units/ml), 
Streptomycin (100  g/ml) and L Glutamine (2mM) (all at final concentration 
from Invitrogen). 
PBS: Phosphate buffered saline was purchased from Invitrogen. 
Tris acetate EDTA (TAE) buffer: 50x stock: 242 g of Tris base in 750 ml dH2O. 
Mixed with 57.2 ml glacial acetic acid and 100 ml 0.5 M EDTA (pH 8.0). Final 
volume was made up to 1000 ml with dH2O. Buffer was used at 1x concentration. 
TBS Tween (TBST): 10x TBS buffer was made using: 876.6 g NaCl, 121.1 g Tris, 
40 ml HCl and adjusted to pH pH 8.0. 10x solution was diluted 1:10 with dH2O 
and 0.05% Tween added. 
2.2 Patients 
Glasgow Royal Infirmary Research Ethics Committee granted approval for 
sampling of peripheral blood, synovial fluid and synovial tissue for cytokine and 
inflammation analysis in June 2000. Patients with RA, PsA, AS and OA, who were 84 
 
greater than 18 years of age and capable of providing informed consent, were 
invited to take part in the project. Such patients were identified from the 
Rheumatology Clinics in North Glasgow Trust, Glasgow Royal Infirmary. Further 
samples from consented patients undergoing arthroplasty (Orthopedic units 
Royal Infirmary and Southern General, Glasgow and Department for Plastic 
Surgery, Royal Infirmary, Glasgow) were transferred to the research unit. Tonsils 
were used as control tissue and were obtained by Mr Simpson, Stobhill Hospital, 
Glasgow. Demographic data were collected and stored in a password protected 
database and samples were blinded to the researchers. Diagnosis of RA and PsA 
are defined by classification criteria described in the introduction. 
2.3 Skin biopsy 
Patients with active psoriatic plaques were identified in the Dermatology 
department (Dr David Burden, Western Infirmary) or Psoriatic arthritis clinic 
(Rheumatology, Royal Infirmary). Having identified a suitable plaque avoiding 
the cape area, the skin was cleansed using chlorhexidine gluconate. Thereafter 
1% lidnocaine with 1:200000 adrenaline was injected into the subdermis. A 5mm 
core punch was then made using a punch biopsy instrument in the affected skin 
(lesion) as well as 1 cm away in skin appearing macroscopically healthy 
(perilesional). A skin hook and scalpel were used to lift the skin cone from the 
subdermis. The skin was then sutured using 1 2x 4.0 Ethilon sutures and a dry 
Mepore dressing was applied. The incision site was observed for 30 minutes for 
bleeding. Patients were asked to attend their local GP practice nurse for suture 
removal at 7 10 days.  
2.4 Tissue preparation  
For cell harvest, explant tissue was transferred to complete medium and 
cultured at 37
oC in 5%CO2/95% O2 to generate fibroblast like synoviocytes (FLS) 
following prolonged incubation and passage of cells. 85 
 
2.4.1 Paraffin embedded tissue 
Tissue sections were prepared and stored for future analysis of tissue protein 
e.g. cytokine expression by immunohistochemistry (IHC). For paraffin embedded 
sections, tissue was stored in formalin for 24 h and transferred to 70% ethanol to 
retard the fixation process. Tissues were paraffin embedded and subsequently 
cut to thickness of 5  m. A minimum of 2 sections were mounted on one slide to 
facilitate isotype staining on the same slide in IHC protocols. For back to back 
sections, single sections were mounted on a slide with the next section being 
used on a different slide having the same surface in common. Sections for 
isotypes were added subsequently. Haematoxylin and eosin (H&E) staining was 
performed on one of the serial sections to allow tissue morphology to be 
assessed.  
2.4.2 Frozen tissue 
Tissues (liver and spleen from mice) were snap frozen in liquid nitrogen in OCT 
(Tissue Tek) and 6mm cryostat sections were cut onto silane coated slides using a 
microtome and stored at –70°C. Briefly, sections were rehydrated in PBS then 
fixed in ice cold acetone/ethanol (75%/25%) at room temperature for 10 min. 
The sections were air dried, then rehydrated in PBS, further washed in water 
and counterstained using Harris’s haematoxylin (BDH Ltd. Lutterworth, 
Leicester, UK). After a final wash, sections were dried for 5 mins, mounted with 
either Cytoseal (Richard Allan Scientific) or Vectashield (Vector) and coverslips 
were sealed with nail varnish. For some experiments, sections were transferred 
subsequently to Strathclyde University for further SERRS analysis (see 
nanoparticle chapter 5).  
2.5 ImmunHistoChemistry (IHC) of paraffin embedded 
sections 
2.5.1 Single staining for light microscopy 
Sections were prepared as previously mentioned (see section 1.3.1). Slides 
containing paraffin embedded sections were heated to 65°C for 35 minutes 86 
 
followed by dewaxing in xylene and rehydration through ethanol to TBS Tween 
(TBST). Endogenous peroxidase activity was blocked using H2O2/methanol 
(5%/95%). To expose the relevant antigen, sections were then microwaved in 
0.5M citrate buffer, pH 6 for 8 min. The sections were blocked for 1 h at RT in 
2.5% serum TBST of the species in which the secondary antibody was raised. The 
relevant primary antibody was applied overnight at 4°C 2.5% serum TBST (see 
working concentrations and companies in Table 2.1, page 88). The following day 
the sections were washed with TBST, incubated with relevant secondary 
antibody for 30 minutes in 5% horse serum containing TBST, washed twice with 
TBST then incubated with substrate Vector ABC (Vector, Peterborough, UK) for 
30 minutes. Sections were washed twice with TBST before developing with 
0.6mg/ml 3,3’ diaminobenzidine tetrahydrochloride (DAB) (Sigma) with 0.01% 
H2O2 for up to 5 min at RT until brown reaction product was apparent. Sections 
were then washed in water and counterstained using Harris’s haematoxylin (BDH 
Ltd. Lutterworth, Leicester, UK). Finally sections were dehydrated in ethanol, 
cleared in xylene and finally mounted in DPX mountant (both from BDH Ltd.). 
Alternatively, the second day staining protocol was altered by using the 
ImmPRESS kit (Vector) in which sections were incubated with a species specific 
polymer for 30 min replacing the secondary antibody. Sections were washed with 
TBST and then developed with ImmPACT DAB (Vector) for up to 2 mins. Further 
staining of the sections was carried out as described above. 
To establish a staining procedure suitable for double colour staining, a variety of 
reagents were tested. Firstly, selected peroxidase substrates Nickel DAB, Nova 
Red and VIP (all Vector) were analysed by single colour staining. IHC procedure 
was not altered. The Nickel DAB staining was carried out following the DAB 
protocol mentioned above with the exception of adding one Nickel drop to the 
DAB reaction causing the usual brown DAB reaction product to appear black with 
the appropriate haematoxylin counterstain. Using Nova Red as reaction product 
appeared with dark red colour (haematoxylin) or dark blue (methyl green 
counterstain). Further VIP developed a purple staining (without counterstain) or 
dark violet stain (methyl green counterstain).  
For back to back sections Nickel DAB was used as peroxidase substrate. 87 
 
2.5.2  Double staining for light microscopy 
Similar to single staining the 0.5% hydrogen peroxidase/methanol incubation and 
heat retrieval in 0.5M citrate buffer (pH 6) was followed by incubation in 2.5% 
species/2.5% human serum with AvidinD (4 drops/ml) (Vector Laboratories, 
Petersborough, U.K.). Surface expression of CCR6 was detected by staining with 
a rabbit anti CCR6 antibody in the presence of Biotin (4 drops/ml, Vector) in 
2.5% horse serum TBST for 1 h at RT, 2 washes with TBST, followed by a 
biotinylated secondary antibody for 30 min (1:200; Vector Laboratories). The 
reaction was developed using VIP. Following incubation for 1 h with in 2.5% 
species/2.5% human serum, goat anti–IL 17 in TBST was added overnight at 4°C. 
On the following day sections were washed with TBST, and then incubated with 
a biotinylated antibody for 30 min and stain developed using either DAB or 
Nickel DAB. The chosen counterstain for DAB was methyl green whereas Nickel 
DAB sections were left unstained. Sections were washed dH2O, dehydrated in 
serial ethanol (from 70%, 90% to 100%), cleared in xylene and mounted in DPX. 
2.5.3 Double staining for fluorescent microscopy 
Sections were prepared as described above. To detect cell markers sections 
were stained for 1 h in 2.5% horse serum TBST at RT with the following 
antibodies: mouse anti CD3, mouse anti CD4, rabbit anti CCR6, mouse anti mast 
cell tryptase (MCT) or mouse anti CD68. After 2 washes with TBST primary 
antibodies were detected by incubating the sections with biotinylated antibody 
for 30 min (1:200; Vector Laboratories) and subsequent addition of streptavidin 
QDot605 (1:250; Invitrogen, Paisley, U.K.) in TBST for 45 min. Goat anti–IL 17 
was added overnight at 4°C, followed by 2 washes with TBST. The next day 
biotinylated anti goat antibody was added for 30 min followed by 2 washes with 
TBST and the addition of avidin FITC (1:500; Vector Laboratories) for 45 min. 
Slides were mounted with Vectashield containing DAPI (Vector Laboratories) and 
analyzed on a fluorescent imaging microscope (BX50; Olympus, Essex, U.K.). 
Images were captured using Apple Open laboratory software. 88 
 
 
Antibody  Manufacturer and clone  Source  Working Concentration 
CD3  Vector  mouse monoclonal  1.25 mg/ml 
CD4  Dako  mouse monoclonal  7.56 mg/ml 
CCR6  Sigma-Aldrich  rabbit polyclonal  0.75 mg/ml 
MCT  Dako  mouse monoclonal  0.43 mg/ml 
CD68  Dako clone PG-M1  mouse monoclonal  1 mg/ml 
IL-17A  R&D  goat polyclonal  5 mg/ml 
IL-23p19  Sigma-Aldrich  rabbit polyclonal  1 mg/ml 
IL-33  Alexis (nessy-1)  mouse monoclonal  5 mg/ml 
ST2  Sigma-Aldrich 
R&D 
rabbit polyclonal 
mouse monoclonal 
1 mg/ml 
10 mg/ml 
MPO  Dako  rabbit polyclonal  3.2 mg/ml 
ki67  Universal Biologics  rabbit polyclonal  2 mg/ml 
isotype  R&D (IL-17A) and Dako (others)  various  various 
Table 2.1 Antibodies for IHC 
Shown are surface marker or cytokine antibodies using in IHC. Left column shows antibody 
target, 2
nd column manufacturer, 3
rd the source and right column the working concentration. 
Dilutions were not mentioned as stock concentration of antibodies can vary. 
 
Cytokine  Company 
human IL-23  eBioscience 
human sST2  R&D systems 
human CCL3 (MIP1alpha)  R&D systems
 
human TNFalpha  Biosource
 
human IL-6  Biosource 
mouse IL-5  R&D systems 
Table 2.2 ELISA cytokines and companies 
Shown are ELISA targets demonstrating cytokines which will be detected by an antibody 
pair (e.g. IL-23: capture antibody against IL-23p19 and detection against IL-23p40) 
Further supplier of ELISAs are shown.  
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2.5.4 Quantification of fluorescent IHC 
Images were captured digitally and the total number of IL 17A+ cells found 
within duplicate tissue areas (two representative 10x fields) of 0.52 mm
2 was 
calculated. Double staining allowed the calculation of the proportion of IL 17A 
expressing cells per cell surface marker. Four tissues were double stained for all 
markers (CD3, CCR6, CD68 and MCT) with studies performed on a further 6 
tissues to confirm the co expression with MCT and CD68. 
2.5.5 Mast cell staining using Toluidine blue 
To stain for mast cells in tissue paraffin embedded sections were prepared as 
described above. Following the dewaxing and rehydrating steps the sections 
were stained in toluidine blue (Sigma) for 1 min, dehydrated and cleared with 
xylene and further mounted with DPX. Due to purple background and good 
visualization of the tissue architecture, counterstaining was omitted.  
2.6 ELISA 
Cytokine expression was tested in serum, synovial fluid and culture supernatant. 
ELISAs were carried out according to the manufacturers protocol. The following 
table summarises the cytokines tested and the manufacturer from which the kits 
were purchased (Table 2.1Table 2.2, page 88). 
2.7 Luminex cytokine analysis 
Cytokine mouse 20 plex kit (Invitrogen) to test mouse serum from IL 33 ear 
injection model was performed according to manufacturers’ instructions. 
2.8 Cell culture 
2.8.1 Culture of adherent cells 
Primary fibroblasts, HaCaTs (CLS cell lines service), neonatal human epidermal 
keratinocytes (nHEK)(Invitrogen), and HeLa cells (ATCC) were cultured in tissue 90 
 
culture flasks with appropriate complete media (fibroblasts: RPMI, HaCaTs and 
HeLa: DMEM, nHEK: epilife from Invitrogen) and split when cells reached 80% 
confluence. Detachment of cells was achieved by incubation with 0.5 – 1 ml 5% 
trypsin in PBS for 5 min. Trypsinization was stopped by adding media containing 
10 % FCS, cells were washed, counted and reseeded to a final concentration of 
10
4/ml.  
2.8.2 Culture of suspension cells 
The immature human mast cell line HMC 1 was cultured in complete media 
(IMDM, Gibco) and 64  l α thioglycerole (Sigma). Cells were split once per week 
and were reseeded at a density of 5x10
4/ml. For stimulation of HMC 1, 1x10
6 
cells were stimulated with human rIL 33 (Biolegend) at varying concentrations 
for 24 h. The culture supernatant was reserved at  20°C for subsequent ELISA. 
2.8.3 Purification of monocytes 
Wash media was prepared from RPMI containing 2 mM L glutamine, 100 IU 
penicillin,
 and 100 µg/ml streptomycin (all obtained from Life Technologies,
 
Paisley, U.K.). Culture media was prepared by the addition of 10% foetal calf 
serum (FCS) (Sigma) to wash medium. 25mls of heparinised peripheral blood 
(provided by Gartnavel Blood transfusion service) were transferred to 50ml 
falcon tubes and diluted with equal volumes of PBS. The blood was carefully 
layered onto Ficoll gradient solution (histopaque, Sigma) and samples were 
centrifuged at 350g for 20 min to allow separation of the blood into its 
component layers. Following centrifugation the interface containing PBMCs was 
carefully removed using a sterile pasteur pipette and placed in a fresh 15ml 
tube. The cells were then washed twice with RPMI (350g, 10 min). Cells were 
finally resuspended in PBS containing 5% Alba (human albumin). Purification of 
CD14 positive monocytes was performed according to the manufacturers 
instructions (Miltenyi). The purity of the suspension of monocytes was confirmed 
by FACS analysis confirming a >90% purity of CD14 positive cells. The number of 
PBMCs was calculated using a haemocytometer (Weber, England). 
For toxicity analysis in nanoparticle experiments, monocytes were cultured 24 h 
in media containing 10% FCS +/  different concentration of nanoparticles.  91 
 
2.8.4 Splenocyte harvest 
To test biological activity of rIL 33 splenocytes were stimulated with rIL 33 and 
their IL 5 production measured. To isolate splenocytes, spleens of BALB/c mice 
and ST2
 /  mice were removed and washed in RPMI 1640 media and then 
dissociated through sterile nitex membrane. The resultant single cell suspension 
was centrifuged (450g, 10 min, 4°C) and the pellet resuspended in 300  l red 
blood cell lysis buffer (Sigma) for 1 min to remove red blood cells. The lysis 
reaction was stopped by the addition of 10 ml RPMI 10% FCS. Cells were washed 
twice with RPMI 10% FCS (450 g, 10 min, 4°C) and then counted for further 
experiments. 
2.9 FACS analysis 
The expression of ST2 on the mast cell line HMC 1 was analysed by FACS. To this 
end 0.5 x 10
6 cells were washed and unspecific antibody binding to Fc receptors 
was block by incubating cells with 50 µl Fc Block (Sigma) for 15 min. 5  l of anti 
ST2 FITC were added and incubated for 15 min at RT in the dark. Cells were 
washed with PBS EDTA and analysed using a FACS calibur machine (BD). To test 
cell death of monocytes due to nanoparticle exposure cells were stained with 
Annexin V and 7 AAD (apoptosis kit, BD biosciences) according to manufacturer’s 
instructions.  
For analysis of mouse cells obtained from an ear digest (see 2.11.2 Cytokine ear 
injection model) cells were blocked as described above and stained with 
antibodies against mouse CD3, CD4, CD19, CD11b, CD11c, F4/80, Gr 1 (3  l per 
FACS pellet, all BD Biosciences). Cells were washed with PBS EDTA, 7 AAD (BD 
Biosciences) was added 5 mins before analysis for dead cell exclusion and 
analysed using a FACS calibur machine (BD). 
FACS data were analysed using FlowJo software (TreeStar). 92 
 
2.10 Animals 
Mice were maintained at the Central Research Facility, University of Glasgow. 
All animal experimentation and husbandry was under the authority of a UK 
Government Home Office Project License. All protocols were approved by the 
Glasgow University local Ethical Review Panel. The following table gives an 
overview of the used mouse strains and the experiments carried out (Table 2.3, 
page 93). Normally, mice were used at the age of 6 or 12 weeks and were age 
matched for each independent experiment. For mast cell deficient mice, the age 
of deficient and control mice was 5  6 months to guarantee deficiency of mast 
cells in the skin. Control mice were bought from Harlan (BALB/c, C57/Bl6 and 
MF 1). ST2
 /  mice were kindly provided by Prof McKenzie (Cambridge) and kit
W 
sh/W sh mice by Prof Liew (Glasgow). 93 
 
 
Experiment  Mouse strain 
TPA skin inflammation model  BALB/c, ST2
-/-, C57/Bl6, kit
W-sh/W-sh 
cytokine ear injection model  BALB/c, ST2
-/-, C57/Bl6, kit
W-sh/W-sh 
wound healing model  BALB/c, ST2
-/- 
splenocyte harvest   BALB/c, ST2
-/- 
nanoparticle experiments  BALB/c, C57/Bl6 
Embryo harvest  MF-1 
Table 2.3 Mouse strains used in experiments 
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2.11 IL-33 related mouse experiments 
2.11.1  TPA skin inflammation model 
The dorsum of mice was shaved and 2 days later cutaneous inflammation was 
induced by the application of phorbol ester 12 O tetradecanoylphorbol 13 
acetate (TPA), as a 50 mM solution in acetone, to the shaved dorsal skin. Each 
animal received 150 µl of this solution, which is equivalent to 7.6 nmol per 
mouse per application. In preliminary studies (carried out by Prof. Graham’s 
laboratory) the following two time courses were found to be optimal), two 
different time courses have been chosen (67). 1) TPA was administered for 2 
days or 2) for 3 days (Figure 2.1). After one day’s rest, mice were culled and 
dorsal skin was harvested, placed on a filter paper and cut with a scalpel into 
squares of ~ 0.5 x 1 cm. These squares were transferred to 10% neutral buffered 
formalin (further stated as formalin) and fixed for 24 h followed by incubation in 
70% ethanol to slow the fixation process. The skin was subsequently paraffin 
embedded and processed as described above. Group numbers ranged between 5 
8 animals per group. To assess inflammation the following parameters were 
analysed: skin thickness, epidermal thickness, epidermal cell layers and staining 
sections for mast cells (toludine blue) and keratinocyte proliferation (ki67). 95 
 
 
 
Figure 2.1 Overview of the timeline - TPA skin inflammation model 
Left hand and right hand graph shows 2 different time lines for the TPA model. On day 1 the 
backs of mice were shaved, the one day break was given to account for irritation of the skin 
due to shaving. Day 3 mice were treated with 150  l of TPA administered onto the back in an 
acetone solution. This was performed under a ventilated hoot. Depending on the model, 
mice were either treated for 2 (left side) or 3 days (right side). After 1 day rest, mice were 
culled and skin harvested. 
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2.11.2  Cytokine ear injection model 
To test if IL 33 induces psoriasis like inflammation a cytokine ear injection 
model was established. IL 33 was tested in a previously reported model initially 
described for the application of IL 23 or IL 22 (69, 70). Mouse rIL 33 (500ng in 
20 l PBS) or PBS was injected intradermally into the left ear pinna of mice (300 
 l insulin needle, G29, Terumo) every alternate day for 2 weeks. Before 
injection ear thickness was measured with a microcaliper (Keoplin (0 10mm) or 
Dial thickness Gauge, G 1A Peakock) (Figure 4.19). To assure proper technique 
intradermal injection was practised on more than 60 mouse ears of cadavers. In 
the week of experiments injection skill was re practised on at least 10 cadaver 
ears to assure proper intradermal administration with no leakage or perforation 
of the ear. 97 
 
 
Figure 2.2 IL-33 intradermal ear injection 
Mice were anaesthetized and left ear was placed on the left index finger and gently held in 
place with the left thumb. 20  l were injected using an insulin syringe with a 29 gauge 
needle (marked with *). Arrow demonstrates injected intradermal volume leading to a 
“blister like formation”. 98 
 
Due to different starting ear thicknesses of kit
W sh/W sh mice compared to 
littermate controls difference of thickness compared to the right ear was 
measured to standardize parameters. 
On day 16, mice were culled, ears harvested, fixed in formalin and tissues 
processed as described above. Spleens were harvested and weighed to 
determine any possible systemic effects of IL 33 and also used as a surrogate 
marker for the bioactivity of IL 33 (systemic injection has been reported to 
induce splenomegaly). To determine epidermal thickness, epidermal cell layers 
and mast cell numbers staining of ear sections with H&E and toludine blue was 
carried out. Thereafter eosinophils were counted and sections stained for MPO. 
Additionally, serum was harvested for cytokine analysis. 
After injection, “blister like formation” was only visible for ~ 15 mins. To 
address immediate effects and swelling, ear thickness was measured on day 15 
after injection over a time course.  
To further to analyse the cellular infiltration at earlier time points, one set of 
mice was culled on day 10 and ears were harvested for ex vivo FACS analysis. 
Briefly, mice ears were transferred in PBS to the lab, split in dorsal and ventral 
half by pulling and splitting at the proximal side where cartilage was exposed. 
Tissue was incubated in eppendorff tubes containing 1 ml of HBSS including 
0.4mg/ml DNase and 0.862 wüntsch units/ml eliberase3 (both Roche) to digest 
the tissue at 37°C for 2 h. Cells were then gently squeezed through nitex 
membrane with the plunger part of a 2 ml syringe. Cells were again cleared 
through nitex membrane, counted and further analysed (see 2.9 FACS analysis). 
2.11.3  Wound healing biopsy model 
For wound healing, ST2
 /  mice or littermate controls were anaesthetized and 
shaved dorsal skin was pulled over a rigid plastic plate. A 5 mm punch biopsy 
was performed inducing 2 biopsies with a single punch (Figure 2.3). Photographs 
were taken with mice sitting on the cage lid with the camera fixed to a stand 
assuring same distance every time wounds have been assessed. Areas were 
captured every second day after wounding. 11 mice per group were used. On 
days of measurement 3 mice/ group were culled for skin harvest decreasing 99 
 
numbers for subsequent measures. Images were analysed measuring the wound 
surface and demonstrating the average percentage of wound reduction 
compared to day 1. 100 
 
 
Figure 2.3 Wound healing model 
Shown is the back of a mouse after single 5 mm biopsy of the dorsal skin leading to 2 
wounds. Mice sitting on a cage lid were photographed with a camera fixed to a stand to 
assure consistent distance. 101 
 
2.11.4  Analysis of mouse embryos 
A male MF 1 mouse was allowed to mate with 2 females for 2 h. Female mice 
were checked for vaginal plugs and positively identified mice were single caged 
and weight was measured daily. On day 9.5 or 10.5, pregnant mice were culled 
and embryos harvested using a dissection microscope. The embryos were fixed in 
10% formalin for 2 3 h, embedded in paraffin and sections were cut. Right 
orientation of sections was checked using H&E and subsequent sections 
containing the dorsal aorta stained using IHC for IL 33 (see above). Placenta 
tissue of the same mouse was used as a positive control for staining. 
2.12 Production of a K14-IL-33 construct 
2.12.1  Cloning of K14-IL-33 
IL 33 was amplified using primers introducing a BamHI site to the 5’ and 3’ end 
of IL 33. Primers and the template were provided by Dr Gilchrist and Pfx DNA 
polymerase reaction (Invitrogen) was used for this experiment. Briefly, in order 
to sub clone IL 33 into the K14 vector, the IL 33 cDNA had to be amplified by 
PCR to introduce a convenient restriction site (BamHI). Template DNA for IL 33 
was provided by Dr Gilchrist for the following PCR reaction. In short, 1 l of the 
DNA were mixed with Pfx polymerase buffer (Invitrogen), 1.25  l of the forward 
primer and the reverse primer (10mM), 1  l of dNTP mix (10mM, New England 
Biolabs), 1.5  l MgSO4 (50 mM) and 0.5  l Pfx polymerase (1.25 units) and the 
volume adjusted with sterile dH2O to 50 µl. 
IL 33 forward primer: AGGATCCATGAGACCTAGAATGAAGTATTC  
IL 33 reverse primer: AAAGCTTTTAGATTTTCGAGAGCTTAAAC 
Amplification was performed using the following conditions: 5 min at 95°C, 
followed by a total of 35 three temperature cycles (15 s at 95°C, 30 s at 55°C 
and 45 s at 72°C) and 10 min at 72°C. The PCR was then separated on an 1% 
agarose gel. Subsequently, the appropriate PCR fragments were cut out of the 
gel and DNA was purified according to the manufacturer’s instructions using a 
Gel Extraction Kit (Qiagen). 102 
 
To blunt ends for further ligation, adenines were added to the ends of the PCR 
product by incubating the product with Taq polymerase and dNTP mix at 72°C 
for 30 min. Of this reaction, 4  l were incubated with 1  l TOPO salt solution 
and 1  l Topovector (PCR 2.1 TOPO, Invitrogen) for 10 min at RT. One Shot® 
TOP10 competent Escherichia coli (E. coli; Invitrogen) cells were transformed 
with DNA as per the manufacturer’s instructions. Briefly, 0.1   0.5 µg plasmid or 
5 µl ligation reaction were added to 50 µl One Shot® cells and mixed by gentle 
tapping. Subsequently, the reactions were incubated on ice for 30 min. 
Following this incubation, the cells were heat shocked at 42°C for 30 s before 
being placed on ice. Following the addition of 250 µl pre warmed SOC media 
(Sigma), the vials were shaken at 3 g for 60 min at 37°C. Each transformation 
was then spread on separate LB agar plates containing 100  g/ml ampicillin 
which were incubated at 37°C overnight. 
 Colonies were then picked, grown in media overnight and plasmid DNA isolated 
from each clone (Minipreparation, Qiagen). To detect clones containing the IL 
33 insert, plasmid DNA as well as a control vector containing K14 promotor 
(provided by Dr Gilchrist) was digested with BamHI (Roche). The digestion 
products were then separated on an agarose gel and inserts of the appropriate 
size (~750bp) identified. K14 vector and insert was cut out and gel purified. 
After shrimp phosphatase (Promega) incubation for 1 h at 37°C to prevent 
religation, enzyme was heat inactivated at 70°C for 15 min and product purified 
(Qiagen). Ligation was performed using Rapid ligation kit (Roche) and product 
transformed into competent cells. Cells were grown and colonies picked. Further 
BAMHI digestion and subsequently KpnI digestion performed (Figure 4.27). Clone 
#2 and #3 were maxipreped (Qiagen) for further transfection. 
2.12.2  Transfection of K14-IL-33 in HaCaT 
The right orientation of the IL 33 insert could not be shown by restriction digest. 
Instead HaCaT cells were transfected with both constructs to test for expression 
of IL 33. As HaCaTs normally express Keratin 14 (225) the K14 promoter should 
be active in these cells leading to expression of IL 33, if it is present in the right 
orientation. For the transfection HaCaT cells were plated in a 6 well plate at 
2*10
5 cells /well and incubated for 2 days to reach ~ 80 % confluency. Cells were 103 
 
then transfected using Lipofectamine 2000 (Invitrogen) according to 
manufactures’ protocol. Transfections with the following constructs were 
performed: mock, construct #2 and #3, and pEF6/V5 His TOPO/LacZ (Invitrogen) 
allowing for β Gal staining to assess the general transfection efficiency 
(Invitrogen). 
24 h after transfection, cells were harvested by trypsinization, cytocentrifuged 
onto slides (7*10
4cells/slide, 450 rpm, 6 min) and subsequently stained for IL 33. 
β Gal staining was performed according to manufactures’ instructions. Staining 
directly in the 6 well plate showed a transfection efficiency of 1 2%. Construct 
#3 was expressing IL 33 (tested by IHC) and was sent for sequencing. 
2.13 Nanoparticle methods 
This part of my laboratory work was done in close collaboration with Dr Ross 
Stevenson, senior postdoctoral fellow, Centre for Molecular Nanometrology, 
WestCHEM, Department of Pure and Applied Chemistry, University of 
Strathclyde. Dr Stevenson was responsible for chemical linkage of NP to 
proteins; biological assays and in vivo experiments were performed by me and ex 
vivo analysis with Dr Stevenson’s help and supervision. Here I briefly describe 
the preparation of protein linked NP (2.13.1), tests to confirm linkage (2.13.2, 
2.13.3), biological activity (2.13.4) and the in vivo use in regard to organ 
distribution and inflammation (2.13.5, 2.13.6). 
2.13.1  Protein linked SERRS active nanoparticles 
Citrate reduced gold nanoparticles were synthesised by the Turkevich method to 
~18.6 nm diameter (size established by scanning electron microscope) (226). In 
certain conditions, the nanoparticle colloid was concentrated by centrifuging 
five 1 ml samples and resuspension of the pellets in 1ml of phosphate buffer 
(10mM pH 7.6). Concentrations of the colloidal solution were calculated using UV 
spectroscopic techniques.  Colloidal nanoparticle suspensions were then labelled 
with the SERRS active linkers (benzotriazole or azo dyes).  Following incubation, 
samples were centrifuged at 5,000 rpm for 20 min to remove unbound dye, and 
the pellet was resuspended in phosphate buffer.   104 
 
In order to link the labelled nanoparticle with the biomolecule, 980 l of 
nanoparticle suspension was incubated with 10  l of 2 mg/ml solution of EDC (1 
ethyl 3 (3 dimethylaminopropyl) carbodiimide hydrochloride and 10  l of 2 
mg/mL solution of NHS (N hydroxysulpho succinimide) for 20 40 min. This 
allowed conjugation of either linkers terminal carboxyl group to an amine group 
of proteins, by formation of a covalent amide bond. 10 µl of 1000 µg/ml 
etanercept (ETA), or control protein (PBS 0.1% BSA sterilised through a 0.2  m 
syringe filter) was added and allowed to conjugate for 14 18hrs. Different 
conditions were investigated testing different concentrations of ETA as well as 
BSA. Further we added BSA at the end of reaction to prevent aggregation of NP 
(see chapter 5). Solutions were twice centrifuged and washed with phosphate 
buffer to remove any unbound protein. 
Functionalized nanoparticles were investigated using a 632.8 nm wavelength 
laser (Leica DM/LM microscope, Renishaw InVia spectrometer, HeNe laser) to 
determine whether the nanoparticles retained SERRS activity.  Raman analysis 
also allowed elucidation of the fingerprint spectrum from the functionalised NP. 
2.13.2  Western blot of protein-linked NP 
To test the concentration of etanercept (ETA) or IgG linked to nanoparticles 
(NP), ETA NP probes, NP alone or IgG NP were analysed by Western blot.  
Samples were incubated in reducing sample buffer (NuPage Invitrogen) at 70°C 
for 10 min to reduce and remove the disulfide linked protein from NP. Samples 
(20  l) and marker (Seablue+2, Invitrogen) were loaded on a 4 12% Bis Tris gel 
(Invitrogen) and run at 200 Volt for 1.5 h. The gel was transferred to a 0.2 
micron nitrocellulose membrane using the iBlot® Gel transfer system 
(Invitrogen). After blocking the membrane for 1 h with 5% semi skimmed milk in 
TBST, the membrane was incubated with goat anti huIgG(Fc) HRP 1:50000 
(Sigma). Membrane was washed for 5 times and then incubated with luminol 
(Millipore) for 1 min. X Ray films (Kodak) were developed at different times 
(10s, 30s, 1 min, 5 min). 105 
 
2.13.3  ETA-NP binding capacity 
To test the capacity for ETA NP to bind TNF, different concentrations of NP 
linked to ETA were incubated with 2000 pg/ml rTNF α in 0.5% BSA RPMI 1640 in 
1.5 ml eppendorff tubes at 37°C for 1 h. After centrifugation (5000 g, 5 min) 
supernatant was analysed for the presence of TNF α by ELISA. Initially, NP TNF 
incubations were performed in RPMI only with results discussed in chapter 5 (106 
 
The use of nanoparticles to image inflammation). 
2.13.4  HeLa cell activation with TNF-α and blockade with 
ETA-NP 
HeLa cells were plated out at 2.5x10
4 cells per well in 200 µl (96 well flat 
bottom plate) and rested overnight at 37°C/5%CO2. The next day cells were 
stimulated with different concentrations of TNF with/without NP linked to ETA 
or control NP. After 6 h incubation, the culture supernatant was harvested and 
analysed by ELISA for IL 6 production. 
This assay was used to validate activity of NP conjugated to different linkers and 
protein. A variation of linkages has been tested to avoid plastic binding and 
aggregation of NP which is discussed in the relevant chapter. 
2.13.5  Nanoparticles in vivo 
Initially, to test if NPs can be detected in tissue 100  l of NP solution was 
injected into the footpad or ear pinna of a euthanized mouse. After 5 min, 
SERRS measurements were performed (Figure 2.4B). For imaging of NP in vivo 
100 µl of a sterile NP solution was injected i.v. into the tail vein of mice. 
Different concentrations were assessed. Mice were culled after 4 – 6 h and laser 
measurements performed in an assigned room. Percutaneous measurements 
were performed before preparing the mouse for direct organ measurements. The 
setup is demonstrated in Figure 2.4A. Due to focusing problems of the initially 
used laser we switched to a new laser (Reporter, DeltaNu) (Figure 2.4C) with a 
cone head. This head touches the examined tissue achieving a fixed distance and 
therefore manages to standardise the laser to the right focus. Data were 
captured with a laptop (software: NuSpec, DeltaNu). 107 
 
 
Figure 2.4 SERRS imaging ex vivo. 
Setup of SERRS laser measurement (A) showing laser, cooling system and filters and power 
source. On the left hand a mouse cadaver was opened, specific organs prepared and 
SERRS signals measured. B: measurement of a footpad after local injection of NPs. C: laser 
system with cone head for standardized laser distance. 108 
 
2.13.6  Carrageenan foot paw injection model 
To test if ETA linked NP can be used to track/image inflammation a carrageenan 
foot paw injection model has been utilised. My aim was to detect systemically 
administered NP at the site of inflammation compared to control NP 
functionalised with IgG. To achieve this, 8 week old BALB/c mice received a 50 
 l subcutaneous (subcutaneous) injection (28 G needle), into one hindpaw (the 
right), of PBS containing carrageenan (300  g per paw, Sigma). The contralateral 
paw (left paw) received 50  l of PBS and was used as the control. Paw edema 
was measured with a calliper at several time points after the injection of 
carrageenan. 
100  l of NP probes were intravenously injected into the tail vein using an insulin 
syringe and 28 G needle 68 h after carrageenan injection. 5 6 h later, mice were 
sacrificed and analysed for SERRS NP signals of both foot paws but also other 
organs. At least 3 mice per group were used. 
2.14 Statistical analysis 
All results are displayed as mean +/  standard error mean (SEM) and all 
statistical analysis was done either by students T test, ANOVA test or Mann 
Whitney test, as indicated in figure legends, using the Graph Pad Prism 4 
software. A p value of < 0.05 was considered statistically significant. 
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3  Interleukin-23 and Interleukin-17 in inflammatory 
arthropathies 
Content of this chapter has been published in the following manuscripts: 
 
-  Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, Leipe J, Melendez AJ, McInnes IB 
Mast cells express IL 17A in rheumatoid arthritis synovium. 
J. Immunol Cutting Edge 2010 Mar 3. 
(selected for “Research Highlights” in Nature Reviews Rheumatology –2010 May 03) 
-  Hueber AJ, Asquith DL, Millar NL, Sturrock R and McInnes IB 
“Interleukin 23 expression in inflammatory arthritis”[ABSTRACT] 
ACR, Philadelphia, USA, Oct 2009 110 
 
3.1 Aim and Introduction 
Recently, the cytokine IL 17A (from now onwards mentioned only as IL 17) has 
been linked to autoimmune disease mechanisms. In rodent models, deficiency or 
blockade of IL 17 leads to suppression of arthritis (227). In humans, expression of 
IL 17 in RA synovium and synovial fluid was first described in 1999 (98). Initial 
phenotyping studies indicated that synovial T cells with plasmacytoid phenotypic 
characteristics expressed IL 17. Most subsequent reports have focused on 
expression in peripheral blood, and few reports have studied Th17 cell markers 
in situ (86, 228). Other cell types including γδ T cells, NKT cells, NK cells, 
neutrophils, eosinophils and innate CD4+ lymphoid tissue inducer like cells (LTi 
like cells) have been reported to produce IL 17 (229, 230). Also recently, mast 
cells have been described to express IL 17A and IL 17F (231). Thus, in tissue, the 
net IL 17 expression may arise from a broad array of adaptive and innate cells.  
Such expression could confound the notion of a Th17 dominant disease state in 
humans despite murine data to that effect. 
Interleukin (IL) 23, a heterodimeric cytokine comprising a unique p19 and shared 
p40 subunit (with IL 12) is implicated in expansion of Th17 cells (see chapter 
1.2). Mice deficient for IL 23 receptor (IL 23R) exhibit impaired expansion and 
function of Th17 cells (232). Furthermore, deletion of IL 23(p19) in a murine 
model of arthritis ameliorated disease suggesting a pro inflammatory role in 
articular inflammation (121). Genome wide analysis has identified single 
nucleotide polymorphisms within the genes encoding IL-23A and IL-23R that are 
strongly associated with psoriasis and AS (233, 234) and antibodies targeting IL 
23p40 yield profound and long lasting beneficial clinical effects in psoriasis (32, 
122). These studies support a pathological role for IL 23 signaling in human 
inflammatory diseases. Despite the foregoing, remarkably few studies have 
delineated IL 23 expression in relevant patient subsets, nor have the relevant 
conditions that could drive IL 23 expression been fully explored. IL 23p19 has 
also been detected in RA synovial membrane where its expression was shown to 
be regulated by activation of the toll like receptor (TLR) signaling pathway 
(113). This part of my work sought to determine the expression of IL-23 that 
could sustain Th17 biology in inflammatory arthritis. Further it sought to 111 
 
re-evaluate the dominant cellular source of IL-17A in established RA 
synovium. 112 
 
3.2 IL-23 expression in inflammatory arthropathies 
3.2.1 Synovial expression of IL-23p19 
Synovial tissue samples from patients with RA (n=5), PsA (n=4) or OA (n=4) were 
obtained from The Centre of Rheumatic Diseases tissue bank (Glasgow Royal 
Infirmary) derived by arthroplasty. To explore IL 23 expression 
immunohistochemical analysis of paraffin sections was performed. At the time of 
this study, only two anti IL 23p19 antibodies were available, a product from 
Biolegend (mouse anti human IL 23p19) and another from Sigma (rabbit anti 
human IL 23p19). It has to be reported that the Biolegend mouse antibody has 
been used in the literature at 10  g/ml, a fairly high concentration for IHC. 
When I explored the staining pattern for this antibody I found it was non 
specific, with no cellular staining distinguishable. Titration of the antibody did 
not improve matters. Furthermore a closer look reveals non specific staining of 
IL 23 in the company datasheet
4 as well as the published manuscript (113). To be 
fair, resolution in published manuscripts may not properly reflect the true 
image. The Sigma rabbit anti human IL 23p19 seemed to be more convincing. It 
is recommended at 10 fold lower concentration and data sheet staining patterns 
showed specific cytosolic expression in tonsils in the DC/macrophage area of 
lymph follicles
5. 
I therefore elected to work up the Sigma antibody for further evaluation in 
synovial tissue. In the samples tested here, staining revealed consistent 
cytoplasmic expression for IL 23p19 in cells in RA and PsA synovial tissue 
primarily within and immediately adjacent to lymphocyte rich aggregates. In 
contrast, we detected no staining in non inflamed OA synovial tissue (Figure 
3.1). This predicts the existence of a microenvironment enriched with local IL 23 
expression in inflammatory arthritis, in which in close proximity to T cells of a 
cytokine milieu might promote differentiation and maintenance of Th17 cells. 
                                         
 
4 http://www.biolegend.com/media_assets/pro_detail/datasheets/Human_IL-
23_Product_Data_Sheet.pdf 
5 http://www.proteinatlas.org/show_image.php?image_id=598283 113 
 
3.2.2 Expression of IL-23 in synovial fluid 
In situ staining for IL-23p19 demonstrated the expression of one subunit of a 
functional heterodimeric cytokine. Next, synovial fluid expression of bioactive IL-23 
by ELISA (recognizing only p19 / p40 heterodimers) was measured. Bioactive IL-
23(p19/p40) was detectable in only 3 out of 15 PsA patients and was below the 
limit of detection in all RA and OA derived fluids (Figure 3.2). Prior studies similarly 
reported only low levels of IL-23 in RA SF (113, 235). This low level detection is 
not entirely explained – but might reflect consumption by adjacent tissues, limited 
specificity of the ELISA system (although it behaves well in PB assays), inhibition 
by a tissue specific factor e.g. bound cytokine or true low levels of IL-23 release 
from cytoplasm given the robust staining pattern observed above.114 
 
 
Figure 3.1 Synovial expression of IL-23 in inflammatory arthropathies. 
Immunohistochemistry analysis using an anti IL-23(p19) primary antibody was used to 
detect endogenous IL-23 in synovial tissue from RA and PsA patients (right panel). IL-23(19) 
was not detectable in synovial tissue from patients with osteoarthritis (OA). Representative 
images of RA (n = 5), PsA (n = 4) and OA (n = 4). Magnification is shown at 40X. Isotype 
controls are shown on the left panel. 
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Figure 3.2 Detection of IL-23 in synovial fluid. 
The concentration of IL-23 in synovial fluid as measured by ELISA from patients with RA (n 
= 15) and PsA (n = 15) compared to OA (n = 8). With IL-23p19 capture antibody and IL-12p40 
detection, biofunctional heterodimeric IL-23 is detected. Only 3 of the PsA group were 
above the detection limit of the ELISA. 116 
 
3.3 The source of IL-17 in rheumatoid arthritis 
The data above were strongly suggestive of IL 23 expression in the inflamed 
synovial compartment and thus this tissue provides a local environment 
optimized for Th17 expansion and maintenance. It is unclear if Th17 cells are 
recruited from the peripheral blood or if Th17 cells differentiate locally from 
recently recruited precursor (naïve) T cell subsets. IL 17 has been detected in 
synovial fluid and evidence for a role of Th17 cells in RA is growing. However, 
protein analysis, in particular, histological analysis of IL 17 expression is hardly 
reported. Further published reports show only few positive cells, provide no 
formal tissue analysis and conclusions about cellular source and occurrence of 
Th17 cells in human tissue must remain debatable. The aim of the following 
experiments was to characterize IL 17 expression in RA and provide formal proof 
of the predominant cellular source of IL 17 production. 
3.3.1 IL-17 is expressed in RA synovium but only scarce in OA 
synovium 
To investigate the expression pattern of IL 17A in rheumatoid tissue IHC was 
performed on tissue derived at arthroplasty. As control, tissue from OA patients 
was obtained and treated in an otherwise identical manner. Extensive work up 
of the antibody to IL 17 was performed using tonsil sections – a variety of 
antibodies were screened for tissue nonspecific staining and the capacity to 
detect cytosolic cytokine. Once a candidate antibody was selected, cytoplasmic 
IL 17A staining was detected in cells of ovoid / plasmacytoid phenotype, as 
previously described, and in cells of more irregular phenotype, both at the 
periphery of lymphocytic aggregates, in the sub lining layer areas and rarely in 
the lining layer (nickel DAB, black, Figure 3.3A). Interestingly, IL 17A positive 
cells were also detected in OA tissue, however, not consistently (DAB, brown, 
Figure 3.3B). 
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Figure 3.3 IL-17A expression in RA/OA synovium. 
A: Immunostaining of IL-17A in different established RA synovial tissue. Nickel-DAB (black), 
counterstaining with haematoxylin. 40x magnification of two areas. Bottom right shows 
isotype (iso). Arrows and boxes mark differently shaped Il-17+ cells. B: IL-17A (DAB 
(brown). OA-1 with few IL-17A+ cells; OA-2 with no IL-17A+ cells detected. 10x and 40x 
fields of a representative OA synovium tissue (n=4 with 2 positive and 2 negative synovial 
OA membranes). Arrows show positive cells. Grey box: area of magnification. Right bottom 
picture: Isotype control of OA-1 118 
 
3.3.2 IL-17 is rarely expressed by Th17 cells in RA synovium 
To formally identify these IL 17A+ cells in RA synovium, co localization studies 
were performed. To investigate cellular markers in combination with cytokine 
expression double staining had to be established. For the successful staining 
procedures with light microscopy immunohistochemical technique was pursued. 
The surface marker chemokine receptor CCR6 has been reported to be expressed 
on Th17 cells. Staining for CCR6 was worked up, and different dyes for chemical 
reactions determined (Figure 3.4). CCR6 was stained with nickel DAB 
counterstained with haematoxylin resulting in a black colour. Staining with Nova 
Red counterstained with methylgreen results in a dark blue colour. CCR6 staining 
pattern demonstrated membrane staining in lymphocytic aggregates but also 
single scattered cells were apparent. However, Nova Red which stains dark red 
in haematoxylin is hard to distinguish to normal DAB or nickel DAB. Also Nova 
Red in methylgreen results in a dark blue stain which is difficult to differentiate 
to DAB. Taken together, the following combination was used for co localization 
of CCR6 and IL 17 (Figure 3.5): VIP (CCR6) and nickel DAB (IL 17) with no 
counterstain; Nova Red (CCR6) and nickel DAB (IL 17) with methylgreen 
counterstain. 
Surprisingly, using both coloration methods distinct staining patterns were 
visualised. CCR6 stained lymphocytic aggregates with membrane attribution and 
IL 17 stained cytosolic in the periphery of these aggregates. However, it cannot 
be ruled out that IL 17 masks CCR6 expression, especially seen in the left panel 
in which black dark staining might conceal purple membrane CCR6 staining 
(Figure 3.5).119 
 
 
Figure 3.4 Establishing staining for CCR6 in RA 
Immunostaining for CCR6 in two different RA synovial tissues: left panel show 10x 
magnification and right panel 40x. Left bottom corners of pictures demonstrate the isotpye. 
To establish counterstain 2 different dyes for the peroxidase reaction and counterstain have 
been used. Top row: Nickel-DAB (black) with haematoxyclin. Bottom row: Nova Red (dark 
blue) with Methylgreen. 120 
 
 
 
Figure 3.5 Doublestaining IL-17 and CCR6 by light IHC 
Left panel demonstrates staining for CCR6 with VIP (purple) and IL-17 with nickel DAB 
(black). Right panel uses DAB (brown) instead of nickel-DAB and counterstains with 
methylgreen which leads to a blue CCR6 (VIP) stain. Cytosolic IL-17 is not co-localised with 
membrane expressed CCR6. Noteworthy is non-specific staining in the isotype (right panel). 
Shown are to examples from 2 independent RA tissues. (#1 and #2). Bottom row: isotype.  121 
 
To address this problem, a back to back approach was chosen. Hereby, tissue 
section were cut, turned and mounted on slides in an “open book” aspect. To 
visualize this, in this procedure, the same surface is apparent on two sections. If 
the tissue block is imaged as a book and opened in the middle, the left and right 
page touched each other. Back to a tissue block, when cutting one section and 
turning the next section, the same surface can be guaranteed and therefore a 
single cut through the tissue or here a cell is shown on both sides. Thus this 
approach can demonstrate staining of 2 targets with single staining of back to 
back sections. 
Nickel DAB with counterstain haematoxylin was used for staining. IL 17 and CCR6 
or CD3 were targets for IHC (Figure 3.6). Due to technical difficulties, back to 
back sections are not absolutely identical. The IL 17 staining pattern obtained, 
confirmed previous staining with cytosolic detection in large cells with irregular 
phenotype. Comparing similar areas few cells seem to be double positive for IL 
17 and CCR6 (squares, Figure 3.6A). However, other cells only express IL 17 
without CCR6 (arrow marked cell as example). Similar results were obtained 
with IL 17 CD3 using the back to back staining method, with few cells possibly 
double positive (square) and others only positive for IL 17 (arrow) (Figure 3.6B). 
To summarize, this method presented few possible double positive cells, 
however, the convincing cellular source of IL 17 was still inconclusive. 
To definitively define the expression pattern, double staining was established 
using fluorescence microscopy. With this technique exact overlay is possible and 
thus certainty for cellular identification should be guaranteed. 122 
 
 
Figure 3.6 Back to back staining CD3/CCR6 and IL-17 
IHC of RA synovium using back to back sections. These were stained with either IL-17 and 
CCR6 (A) or IL-17 and CD3 (B). To row shows a positive cell for IL-17 in the sublining layer 
(square) which seems to be positive for CCR6 as well. Other cells are only single positive 
(arrow). Similar result was achieved with IL-17 and CD3 with few possible double positive 
cells (square). Also single positive cells are detectable (arrow). Nickel-DAB with 
haematoxylin counterstain. N=1. 
(A) 40x magnification, (B, top row) 10x, (B, bottom row) 40x. No isotype shown.  123 
 
Cells were stained as described in the methods chapter. Expression of IL 17 was 
compared initially with CD4 and CD3. IL 17 stained with FITC is shown in green 
where cellular markers are in red (Figure 3.7). CD4 and CD3 positive cells 
accumulate in lymphocytic infiltrates with membranous staining pattern (upper 
row). The IL 17 staining pattern observed confirmed previous IHC pictures with 
cytosolic accumulation in the periphery of this tertiary aggregates (middle row). 
To visualize cells DAPI (in blue) was used. Merged pictures clearly show distinct 
cells in regard to IL 17 and CD4/CD3 expression (bottom row). 
Although occasional CD4 IL 17 double positive cells were identified, the majority 
of IL 17 positive cells were CD4 negative (<1%), consistent with the notion that 
CD4+ Th17 cells represent a minority of the IL 17 producing population in 
synovitis (Figure 3.7 upper left panel, Table 3.1). This also renders it unlikely 
that LTi like cells are major contributors as these cells express CD4 (230). 
Moreover, counterstaining with CCR6 did not co localize with IL 17 either (Figure 
3.8). Strikingly, an IL 17 positive cell is in close proximity to a CCR6 positive 
cell. CD3/ CD8 double positive T cells have been shown to produce IL 17 (236). 
Of interest, only 1 8% of IL 17 expressing cells were found to express CD3 (Figure 
3.7, Table 3.1).  
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Figure 3.7 Doublestaining of Th17 cell markers and IL-17A. 
Th17 cells are hardly detectable in established RA synovium. Synovial tissue samples from 
RA patients (n = 10) were stained for IL-17 (green) and CD4 (left panel) or CD3 (right panel) 
(both red). Sections were counterstained with DAPI (blue). Bottom row show merged 
staining. Images are shown at 40x magnification. 
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Figure 3.8 Doublestaining of Th17 marker CCR6 with IL-17A. 
CCR6 (red, top left) does not colocalize with IL-17 (green, top right). Sections were 
counterstained with DAPI (blue). Bottom image shows merged staining. Images are shown 
at 40x magnification with bottom picture electronically magnified. 126 
 
3.3.3 IL-17 is produced by innate immune cells mainly mast cells 
Results described above exclude T cells as the main source of IL 17 in 
established RA synovium. Therefore the question arose   which cells produce IL 
17 in the synovium? IL 17 positive cells were bigger in size, some demonstrated 
ovoid/plasmacytoid or irregular shape and commonly these cells were detected 
in the periphery of lymphocytic aggregates. With the phenotypically distinct 
subset of IL 17+ cells of irregular shape and this expression pattern, macrophages 
were postulated as a potential lineage. 
Double staining was performed therefore for IL 17 and CD68 (Figure 3.9). CD68 is 
a late endosomal protein primarily detected on monocytes and macrophages and 
is considered a pan  macrophage marker. Staining revealed that up to 35% of IL 
17 positive cells were CD68 positive (Table 3.1). Figure 3.9 demonstrates double 
positive cells (arrow); however, still some cells expressed only IL 17 (square). 
Moreover, expression of CD68 in IL 17 expressing cells is weak and thus more 
difficult to detect (arrows).  
Mast cells have been reported to produce IL 17 (231). To determine whether 
mast cells might be an additional source for IL 17, we co localized mast cell 
tryptase (MCT) and IL 17 in 10 RA synovial tissues (Figure 3.10). Surprisingly, the 
majority of IL 17 cells double stained strongly with MCT (46–100% of IL 17–
expressing cells per tissue area across patients), clearly demonstrating that mast 
cells are key producers of IL 17A in RA synovium (Table 3.1). Interestingly, MCT 
stained cytosolic but also weakly scattered around the cells, a typical staining 
pattern for mast cells. Table 3.1 summarizes the occurrence of IL 17 positive 
cells in conjunction with the markers CD3, CD68 and MCT. Initially 4 patient 
tissues were examined and for confirmatory studies for CD68 and MCT, numbers 
were increased to n = 10. 
Of marked importance, these studies therefore identified mast cells, a tissue 
resident innate immune cell population, as the predominant cellular source of IL 
17 in established rheumatoid arthritis. These findings contrast with expectations 
regarding the cellular source of IL 17 in the inflamed joint and suggest a 
paradigm shift in the understanding of how the IL 17 axis operates in human 
inflammatory disease as opposed to murine systems.127 
 
 
Figure 3.9 Doublestaining of IL-17 pos. cells with CD68 
RA synovium, n=10. fluorescent microscopy. CD68 (red) and IL-17 (green) are shown single 
stained and merged with DAPI (blue) counterstain. 40x magnification 
 
 
Figure 3.10 Mast cells express IL-17A in RA synovium. 
MCT (red) and IL-17A (green) are shown single-stained and merged with DAPI (blue) 
counterstain (left panel, 40x magnification). This is further digitally magnified to 
demonstrate cellular structure (right panel). 
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cells  
per mm
2 
percentage of  
IL-17+ cells 
(mean) 
percentage of 
IL-17+ cells 
(min/max) 
CD3 analysis  CD3- IL-17+  64     
(n=4)  CD3+ IL-17+  2  3.4%  0.88% / 7.94% 
CD68 analysis  CD68- IL-17+  57     
(n=10)  CD68+ IL-17+  6  9.8%  0% / 35% 
MCT analysis  MCT- IL-17+  8     
(n=10)  MCT+ IL-17+  83  91%  45.71 % / 100% 
Table 3.1 Percentage of double positive cells compared to IL-17+ cells. 
Absolute cell numbers (3rd column) and ratios are shown for CD3+ IL-17+ (n=4), CD68+IL-
17+ (n=10) and mast cell tryptase (MCT)+ IL-17+ (n=10) to total amount of IL-17+ cells (4th 
column). Cell numbers were assessed in 2 independent fields with each ~0.5mm2. 129 
 
3.4 Discussion & conclusion 
Th17 cells have been proposed as causal for a variety of autoimmune diseases 
including multiple sclerosis, inflammatory arthritis and psoriasis. Disease related 
mouse models support this notion. Using gene deficiency approaches (e.g. IL 17 
receptor deficient mice) most experiments strengthen this notion. In contrast, 
human data are rather rare, focus mainly on peripheral blood studies and are 
limited to disease tissue due to limited resources. In this chapter, tissue at the 
site of inflammation was the focus. Thus it was investigated whether a Th17 cell 
favorable environment exists comprising expression of IL 23, a main player for 
Th17 cell biology.  It is already known that IL 6, IL 1 and IL 21 are present in the 
RA synovium and as such the cytokine milieu is a priori attractive as a Th17 
enriching environment.  
The cytokine IL 23 (or at least on subunit) was detected in inflammatory arthritis 
with no expression in osteoarthritis. In synovial fluid only low levels were 
present in PsA (3 of 15 positive samples), with no detection in RA or OA. 
Interestingly, when focussing on peripheral blood significant higher expression 
was present in PsA patients compared to healthy controls. To address a potential 
mechanism by which IL 23 is secreted it was determined if IL 23 was secreted 
upon the interactions of T cells and macrophages. Utilising an in vitro model of 
synovitis healthy human CD3+ T cells were activated in the presence of IL 2, IL 6 
and TNF α for 6 days (TcKs, previously been shown to represent synovial T cells) 
and co cultured with syngeneic MCSF matured CD14+ macrophages. Indeed, co 
culture resulted in the secretion of IL 23 in addition to IL 1β and IL 6 (personal 
communication Dr Asquith, University of Glasgow). To summarize, the above 
data show the expression of IL 23 in synovitis which appears to be specific to the 
pathology of a proportion of patients with PsA. Furthermore, data suggest that 
within the synovium IL 23 secretion is mediated through the interactions of T 
cells and macrophages; thereby providing an environment that is supportive of 
Th17 cell polarization and expansion necessary for driving disease pathology. 
As a next step the cellular source of IL 17 in RA synovium was sought. Utilizing 
the marker CCR6 for Th17 cells, IHC double staining for IL 17 and CCR6 was 
performed. No convincing positivity was detectable raising a number of critical 130 
 
questions concerning the prominence of the Th17 responses in RA.  These 
include   No detection due to technical difficulties?; Downregulation of CCR6 due 
to migration into the tissue or due to local stimuli?; Or lastly, is IL 17 expressed 
by other cells? To address these points methodology was adapted to embrace 
fluorescent microscopy and other markers for Th17 cells such as CD3 and CD4 
were added to the investigation. With high degree of plausibility, it was 
demonstrated that Th17 cells hardly exist in the tissue examined. IL 17 
production by macrophages has been suggested in allergic lung inflammation 
(237). Consistent with this, up to 35% of IL 17 positive cells were macrophages 
(CD68 positive) in RA synovium. More surprisingly, mast cells accounted as main 
source in the synovium. These data were confirmed by Dr Veale and colleagues; 
further they demonstrated that neutrophils express IL 17 as well in RA synovium 
(238).  
These data only provide a snapshot of the disease process. Gathering samples 
from arthroplasty selects patients with RA at established to late stage of the 
disease. Nevertheless, when comparing RA tissue sections with OA samples a 
total different degree in inflammation was obvious. This was reflected by the 
amount of IL 17 positive cells detected. In every RA tissue IL 17 positive cells 
were present, compared to only 2 out of 4 OA samples. Furthermore expression 
in positive OA samples was scarce (Figure 3.3). In contrast to this still inflamed 
established disease is the urge to determine what initiates the pathologic 
disease process. For this question tissue from early arthritis or even pre arthritis 
is needed. Leipe et al focussed on peripheral blood and synovial fluid and 
showed that Th17 cell frequencies and IL 17 production strongly correlated with 
systemic disease activity at both, the onset and the progression of the diseases 
(personal communication, Dr Leipe, University of Munich, data in press, Arthritis 
& Rheumatism). Th17 cells were reduced to control levels in patients with 
treatment controlled disease activity. At onset of disease, Th17 cells were 
enriched in the synovial fluid, and increased frequencies of synovial Th17 cells 
expressed CCR4 and CCR6, indicative of selective migration of Th17 cells to the 
joints. Unfortunately, synovial fluid as follow up was not obtainable to test for 
Th17 occurrence. Thus to determine Th17 cell tissue expression in early disease 
examination of synovial biopsies is mandatory.  131 
 
What drives mast cells to produce IL 17? In collaboration with Dr Alirio Melendez 
he demonstrated that CD34 progenitor derived mast cells produce IL 17 in 
response to various stimuli which have been suggested to play a role in RA (239) 
(Figure 3.11) (this collaborative work was performed by Dr Melendez and is here 
shown for completeness). These stimuli included TNF α, IgG complexes, the 
complement component C5a and lipopolysaccharide (LPS). Further mast cells 
express the gene encoding the transcription factor retinoic acid receptor related 
orphan receptor C. (RORC) (a transcription factor specific for Th17 cells, see 
1.2, Th17 cells and their role in rheumatoid arthritis). Expression is increased by 
the factors that induce IL 17 production. RORC could be silenced by small 
interfering RNA which then blocked expression of IL 17, but not IL 5 or IL 6. 
Thus, in human mast cells the production of IL 17 appears specifically to be 
RORC dependent. 
In conclusion, this chapter demonstrates that proportionally mast cells and not 
Th17 cells appear to be a major source of IL 17 in established RA synovium. 
Further in collaboration with Dr Melendez we showed that such production can 
be driven by a variety of pathways abundantly expressed therein. 132 
 
 
Figure 3.11 RORC dependent IL-17A production by CD34+ derived mast cells. 
Cytokine release was determined from mast cells (untransfected (A) or siRNA-RORC 
transfected (B)) after 24 hrs stimulation with TNFα, IgG-complexes, C5a and LPS, compared 
to a basal secretion (un-stimulated cells). Cell culture supernatants were analyzed for 
bioactive IL-1β, IL-5, IL-6 and IL-17A by ELISA. RORC gene expression was determined by 
quantitative RT-PCR and silenced by siRNA targeting RORC (C). Results shown are the 
mean plus the standard deviation of triplicate measurements of three separate experiments. 
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4  Analysis of Interleukin-33 as an alarmin in 
psoriasis 
Content of this chapter has been presented at the following meetings: 
 
-  “The alarmin IL 33 is overexpressed in psoriasis and induces ST2 dependent psoriasis like 
dermatitis” 
EWRR Abstract Award, Oral presentation 
EWRR, Bamberg, Germany, March 2010 
 
-  “The alarmin interleukin 33 and its role in psoriasis” 
Invited speaker 
EULAR, Rome, Italy, June 2010 
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4.1 Aim and Introduction 
 
IL 33 is a novel cytokine of the IL 1 family and recently has been described to 
function as an alarmin. Arguments supporting this idea are expression in tissues 
with predominant barrier function, release upon cell death and broad biologic 
function with activation of several components of the immune system. The 
cellular expression is mainly in the nucleus in endothelial and epithelial cells but 
other cells have been reported to express IL 33. Initially described as “high 
endothelial nuclear factor” for its expression pattern in vessels, further work 
focused on its biology in regard to stromal organ expression and its effector 
function via the receptor ST2. Two recent reports focused on epithelial 
expression in the skin in diseases such as atopic dermatitis and psoriasis   
Theoharides showed higher expression in psoriasis of epithelial IL 33 compared 
to healthy skin: however the biology of IL 33 in these diseases is quite unclear 
(173, 194). 
Psoriasis is a disease which provides an ideal model choice to study IL 33: 
Psoriasis plaques occur at areas where constant microtrauma irritates the skin 
and tissue. These are commonly knees, scalp and elbows. Another feature of 
psoriasis is Koebners phenomenon by which physical trauma to the skin can 
trigger a psoriasis lesion. Whilst disruption of the body barrier “skin” and 
constant mechanical microtrauma can lead to inflammation, the role of IL 33 has 
not been studied in this context despite it potentially fulfilling as an alarmin all 
features necessary to trigger inflammation. Thus this chapter aims to 
understand the role of IL-33 in psoriasis with the specific task of exploring the 
following hypothesis (Figure 4.1):  
‘IL 33 is expressed by human keratinocytes; an insult to the skin releases IL 33 
due to cell damage of some kind. Dermal immune cells, especially mast cells 
which express the IL 33 receptor ST2 are stimulated by IL 33 and become 
activated. Mast cells produce cytokines and chemokines which recruit other 
immune cells and in the appropriate context (e.g. a psoriasis patient) 
inflammation is maintained and lesions develop.’ 135 
 
 
 
Figure 4.1 Hypothesis for the role of IL-33 in psoriasis 
Left image shows a histological section of the human skin. Aim is to examine if IL-33 
release by an insult can activate immune cells and lead to skin inflammation. 
 
 
Furthermore, and provoked by ideas emerging in the exploration of the potential 
role of IL 33 in barrier tissues, this chapter also addresses the expression of IL 33 
in arthritis and provides entirely novel preliminary construct data for a 
transgenic mouse expressing IL 33 under a keratinocyte 14 promoter. In 
particular, IL 33 expression during embryogenesis has been determined. 
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4.2 IL-33 and ST2 is expressed in inflammatory tissue 
such as psoriasis 
4.2.1 Expression of IL-33 and ST2 in autoimmune diseases 
IL 33 has been reported to be expressed in cells of body barriers but also in 
associated inflammatory tissues for example tonsils. The aim of the following 
experiments was to investigate IL 33 expression in inflammatory diseases such as 
inflammatory arthritis and psoriasis. To evaluate IL 33 expression, IHC staining 
was performed on tonsil tissue serving as a positive control (Figure 4.2). 
Consistent with previous reports, IL 33 was detected in the nuclei of endothelial 
cell area. These cells could also be fibroblast reticular cells described by 
Moussion (147). After establishing the methodology for IHC of IL 33, skin from 
healthy individuals was investigated. Strong nuclear staining was detected in 
endothelial cells in the dermis (black arrows), but also weak staining of nuclear 
IL 33 was noted in the stratum spinosum of the epidermis (dashed arrows) 
(Figure 4.3). 
Focusing on inflamed tissue, psoriasis skin was studied next. Hereby, two sample 
types were examined: Biopsies of lesions (psoriasis plaques) and perilesions. 
Perilesions were defined to be macroscopic healthy skin with no signs of 
inflammation such as redness, induration or scaling but to be in close 
conjunction to a psoriasis lesion (approx 1 cm distance from the leading edge of 
the psoriatic lesion). IHC revealed strong epidermal expression of nuclear IL 33 
in the stratum spinosum of lesional skin (Figure 4.4). Compared to other body 
barriers such as bronchial epithelium in which local tissue stromal stem cells 
express IL 33, basal keratinocytes (local epidermal stem cells) did not stain for 
IL 33 (240). Evaluating the number of IL 33 positive cells, lesional skin appeared 
to express higher levels of cytokine than perilesional skin. Further epidermal 
expression compared to endothelial staining appeared stronger in psoriasis skin 
than healthy skin (Figure 4.3 compared to Figure 4.4). This subjective evaluation 
has been confirmed with mRNA data by Theoharides et al (194). Together these 
data suggest that IL 33 is upregulated in at least lesional psoriasis and when 
considered in conjunction with data from Theoharides et al even in perilesional 
skin compared to healthy skin. (We did not reproduce those data for time and 137 
 
resource constraints) 
 
 
Figure 4.2 IL-33 in tonsil – work up of IHC staining 
Paraffin sections of tonsils have been stained for IL-33 (brown dye) using Nessy-1 as 
primary antibody. Top row shows parafollicular nuclear staining pattern for IL-33. Bottom 
row shows the isotype staining. Left panel 10x magnification, right panel 40x. 
Representative pictures of at least n=3. Counterstain with haematoxylin. 
 
 
Figure 4.3 IL-33 expression in healthy skin 
Immunostaining for IL-33 in healthy skin (n=2). Right image shows IL-33 (brown dye) with 
positivity in endothelial cells in the dermis (black arrows). Weak staining is demonstrated in 
the epidermis with IL-33 only expressed in the stratum spinosum (dashed arrows). 
40x magnification, counterstain haematoxylin. 138 
 
 
 
Figure 4.4 IL-33 in psoriasis 
Psoriasis skin expresses IL-33 in the stratum spinosum. Lesional and perilesional skin was 
stained by IHC with anti IL-33 (Nessy-1) (brown dye). Left panel shows lesional plaque 
psoriasis sections with two donors (top and middle) and isotype control (bottom). Right 
panel shows perilesional skin sections (biopsy tissue 1 cm distance to a psoriatic plaque) of 
the same patients. Nuclear staining is detected in all samples in the dermis (endothelial 
staining) and epidermis restricted to the stratum spinosum. No staining is visible in the 
stratum basale (epidermal stem cells). Magnification 40x. Counterstain with haematoxylin. 
Representative histology of n=5. 
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In Figure 4.3 and Figure 4.4 basal stem cells are shown without expression of IL 
33. To confirm this restriction, keratinocyte cell lines were examined for IL 33 
expression. Two cell lines were tested: HaCaT, a human immortal non cancerous 
keratinocyte cell line and nHEK which are neonatal foreskin derived human 
epidermal keratinocytes which both reflect basal keratinocytes. Cells were 
cultured on chamber slides and stained for IL 33. Procedures were slightly 
altered compared to paraffin IHC as the fixation process was different for the 
cell lines. In concordance with my skin expression data, IL 33 did not stain in 
keratinocyte cell lines (Figure 4.5). However, in nHEK only a few positive cells 
were detected (less than 1%). Also stimulation with cytokines (IL 1 or TNF α) or 
LPS did not upregulate IL 33 (data not shown, similar pictures like Figure 4.5). 
To account for the method alterations applied to cell lines, other experiments 
demonstrated IL 33 in cultured cells as positive control (see “Figure 4.10 IL 33 
expression in synovial fibroblasts” and “Figure 4.28 Transfection of HaCaTs with 
K14 IL 33”). In conclusion these data confirm the lack of IL 33 expression in 
basal keratinocytes. 
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Figure 4.5 IL-33 is not expressed by basal keratinocyte stem cells 
IL-33 immunostaining of HaCaTs and nHEK cells (n=2). Experiments to active/differentiate 
HaCaTs to express IL-33 lead to no result (see Figure 4.28 Transfection of HaCaTs with K14 
IL-33). 141 
 
Next, the expression of the IL 33 receptor ST2 was determined in skin. Healthy 
tissue from 2 donors was stained by IHC (Figure 4.6). Positive cells were 
detected in the dermis, most likely revealing expression in endothelial cells. 
Staining could also be observed in the basal keratinocyte cell layer. The cellular 
staining pattern was associated with membrane and cytosolic localisation, but 
unexpectedly, was also partly nuclear. Controls demonstrated no non specific 
binding of the isotype antibody. 
In contrast to healthy skin, psoriasis biopsies showed a different pattern of ST2 
expression. Here, ST2 was widely expressed in the cellular dermal infiltrates, 
but also in vessels and basal keratinocytes (Figure 4.7). In comparison to the 
lesional skin, ST2 was expressed in perilesional skin at lower levels, limited to 
the vessels and keratinocytes and a few scattered mononuclear cells. Cellular 
expression ranged again from nuclear, cytosolic to membranous patterns. Thus, 
ST2 expression is higher expressed in lesional psoriasis skin compared to 
perilesional and healthy skin. This demonstrates a system in which endothelial 
cells can potentially react upon local release of IL 33. While ST2 in healthy skin 
could lead to an immune response (ie fulfilling alarmin type function), inflamed 
psoriasis lesions highly express ST2 and therefore could be more susceptible to 
local IL 33 production and lesion induction. 
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Figure 4.6 ST2 expression in healthy skin 
ST2 immunostaining in healthy skin (n=2). Staining is limited to endothelial cells and 
inflammatory cells guarding the epidermis. Staining of keratinocytes accumulates in the 
basal layer. Staining pattern ranges from membrane, cytosolic but also nuclear expression. 
HS-1 and HS-2: Healthy skin donor 1 and 2. Top row: 10x magnification, second and third 
row show different areas (40x magnification). Bottom row: Isotype control of HS-1 (10x left 
and 40x right). 
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Figure 4.7 ST2 expression in psoriatic skin. 
ST2 immunostaining in psoriasis (lesional and perilesional, n=5). ST2 is widely expressed in 
cellular infiltrates in the dermis but also in endothelial cells (1
st and 2
nd row). Staining of 
keratinocytes accumulates in the basal layer. 3
rd row shows perilesional skin as 
comparison. Less ST2 is present due to lack of cellular infiltrates. Staining pattern ranges 
from membrane, cytosolic but also nuclear expression. Bottom row: isotype. Ps-1 and Ps-2: 
psoriasis patient donor 1 and 2. Left column 10x magnification, right column 40x. 144 
 
Whereas in skin IL 33 and ST2 is present representing a potential alarmin – data 
about IL 33/ST2 expression in inflammatory arthritis have been thus far only 
sparsely reported.  Girard and colleagues showed that IL 33 is expressed in 
endothelial cells in the RA synovium; another group however, demonstrate IL 33 
in RA synovial cells, speculating expression in endothelial cells but also 
macrophages (136, 145). ST2 staining is reported in vitro derived synoviocytes, 
however, tissue staining had not been formally described as I set out in my 
thesis. 
Therefore I sought to determine IL 33 and ST2 expression in inflammatory 
arthritis to possibly link the hypothesis of this chapter for psoriasis with inflamed 
joint pathogenesis. Staining was performed in 9 individual RA and 3 PsA synovial 
tissues. Surprisingly, expression was limited in all tissues to endothelial 
structures (Figure 4.8). Inflammation severity ranged between tissues, but even 
in highly inflamed sections no staining of inflammatory cells for IL 33 could be 
detected (e.g. # 1, 2, 6, 7, 8, Figure 4.8). Similar results were obtained in PsA 
synovia (data not shown). Further, to test whether ST2 is located with IL 33, 
staining for ST2 and IL 33 in the same area was examined. As with the psoriasis 
data, ST2 was widely expressed in cellular infiltrates of lymphocytic aggregates 
in the RA synovium (Figure 4.9, top left image). In contrast, IL 33 was only 
weakly expressed in endothelial structures surrounded by ST2 expressing cells. 
Kuchler et al showed that over time, and dose dependently, TNF α 
downregulated IL 33 in HUVECs (human umbilical vein derived endothelial cells) 
(178). The conclusion that IL 33 is downregulated by local proinflammatory 
microenvironment as suggested by Kuchler et al can not be drawn due to the low 
numbers of samples evaluated in my study; this remains an area requiring future 
analysis. 
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Figure 4.8 IL-33 expression in rheumatoid arthritis 
IL-33 immunostaining of RA tissue derived from arthroplasty or arthroscopy (n=9). IL-33 is 
limited to endothelial cells (brown staining). No expression in fibroblasts or macrophages is 
detected. Top left and top middle image 10x magnification, all others 40x. grey box show 
isotype control for sample #1. #1-9 show different tissues of individual donors. Counterstain 
with haematoxylin. 
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Figure 4.9 ST2 and IL-33 expression in rheumatoid arthritis 
Immunostaining for ST2 and IL-33 in one RA tissue (DAB, brown dye). ST2 is detected in 
multiple cells, mainly mononuclear inflammatory infiltrates. Also endothelial cells are 
positive. Top left (10x) and middle left (40x) image show ST2, bottom left (40x) demonstrates 
IL-33 staining which is further digitally magnified to show endothelial nuclear staining. Right 
column: isotype controls. Counterstain with haematoxylin. 
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IL 33 has been reported to be expressed in fibroblasts derived from synovial 
tissue. This supports IL 33 expression reported in other manuscripts, however, 
contradicts the in situ observations stated above (Figure 4.8 and Figure 4.9). 
Therefore synovial fibroblasts were examined for their expression of IL 33 by 
IHC. Fibroblasts were cultured until 80 % confluency and then split and plated on 
chamber slides, stimulated with or without TNF α and IL 1. 18 hrs later cells 
were fixed and stained for IL 33 using the same protocol as for synovial staining. 
In confirmation with the literature, IL 33 was detected in a nuclear expression 
pattern in in vitro cultured fibroblasts and upregulated with stimulation (Figure 
4.10). Interestingly, only the stimulus to re plate fibroblasts lead to IL 33 
expression in a few cells (media only control). This was not the case in longer 
cultured cells (personal communication, Mr J. Reilly, Mr N. Millar, University of 
Glasgow).  At this time I am unable to reconcile the dataset herein reported and 
that observed elsewhere –clearly fibroblasts have the potential to express IL 33 –
those from human tendinopathy and ex vivo lines as noted above are clearly 
positive.  In future studies in situ hybridisation might usefully delineate the 
origin of IL 33 expression in synovial tissue ex vivo. 
 
 
 
 
Figure 4.10 IL-33 expression in synovial fibroblasts 
Cultured fibroblasts have been stimulated with TNF and IL-1 (middle image) (n=1). After 
fixation IL-33 has been determined by IHC (DAB, brown dye). In the media only control (left 
image) view cells express IL-33 which is limited to the nucleus. Stimulation upregulated 
nuclear IL-33 (middle image). Right image: isotype. Magnification 40x, counterstain with 
haematoxylin 
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In addition to tissue cytokine and receptor expression and given the peculiar 
nature of IL 1 superfamily receptor and soluble receptor components, I also 
wished to define the soluble receptor expression in the synovial and serum 
compartment. Soluble ST2 expression has been reported to be significant higher 
in synovial fluid of RA patients compared to osteoarthritis fluid, but also in RA 
serum compared to healthy controls (180, 241). Mok et al demonstrated higher 
expression of sST2 in SLE patients (151). Here, I sought to determine the levels 
of sST2 in PsA serum and fluid compared to healthy controls or osteoarthritis as 
control, respectively. Similar to RA, sST2 was significantly elevated in PsA serum 
samples (n=36) compared to healthy controls (n=41) (unpaired t test, p = 0.005, 
Figure 4.11, left panel). These levels were lower than lowest levels reported 
with heart failure or acute myocardial infarction (188, 242). Focussing on 
synovial fluid samples, 16 PsA and 18 OA samples were analysed. Only in 5 PsA 
samples was sST2 detectable, all other samples levels were below the threshold 
of the assay (Figure 4.11, right panel). This could reflect true fluid 
concentrations or be due to the fact of sample storage, possible freeze thawing 
or age of the sample.  It is also possible that consumption by tissue binding or 
neutralisation of the binding assay by free IL 33 could interfere with detection. 
To conclude, IL 33 and ST2 is expressed in inflammatory disease tissue. The 
expression of IL 33 in vascular endothelial cells is undoubtedly. Evidence that IL 
33 plays a role in autoimmune arthritis is strongly demonstrated by local 
expression of ST2 and also elevated sST2 in synovial fluid. Supporting other 
reports, I was able to detect IL 33 in synovial tissue, however, with only low 
expression in endothelial cells. This could be due to the stage of disease (in this 
case established arthritis) showing possible differences of IL 33 expression in 
early vs. established disease. These data deliver insights that IL 33/ST2 might 
play a role in joint inflammation or is involved in maintenance of the disease. 
Further work is required to address these points. 
Expression in skin, especially in psoriasis is evident. Thus after showing how mast 
cells act on IL 33, next experiments sought out to address the influence IL 
33/ST2 on skin inflammation. 
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Figure 4.11 sST2 expression in PsA and healthy control serum and PsA and OA synovial 
fluid 
Soluble ST2 serum levels show a significant increase in PsA patients compared to healthy 
controls measured by ELISA (left panel). Detection of sST2 levels in PsA SF compared to 
OA fluid. Only in 5 out of 16 PsA patients sST2 is detectable (right panel). The rest of 
samples are below detection threshold. Unpaired t test, p=0.005. Line indicates mean. 150 
 
4.2.2 Interaction of IL-33 with mast cells 
I next sought to define cellular subsets based upon the foregoing datasets and to 
move towards cellular testing systems to evaluate IL 33 effects in vitro. Mast 
cells and Th2 cells have been reported to express high levels of ST2 (132). 
Furthermore many reports have been published suggesting that mast cells 
respond by cytokine/chemokine production upon IL 33 stimulation. With IHC 
data suggesting that keratinocytes express ST2, I sought to test if the 
keratinocyte cell line HaCaT and the mast cell line HMC 1 (as positive control) 
express ST2 and can be stimulated with IL 33. 
HaCaT and HMC 1 cells were stained with ST2 FITC antibody and analysed by 
FACS with dead cell exclusion (Viaprobe, 7 AAD). For HMC 1 cells a clear shift in 
expression of ST2 was detectable (Figure 4.12 A). However, very few HaCaTs 
expressed ST2 (less than 3%, Figure 4.12 B). In parallel, cells were tested for 
their capacity to respond to IL 33. HaCaTs did not respond to IL 33 (data not 
shown). HMC 1 demonstrated dose dependent production of huCCL 3 (MIP1 
alpha) confirming data from the literature (Figure 4.13).  151 
 
 
Figure 4.12 Expression of ST2 in HMC-1 and HaCaTs 
FACS analysis of HMC-1 (A, n=1) and HaCaTs (B, n=2)  show expression of ST2 in mast cells 
but only few HaCaTs express ST2. A: left dot blot shows forward sideward scatter plot of 
HMC-1, right histogram of HMC-1 expression (green line) and isotype control (red line). B: 
left dot blot, HaCaTs stained with isotype control and dead cell exclusion marker (viaprobe, 
7-AAD). Right: ST2 in HaCaTs. 
 
Figure 4.13 Stimulation of HMC-1 with IL-33 
HMC-1 (1*106/ml) stimulated with IL-33 for 24 hrs produce dose dependently huCCL-3 (left 
graph). Right graph shows stimulation with 100 ng/ml IL-33. Mean and SEM of 4 
independent experiments done in at least triplicates. ** p<0.01, paired t test. CCL3 = 
MIP1alpha. 152 
 
4.3 The role of IL-33 in skin inflammation mouse models 
4.3.1 TPA induced skin inflammation 
The preceding datasets clearly demonstrate IL 33 / ST2 expression in skin – 
however, little has been defined as to their functional significance. Phorbol 
esters administered on the skin can induce an inflammation process which shows 
in wild type mice a transient inflammatory response (67). To test the influence 
of IL 33 in this model wild type mice (BALB/c) compared to ST2 deficient mice 
were investigated. With the hypothesis that this inflammation process also leads 
to release of IL 33, subsequently inflammation processes should be reduced in 
the ST2 deficient mice. Jamieson et al analysed epidermal thickness as a 
hallmark of dermatitis/psoriasis as well as cellular infiltrates (67). 
Tested in 2 independent experiments, backs of mice were shaved, rested for 1 
day and then treated with TPA for 2 subsequent days. After 1 day rest, skin was 
harvested and processed. Epidermal thickness measured by histology showed 
significant differences whereby ST2 deficient mice exhibited nearly normal 
epidermis compared to inflamed thickened epidermis in wildtype mice (p<0.01, 
Figure 4.14 A, C). Also cell layers were significant increased in wildtype 
littermates (p<0.001, Figure 4.14 B, C). Furthermore, cellular infiltrates 
appeared to be reduced in the ST2 deficient mice; however, this was not 
objectively analysed. To determine if the keratinocyte proliferation was 
different in ST2 deficient compared to wildtype mice, IHC for ki67 (a 
proliferation marker) was performed. Significantly less ki67 was detected in ST2 
deficient mice, demonstrating reduced levels of proliferation compared to 
wildtype mice (p<0.05, Figure 4.15). 153 
 
 
Figure 4.14 TPA induced skin inflammation – Role of IL-33/ST2 
TPA treatment of mouse skin for 2 days in WT (n=15) or ST2 deficient mice (ST2
-/-, n=16) of 
two pooled independent experiments. Histological analysis shows a significant decrease in 
ST2
-/- mice of epidermal thickness (A) and cell layers (B). C shows representative histology 
images, left column wildtype BALB/c mice, right ST2 deficient mice. Top row 10x 
magnification, bottom 40x. Staining with haematoxylin and eosin. 
Unpaired t test, ** p<0.01, *** p<0.001. 154 
 
 
 
Figure 4.15 TPA induced skin inflammation – Ki67 proliferation analysis. 
Immunostaining for ki67 (DAB, brown dye) in TPA treated skin. Significant decrease of ki67 
expression ranking in ST2 deficient mice (graph) (similar ranking method published in 
(130)). Bottom images show representative histology for BALB/c wildtype (n=7) and ST2-/- 
mice (n=8). Mann Whitney test, * p<0.05. 155 
 
To test if this effect was more marked in a longer time course, mice were 
treated with TPA 3 days instead of 2 with once again a day allowed for recovery 
before skin harvest. Surprisingly, in this 3 day TPA model, no differences in 
epidermal thickness and cell layers were observed (Figure 4.16).  This suggests 
that the effects of IL 33 are manifest at an early time point – again consistent 
with alarmin type function. 
In parallel, TPA painting in wildtype (C57Bl/6) and mast cell deficient mice 
(kit
ws h/ws h) showed no difference in epidermal thickness (Figure 4.17 A). Mice 
were used at age of 8 weeks; while a published manuscript stated that in kit
ws 
h/ws h mice mast cells still reside in the skin up to 8 weeks, no mast cells were 
detectable in this experiment and hence likely reflect true mast cell deficient 
mice (Figure 4.17 B). 156 
 
 
Figure 4.16 TPA induced skin inflammation ST2 dependency resolved after 3 days. 
TPA treatment of mouse skin for 3 days in WT (n=7) or ST2 deficient mice (ST2
-/-, n=8). 
Histological analysis show no difference in of epidermal thickness (A) or cell layers (B). 
 
 
 
Figure 4.17 TPA induced skin inflammation in mast cell deficient mice – no difference after 3 
days. 
TPA treatment of mouse skin for 3 days in WT (n=9) or mast cell deficient mice (kit
ws-h/ws-h, 
n=8). Histological analysis shows no difference in epidermal thickness (A). B shows 
toludine blue staining for mast cells of mouse skin (purple staining). Representative image 
wildtype C57/Bl6 (top) and kit
ws-h/ws-h (bottom) mouse skin. 10x magnification. 157 
 
 
4.3.2 IL-33 intradermal ear injections – a model of skin 
inflammation 
The above data demonstrate that ST2 deficiency protects skin in early phases of 
inflammation induced by phorbol esters. This is likely an indirect effect by 
preventing IL 33 signalling. As next step I sought to determine what effect IL 33 
administration would have when exposed to local skin structures.  
To test the bioactivity of IL 33, mouse splenocytes from ST2 deficient mice or 
BALB/c control mice were stimulated with IL 33 for 24 h and supernatants 
harvested for IL 5 analysis. Cells responded dose dependently with IL 5 
production (Figure 4.18). This effect was totally abolished in ST2 deficient 
splenocytes. These data confirm the bioactivity of the recombinant preparations 
of cytokine employed herein. 
Thereafter, a psoriasis model was used in which recombinant cytokine was 
injected intradermally every alternate day into the ear pinna of a mouse. Similar 
to previously reported cytokine injections that included 500 ng of IL 22 or IL 23, 
injection of 500 ng IL 33 was used as described in the methods chapter. Time 
scale and injections of this model are shown in Figure 4.19 A. On day 16 of the 
model, mice were sacrificed, and ears, serum and spleen harvested. Spleen 
weight was determined as a surrogate for bioactivity. Interestingly, spleen size 
and weight increased in IL 33 injected mice compared to controls showing a 
possible leakage from the site of injection (Figure 4.19 B). 158 
 
 
Figure 4.18 Validation of the biological function of recombinant IL-33 
Splenocytes of BALB/c (WT) or ST2 deficient mice (ST2-/-) were cultured 24 h with IL-33 at 
different doses (0, 0.1, 1 or 10 ng/ml). Supernatant was harvested and tested by ELISA for 
IL-5. Shown are means with SEM of triplicates (n=1). 
 
 
Figure 4.19 Model of injection and in vivo biological activity of IL-33 
A. Ear injection model with injection of 20  l of PBS or IL-33 every alternate day (arrows). 
Harvest of ear, spleen and serum on day 16. B. Splenomegaly at day 16 after injection of IL-
33 (right image, representative picture). Left graph mean weight of n=5/group. Results are 
reported as means +/- SEM, Unpaired t test, p<0.001. 159 
 
Mice were anesthetised, ear thickness was measured with a calliper and then 
cytokine or PBS injected (20  l volume). In the first week, no differences in ear 
swelling were observed. However, from day 11 onwards a differential phenotype 
between PBS and IL 33 injected mice was detected. On day 16 a significant 
difference in ear thickness was measured between groups (Figure 4.20 A). To 
test if IL 33 had an immediate effect on this tissue, mice were measured post 
injection on day 15. Measurements were performed 15, 30 and 60 min after 
injection; further 2 h and 24 h time points were added (Figure 4.20 B). To 
determine a difference, delta thickness compared to time point zero was used. 
Whereas the PBS group which showed initial swelling due to the injected 
volume, resolved swelling after ~ 60 min, the IL 33 group reached higher levels 
of ear thickness and sustained these over time. This significant difference of ear 
swelling demonstrated a higher response to the injection with IL 33 than with 
PBS. 
To address possible methodological errors, ears were harvested on day 16, fixed 
and processed for histology. In haematoxylin and eosin (H&E) staining ear 
thickness but also epidermal thickness was determined. In agreement with the 
calliper measurements significant increase in ear and epidermal thickness was 
seen in the IL 33 administered group (Figure 4.21). 
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Figure 4.20 IL-33 induces ear swelling in an ear injection model   
Ears from BALB/c mice (n = 5 for each group) were injected intradermally every other day 
with 500 ng IL-33 or PBS in a total volume of 20  l. Ear thickness was measured before each 
injection (A). Time course of swelling after injection was measured on day 15 showing 
relative thickness difference in both groups (B). Filled squares: IL-33, open circles: PBS. 
Results are reported as means +/- SEM and analysed by 2 way anova. *** p<0.0001. 
Representative experiments of at least n = 2. 
 
Figure 4.21 IL-33 injection- histological readout (H&E) 
On day 16 ears were collected for H&E (A) and were analysed for ear and epidermal 
thickness (B). A shows representative images of PBS injected (left) and IL-33 injected ears 
(right). Magnification 10x (top) and 40x (bottom). B: Filled squares: IL-33, open circles: PBS. 
Results are reported as means +/- SEM and analysed by unpaired t test; *** p<0.0001, ** 
p<0.01. Representative experiments of at least n = 2. 161 
 
To determine the cellular components subserving this increased tissue 
induration, H&E sections were analysed for cellularity staining, and further 
sections were stained with toludine blue for mast cell determination. On day 16, 
a significantly higher number of mast cells were present in the IL 33 treated 
group compared to PBS (purple stain, Figure 4.22 A, B). Also significantly more 
eosinophils were visible in the IL 33 injected group (pink stain, Figure 4.22 C). 162 
 
 
Figure 4.22 IL-33 ear injection –infiltration of mast cells and eosinophils 
On day 16 ears (n=5/group) were collected for toludine blue and H&E staining (A, B) and 
were analysed for cellular expression. A: Mast cell staining (purple, toludine blue) with 
representative image of PBS group (left) and IL-33 group (right). B: Quantification of mast 
cell numbers. Filled squares: IL-33, open circles: PBS. C: Eosinophil count with 
representative images (40x magnification): bottom right PBS, bottom left: IL-33 and top right 
digitally magnified to demonstrate eosinophil morphology. Results are reported as means 
+/- SEM and analysed by unpaired t test. *** p<0.0001, ** p<0.01. Representative experiments 
of n = 2. 
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Next, I investigated if the effect of IL 33 on ear inflammation, associated with 
thickening of the ear but also the epidermis as well as cellular infiltration, was 
specific or due to experimental errors such as LPS contamination or other 
influences. To address this question the IL 33 ear injection model was performed 
in wildtype (BALB/c) mice and ST2 deficient mice. This would render IL 33 
signaling impossible with deficiency in its receptor. Injection into wildtype mice 
demonstrated again the potential for ear swelling over time compared to PBS 
controls (Figure 4.23 A). Injecting IL 33 in the same experiment into ST2 
deficient mice led to no increase in ear thickness (Figure 4.23 B). Also 
histological ear analysis on day 16 demonstrated no increase in histological ear 
or epidermal thickness (Figure 4.23 C). Ear size rather reflects values measured 
with the PBS control mice (Figure 4.21 B). 
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Figure 4.23 IL-33 ear inflammation is ST2 dependent 
ST2 deficient mice (ST2
-/-) are protected from increase in ear thickness when treated with 
intradermal IL-33 compared to control BALB/c mice (n=8 per group, one experiment)(B). A 
shows control experiment with PBS and IL-33 group (2 way Anova, *** p<0.005). Histology 
analysis confirms normal ear (C) and epidermal (D) thickness , unpaired t test, ** p<0.01, *** 
p<0.005). WT: wildtype control mice. Results are reported as means +/- SEM. 165 
 
Whereas the above experiments provide proof of concept that IL 33 induces ST2 
specific psoriasis like dermatitis the next question I sought to address was if this 
effect was mast cell dependent. To test this I made use of mast cell deficient 
mice (kit
ws h/ws h mice). Previously mast cell numbers have been examined and 
these experiments revealed that mice with age 8 weeks still have mast cells 
present in the skin despite organ deficiency (243). To ascertain that the mice 
were totally deficient for mast cells I used mice with age of ~ 6 months. 
Surprisingly, mast cell deficient mice have thinner ears than control littermates 
(C57BL/6 mice)(~200  m compared to 300  m). To account for this difference, 
both ears per mouse were measured and delta thickness (  thickness) left to 
right was determined.  
Over the time course of IL 33 injection mast cell deficient mice reached a 
similar   thickness at day 16 compared to controls (Figure 4.24 A). However, 
there was significant difference over the whole experiment (2 way anova, p < 
0.05) that was also elucidated with a reduced value of the area under the curve 
(AUC, Figure 4.24 B). When focussing on the first 9 days of this experiment an 
initial delay in response to IL 33 is evident (Figure 4.24 C, focused on the shaded 
part of the curve in Figure A). This could explain the significant difference; over 
time, however, mast cell deficient mice catch up most likely due to the 
influence of other ST2 expressing cells. This demonstrates a partial influence of 
mast cells for early responses in IL 33 exposition. 
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Figure 4.24 IL-33 initial effect in ear inflammation is partial dependent on mast cells 
IL-33 injection model in mast cell deficient mice (Kit
ws-h/ws-h, age of 6 months) demonstrate 
initial impaired response to IL-33 with reduce thickening of the ear (A, C). However, on day 
16 there is no difference in thickness comparing WT to Kit
ws-h/ws-h mice. B: area under the 
curve (AUC) of graph A. C: focused on gray shaded area in A to visualise early time point. 
Filled squares: IL-33, open circles: PBS. 2 way anova (A): p < 0.05. Results are reported as 
means +/- SEM. N=6 per group, one experiment. 
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Systemic responses were verified by increase in weight and size of spleens 
(Figure 4.18). To determine what cytokines change systemically in the serum of 
IL 33 treated mice, serum from the cull day (day 16) was harvested and analysed 
by luminex. This included the following: IL 1β, IL 1ra, IL 2, IL 2R, IL 4, IL 5, IL 6, 
IL 7, IL 8, IL 10, IL 12 (p40), IL 13, IL 15, IL 17, TNF α, IFN α, IFN γ, GM CSF, 
MIP 1α, MIP 1β, IP 10, MIG, Eotaxin, RANTES, and MCP 1. Interestingly, 
significant differences were detected only in the signature cytokines IL 5 and IL 
13 (Figure 4.25 A). Also a significant increase in KC and MCP 1 was identified. All 
other cytokines/chemokines were either not detectable or there were no 
differences in their expression patterns observed. 
To determine if neutrophils are increased in IL 33 treated ears recruited by KC, 
IHC for myeloperoxidase (a marker for neutrophil granulocytes) was performed. 
MPO was only detected in IL 33 treated ears (Figure 4.25 B) thus showing an 
accumulation of neutrophils which could have been recruited by KC.  
While end point studies revealed an increase in mast cells, eosinophils and 
neutrophils (Figure 4.22, Figure 4.25 B) the initial triggers of inflammation are 
unclear. To investigate what cells are recruited in the early phase of swelling 
the injection model was performed in 2 independent experiments (n = 2 per 
group) and at day 10 ears were harvested, cells isolated and analysed by FACS 
for lineage markers. At day 10, a significant change in ear thickness was already 
measurable (Figure 4.25 C). Harvested “ear” cells were stained for CD3, CD4, 
CD19, CD11b, CD11c, F4/80, Gr 1 to cover T and B cells, the myeloid lineage 
with monocytes, macrophages and DC and neutrophils. No difference was 
observed with the exception of the lineage of macrophages and neutrophils. 
Macrophages changed from a mean of 8.19% (PBS) to 14.33% (IL 33) (data not 
shown). More impressive however, was the influx of neutrophils with more than 
8 fold increase from a mean of 0.73% (PBS) to 6.03% (IL 33) (Figure 4.25 D, E). 
This clearly demonstrates an early influx of neutrophils into the tissue mediated 
by IL 33.168 
 
 
Figure 4.25 Cellular recruitment by IL-33 
On day 16 of IL-33 or PBS injected mice (see Figure 4.20), serum was collected and 
cytokines and chemokines measured by luminex assay (all pg/ml) (A). Ears collected were 
immunostained for neutrophils using myeloperoxidase (B). Images shown are 
representative of n = 5/group (one experiment). On day 10 (C), infiltrating cells were 
harvested and stained for lineage marker CD11b and Gr-1 (D). Shown is a representative dot 
blot. Neutrophils were analysed by CD11b Gr-1 positivity (n = 4/group of 2 pooled 
independent experiments) (E). Unpaired t test, ** p < 0.01, *** p < 0.0001 (A,E), 2 way anova 
(C), *** p < 0.001. Results are reported as means +/- SEM. 
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4.4 Addendum - Miscellaneous biologic questions 
surrounding IL-33 
The general biology of IL 33 remains quite intriguing.  Driven by curiosity I also 
undertook a variety of distinct but related experimental protocols which will 
form the foundation for future programmes of work – they are described briefly 
below. 170 
 
4.4.1 IL-33 in wound healing 
With this robust ability to recruit inflammatory cells IL 33 fulfils its role as a 
danger signal or alarmin. In regard to the initial hypothesis, it was proposed that 
an insult (mainly mechanical damage) leads to release of IL 33. In an individual 
with psoriasis clinically this mechanical trauma can lead to a new lesion.  
But what happens with a healthy individual? After a skin injury, wound healing 
starts immediately and is described in three phases that overlap in time: 
inflammation, tissue formation and tissue remodeling (244, 245). These phases 
proceed with a complicated but well organized and integrated interaction among 
various types of tissues and cells. During the inflammatory phase, platelet 
aggregation at the injury site is followed by infiltration of leukocytes, including 
neutrophils and macrophages, into the wound site. In the tissue formation 
phase, re epithelialisation and newly formed granulation tissue begin to cover 
the wound area to repair tissue destruction. And further extracellular matrix 
reorganisation occurs with wound contraction and collagen remodelling. 
To test the hypothesis that mechanical injury promotes release of IL 33 and this 
alarmin thereby recruit cells such as macrophages and neutrophils with the 
purpose of tissue repair the ST2 deficient mouse was used in a wound healing 
model. Five mm biopsies (2 per mouse) were induced on the shaved back of the 
anaesthetised mouse and photographs taken every day for analysis of the wound 
area (see methods chapter). Starting with n = 11 per group, every time point 3 
mice very sacrificed for possible histological analysis. At day 7 the experiment 
was terminated. Comparing the area of decrease in wound surface no significant 
difference between wildtype BALB/c mice and ST2 deficient mice were observed 
(Figure 4.26). To conclude, IL 33 does not possess a pivotal role in tissue repair, 
however, local overexpression of IL 33 might unbalance the healing process by 
maintaining neutrophil recruitment. 171 
 
 
Figure 4.26 ST2 deficiency does not influence wound healing 
Wound healing model with punch biopsies and measurement of healing in wildtype BALB/c 
(WT, open square) and ST2 deficient mice (ST2
-/-, black square). No significant difference 
between groups. Day 3 and day 5 3 mice per group were sacrificed, therefore numbers 
between days differ. n = number of biopsies (2 biopsies/mouse), one experiment. 172 
 
4.4.2 IL-33 expressed under the K14 promotor 
IL 1 family members have been shown to induce dermatitis when overexpressed 
in the skin under the influence of cytokeratin promoters. Recent studies from 
Blumberg et al demonstrated that IL 1F6 under a K14 promotor (K14) induces 
skin inflammation similar to psoriasis with acanthosis, hyperkeratosis, the 
presence of a mixed inflammatory cell infiltrate, and increased cytokine and 
chemokine expression (130). Here, I sought to test if IL 33 when overexpressed 
in the skin will lead to a skin phenotype. For this purpose a construct expressing 
IL 33 under K14 was designed and cloned. 
Human IL 33 was amplified with BamHI sites and cloned into the K14 containing 
vector (DNA and vector provided by Dr Gilchrist, Glasgow University) (Figure 4.27 
A, B). Figure 4.27 B shows the construct with K14, a β globin as spacer, IL 33 and 
the K14 pA part. Also BamHI sites flanking IL 33 as well as KpnI restriction site is 
shown. After digesting the new plasmid clones #1 5 contain IL 33 (Figure 4.27 C). 
Due to both sides containing BamHI, the construct could be orientated in both 
directions. Digesting the plasmid with KpnI led to two different patterns (Figure 
4.27 D, red box): a single band (#2) and two bands (#3). Form this result no 
conclusion about the orientation of IL 33 could be drawn nor would further 
restriction digest answer this. 
For this reason plasmid #2 and #3 were maxipreped and sent for sequencing. To 
test which of the plasmids translate for IL 33, HaCaT cells which express K14 
were transfected using Lipofectamine (225). Cells were transfected with the 
constructs and 24 h later stained for IL 33 by IHC. To control for baseline levels, 
stained HaCaTs did not express IL 33 nor did stimulation for differentiation with 
Vitamin D3 induce IL 33 (Figure 4.28 A). Mock transfection was negative, as was 
construct #2, however, construct #3 was expressed in HaCaTs with ~ 9% 
transfection efficiency (Figure 4.28 B E). 
With the sequence results confirming protein data, construct #3 was ready for 
pronuclear injection to generate a transgenic K14 IL 33 mouse; this will be 
outsourced in the future.  173 
 
 
Figure 4.27 Construct and design of the K14 IL-33 plasmid. 
A: Applification of IL-33. B. Schematic of the construct with K14 promotor, β-globin and IL-
33 insert, this is flanked by BamHI restriction sites, 3 prime K14 polyA tail. C. Restriction 
digest with BamHI which shows IL-33 insert in probe #1-5. D. Digest with KpnI; two different 
samples with different band pattern (#2 and 3, red box).174 
 
 
Figure 4.28 Transfection of HaCaTs with K14 IL-33 
A. Control with HaCaTs treated with vehicle or Vitamin D3 to upregulate IL-33. No staining 
by IHC detected. 40x magnification. 
B-E show transfection of HaCaTs with B mock, C #2, D and E #3.  24 h later cells were 
stained for IL-33 (A-D) or isotype (E). D: Nuclear staining in #3 (DAB, brown dye). Left 
column 10x, right column 40x.  
Counterstain with haematoxylin. N=1. 
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4.4.3 Embryonic function of IL-33 
As discussed in the introduction IL 33 is a cytokine with two possible functions. 
Nuclear localisation renders a function as a repressor of transcription with its 
homeodomain like helix turn helix structure. On the other hand, release of IL 33 
can lead to dramatic inflammatory responses or regulation thereof. Being 
initially described as high endothelial nuclear factor, a marker for endothelial 
cells, the question arose as to how far back in development a function could be 
assigned for IL 33. To address this question, the Gene Expression Nervous System 
Atlas (GENSAT) database from the National Center for Biotechnology Information 
(NCBI) was search for IL 33 expression. Embryos age D10.5 were tested with an 
IL 33 P33 labelled RNA probe by in situ hybridisation. Staining accumulates at 
the dorsal aorta (GENSAT, Image 42416
6) (Figure 4.30 C). 
This result demonstrates early expression of IL 33 mRNA in embryonic dorsal 
aorta. To address if IL 33 is present as protein to confirm and support this result 
breeding pairs were set up and embryos harvested at day 9.5 and 10.5 (Figure 
4.29). Embryos were fixed, processed, sections cut for histology and stained with 
H&E (Figure 4.29). Structures are visible with sagittal orientation and dorsal 
aorta. Next, embryonic sections from day 9.5 and 10.5 were examined for the 
protein expression of IL 33 using mouse anti human IL 33 which crossreacts with 
mouse IL 33. While the method worked and maternal vascular uterus tissue 
stained for nuclear IL 33, embryos at both age did not express IL 33 (Figure 4.30 
A, B). Focussing on the dorsal aorta, at the same region GENSAT IL 33 
hybridisation showed IL 33 expression, no staining by IHC could be detected 
(Figure 4.30 B, C). Thus embryo at day D9.5 and D10.5 do not express IL 33. 
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Figure 4.29 Embryo preparation day D9.5 
Pregnant mouse with minimal weight increase (left graph) and harvest of embryos at day 
D9.5 and D10.5 (not shown). After fixation and processing, embryos orientated and 
sectioned to obtain a sagittal section containing the dorsal aorta for IHC (right image). 
Composition from multiple images from 5x magnification. Staining with H&E. 177 
 
 
Figure 4.30 IL-33 is not expressed in the dorsal aorta day 9.5 or 10.5 
Immunostaining for IL-33 using mouse anti human IL-33 (Nessy-1) (n=1). A shows isotype 
control (left image) and maternal vascular uterus tissue which expresses nuclear IL-33 (right 
image, DAB, brown dye). B: dorsal aorta (10x, left image, 40x, right image) with no detection 
of IL-33. C: Pictures from GENSAT image 42416 to demonstrate area of interest. 178 
 
4.5 Discussion 
This chapter aimed to understand the role of IL 33 in psoriasis. Furthermore, 
more basic questions as to the biology of IL 33 were addressed as an adjunct 
component of my thesis work – this lead ultimately to embryogenesis based 
experimentation –in turn this sets the basis for extensive future exciting studies. 
IL-33 in arthritis   
Different reports have revealed the importance of IL 33 in inflammatory arthritis 
usually studying murine models of disease. Xu et al showed that IL 33 can 
exacerbate CIA and this was dependent on mast cells (146). Using an antibody 
induced arthritis model delivered further evidence that mast cells are crucial for 
IL 33 mediated inflammation in arthritis (197). On the other hand, CIA in ST2 
deficient mice or treatment with ST2 Fc or anti ST2 ameliorated severity (145, 
146, 246). With this strong evidence that IL 33 is a “bad” player in arthritis 
translation to human disease is mandatory. However, evidence for this is not as 
clear as the mouse data. First, IL 33 expression in synovium has been shown by 
three groups (136, 145, 146). Clear nuclear staining is visible; however, double 
staining approaches did not convincingly identify the origin of the cell. Further 1 
out of 3 groups present IL 33 only in endothelial cells (136). 
My own data show IL 33 expressed in endothelial cells, but not so much in other 
cells which are suggested as potential sources in the literature such as 
fibroblasts or macrophages (Figure 4.8 and Figure 4.9). It is possible to argue 
that fibroblasts express IL 33 with strong in vitro data supporting that fact 
(Figure 4.10). However, all publications and my own data do not confirm that 
fibroblasts are expressing IL 33 in situ. This is interesting since in vitro TNF and 
IL 1 strongly upregulate IL 33 in fibroblasts; these two cytokines are clearly 
present in RA synovium. Moreover, when splitting fibroblasts or stressing them in 
vitro (for example by scratching), expression of IL 33 is observed (own data, Mr 
Millar, Glasgow University). Thus it has to be questioned if IL 33 expression by 
fibroblasts could be an in vitro phenomenon. Moussion reported desmin positive 
fibroblastic reticular cells in tonsil tissue (147). Double staining in other 
inflammatory tissue has to be performed to determine if these cells are also 179 
 
present in RA synovium. In addition, CIA and AIA models test initiation and early 
phases of disease. With human biopsies studied so far, only snap shots of 
established diseases have been examined.  
Recently, a new issue arose. By redefining the biology of IL 33, a common 
conclusion is that IL 33 is released by necrosis and is deactivated by apoptosis 
associated caspases rather than activated by caspase 1 ((142, 143). All in vivo 
studies with IL 33 used a so called “mature” IL 33 which reflects the IL 1 like 
cytokine domain initially described by Schmitz et al (132). While this potent 
truncated recombinant cytokine might reflect the true biology of full length 
necrosis released IL 33, studies still need to be performed to clarify this issue. 
Focusing on the counterpart of IL 33, more and more studies report significantly 
elevated levels of sST2 in inflammatory diseases, raising the possibility that a 
decoy mechanism is in place to regulate IL 33 release and effector function. 
When comparing different studies a few inconsistencies merit attention. 
Elevated soluble ST2 has been reported in multiple myocardial infarction 
studies. Shimpo et al report four quartiles with the following ranges: I: 0.085–
0.179 (n = 204), II: 0.180–0.235 (n = 202), III: 0.236–0.346 (n = 202) and IV: 0.347–
6.88 ng/ml (n = 202) (brackets show patient numbers) (242). Weir et al reported 
in his cohort at baseline a median of 0.263 ng/ml (n = 100) (188). When focusing 
on inflammatory diseases only one, an SLE cohort serum analysis, has been 
reported. Mok et al show levels in their healthy controls with a mean of 0.36 
ng/ml (n = 28) compared to active SLE patients with 0.51 ng/ml (n = 61) (151). 
Surprisingly, these levels in healthy individuals reflect quartile III to IV in 
Shimpo’s study and are higher than levels reported in Weir et al’s manuscript. 
These levels would indicate a high risk for mortality. The question is if these 
different results are due to technical differences or differences in patients/ 
individual ethnicity. In comparison, the serum samples from individuals and PsA 
patients tested in this thesis were 0.033 ng/ml (n = 41) and 0.05 ng/ml (n = 36) 
respectively. This might again reflect technical differences or lack of numbers. 
More studies need to be performed in healthy controls to standardise the test for 
biomarker accreditation. 180 
 
In summary, more human studies are needed to translate and verify results from 
mouse arthritis models, further the biology of IL 33 needs to be re addressed in 
these models and sST2 as marker in inflammation more examined. 
IL-33 in psoriasis – a new role for a new cytokine? 
In this work, IL 33 overexpression in lesional psoriasis compared to perilesional 
or healthy skin was demonstrated (Figure 4.4). This has been confirmed by 
another group showing increased IL 33 mRNA levels from biopsies (194). When 
scratching a lesion of a psoriasis patient commonly this area can flare and even 
spread. Further mechanical damage of the skin can induce new lesions. This 
could concur with enhanced IL 33 mRNA levels of perilesional skin compared to 
healthy controls (194). To test this hypothesis two models have been used: TPA 
administration on the back skin and IL 33 intradermal injection. The phorbol 
ester TPA induces an non specific inflammation; here, it was demonstrated that 
ST2 has influence in the initial phase of inflammation and an effect on epidermal 
reaction including proliferation measured by thickening of this skin layer and a 
marker for proliferation (ki67) (Figure 4.14, Figure 4.15). What is unclear is how 
TPA induces IL 33 release. Further it is unknown what levels of IL 33 are 
achieved. Already after 2 days of TPA treatment a difference in epidermal 
thickness is observable, which is lost in a 3 day treatment. While this points to 
an innate early role for IL 33 long term data in this model are not available. For 
example TPA in D6 deficient mice, which develop a phenotype similar to 
psoriasis, is used 5 to 7 days and a resolution phase of up to one week has been 
studied (67). Thus IL 33 biology in a TPA model still leaves open questions. 
My other model, namely IL 33 intradermal injections, tackles the question from 
a different angle. IL 33 induces a ‘psoriasis like’ dermopathy in injected ears. 
This is ST2 dependent and partially mast cell dependent (4.3.2). It is unclear in 
what physiologic range the dose of 500 ng in 20  l per injection lies. From its 
potency it is unlikely to be realistic as repeated injections of IL 33 lead to 
splenomegaly. This is not a common feature during even remittent trauma in 
humans. However, data obtained give a hint to a micro/cellular level expressed 
during injury and damage. That this effect is multifactorial is demonstrated by 
the mast cell deficient experiment. There, only an initial partial difference is 
seen (Figure 4.24). It makes sense as other cells than mast cells express ST2 such 181 
 
as endothelial cells and maybe keratinocytes (Figure 4.7). Interestingly, KC is 
elevated in serum of mice treated with IL 33. This could explain recruitment and 
accumulation of neutrophils (Figure 4.25). Moreover, when injecting IL 33 
intraperitoneal, neutrophils are recruited; this can be blocked with anti KC 
antibodies (personal communication, Dr Alves Filho, Glasgow University). Verri 
et al reported that IL 33 induced neutrophil migration in an arthritis model 
(247). 
In contrast, beside KC, Th2 cytokines are also increased. While data in this 
chapter could explain a possible mechanism in psoriasis, Th2 related atopic 
dermatitis would be a similar phenotype with a totally different underlying 
pathogenesis. Melendez et al showed that IL 33 is upregulated in atopic 
dermatitis patients (173); also other IL 1 family members have been linked to 
atopic dermatitis, where transgenic mice expressing IL18 from the keratin 5 
promoter exhibit many features of atopic dermatitis, including infiltrates with 
eosinophils, mast cells and neutrophils (248). However, also an increase in tissue 
IL 12 and TNF α mRNA was observed. With the assumption that IL 33 regulates a 
Th2 type response, upregulation in psoriasis could be interpreted as a rescue 
mechanism to balance against the Th1/Th17 axis. On the contrary, Melendez 
showed that primary mast cells can produce IL 17 upon IL 33 stimulation which 
rather supports a role for psoriasis than atopic dermatitis in this context 
(personal communication, Dr Melendez, Glasgow University). Unfortunately, in 
ear models performed in this thesis, mRNA was not obtainable due to technical 
failure. 
In conclusion, IL 33 is upregulated in psoriasis. With its ability to induce an acute 
dermatitis and its potency as an alarmin IL 33 will most likely be a crucial player 
in this network of alarmin/cytokine/cell interaction. 
Embryonic IL-33 
The last aim of this chapter was to determine embryonic expression of IL 33. 
This subserves a core desire to understand the biology of nuclear IL 33 
expression. With GENSAT data, this experiment seemed to be conservative. 
However, staining embryo tissue revealed that IL 33 is not expressed in the 
embryo, especially not in the dorsal aorta (Figure 4.30). However, a closer look 182 
 
at IL 33 is needed before drawing early conclusions. Ensembl describes 4 variants 
of IL 33 (Figure 4.31). Surprisingly, the variant IL 33 003 only possesses exons for 
the homeodomain which is accounted as nuclear repressor. In addition, 
compared to full length IL 33, IL 33 003 contains a non coding exon 2 (Figure 
4.31 D). Taking this sequence of 120 bp (exon 2) of the homeodomain splice 
variant and using the blast machinery for mouse EST (expressed sequence tag) 
two hits are achieved. One cDNA hit for mouse male adult bladder and a second 
for cDNA of mouse embryo (day 16). This confirms the GENSAT data with IL 33 
expression in the embryo. Further it can explain why anti IL 33 did not stain 
embryo tissue. This antibody Nessy 1 has been raised against the IL 1 like 
cytokine domain, which is not expressed by this variant. Using an antibody 
against the N terminal part could determine if this protein is also translated at 
that development stage. Further PCR analysis could verify expression of 
different splice variants in the embryo. This is ongoing work. 183 
 
 
Figure 4.31 Splice variants of IL-33. 
Using Ensembl.org image has been imported. 4 splice variants for IL-33 are described there. 
IL-33-003 contains similar to 001 and 002 the homeodomain like HTH (A, C). In contrast, 003 
lacks the IL-1 like cytokine domain (B, C dashed box). A non coding exon is unique to 003 
(D). 184 
 
5  The use of nanoparticles to image inflammation 
Content of this chapter has been published in the following manuscript: 
 
-  Graham D, Thompson DG, Mckenzie F, Faulds K, Stevenson R, Ingram A, Stokes R, McFarlane 
E, Alexander J, Garside P, Hueber A, McInnes IB 
Functionalised nanoparticles and SERRS for bioanalysis. 
Proc. SPIE. 2009 Feb, Vol. 7192, 719202; DOI:10.1117/12.810161 
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5.1 Aim and Introduction 
Imaging of inflammation in vivo and in particular cytokine accumulation at the 
cellular/molecular resolution level is still not possible due to lack of technology 
which is sufficiently sensitive and specific. I set out to explore the notion that 
surface enhanced resonance Raman scattering (SERRS) technology could be 
utilized to facilitate nanoparticle imaging as a potential way to develop 
techniques from non specific, descriptive imaging to specific, disease targeting 
detection. 
Although a wide range of imaging options exists including X ray, ultrasound, 
magnetic resonance imaging (MRI), computer tomography (CT), positron emission 
tomography (PET), and single photon emission computer tomography (SPECT), all 
of which have led to improvements in sensitivity and specificity, these 
techniques are expensive and often limited in their ability to detect early 
subclinical inflammation. Fluorescence imaging is far more advanced in in vitro 
and ex vivo analyses; however, limited tissue penetration and energy induced 
heat limit this methods.  
Functionalised nanoparticles have been used in a number of studies and more 
recently as substrates for SERRS based imaging approaches. The advantages of 
using metallic nanoparticles are that they are very bright in terms of their 
optical characteristics and also can be functionalised to provide a SERRS 
response and hence provide a unique Raman fingerprint. Nie and co workers 
have reported the use of SERRS labeled gold nanoparticles that were stabilized 
using PEG and subsequently functionalised with antibodies for the in vivo 
detection of EGF receptors in a cancer mouse model (223). Gambhir and 
colleagues demonstrated that SERRS active nanoparticles can be noninvasively 
multiplex imaged in vivo with spectral fingerprints of up to 10 different types 
(249). 
The aim of this chapter was to establish SERRS imaging in vivo and to build the 
foundation for future noninvasive imaging of inflammation. Thus I sought to 
determine biological stability and activity of protein linked nanoparticles 
and their accumulation and imaging properties in vivo. 186 
 
At first it should be mentioned that this work was accompanied by different 
limitations and problems: Batch inconsistencies were the main problem with 
differences in protein concentrations but also in SERRS intensity. Also 
nanoparticles aggregated over time and therefore interfered with experimental 
setups. Thus most of the experiments are only performed once, with difficulties 
for inter comparability and reproducibility due to batch differences. Further 
some experiments are lacking a proper control such as the HeLa bioactivity 
assays with lack a NP only or NP IgG control due to lack of material. Further, 
during this collaborative work the detection laser was switched and NPs with a 
size of 10 20 nm were switched to Nanotags with a size of ~ 60 nm. Due to these 
multiple variables and problems during the experimental workup of nanoparticle 
biology the data generated here have to be interpreted very carefully. 
Moreover, these data bring only premature information about nanoparticle 
biology. Retrospectively, in vivo experiments have been conducted too early and 
more basic in vitro biological work up has to be established. In summary, this 
chapter provides only a glance on a possible future imaging modality which 
still has to proof its capacity.   
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5.2 Size and form of nanoparticles 
Nanoparticle sizes range from 10 nm to 500 nm. The size of NP has different 
effects depending on the context. Smaller sizes can have larger extinction 
coefficients therefore offering advantages compared to bigger NPs. In contrast, 
larger NPs are a better target for phagocytosis and thus most likely are targeted 
for inflammatory tissues. However, they could also more likely accumulate in 
the reticulo endothelial system (liver and spleen) or induce side effects in the 
lung (204, 205). In collaboration with Dr R Stokes (University of Strathclyde) 
transmission electron microscopy (SEM) was performed to determine the size of 
NPs (called nanotags) used in some of the experiments (Figure 5.1). The image 
demonstrates round particles with size below 100 nm (~60 nm). This shows that 
these particles are spherical, compared to other reported nano rods or tubes. 
These nanotags have been used for imaging analysis in vivo due to their very 
bright SERRS signal ability. Other nanoparticles used had a size of 10 – 20 nm 
(image not shown, information provided by Dr Stevenson, University of 
Strathclyde). Gold nanoparticles were prepared following the Turkevich method.  
Briefly, HAuCl4 was reduced using citrate to afford colloidal gold with a 
diameter of approximately 19 nm.  Nanotags were obtained through a material 
transfer agreement with Oxonica Materials Inc. and their synthesis was 
undisclosed. 
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Figure 5.1 SEM on nanoparticles (nanotags) 
SEM of nanotags determine their size below 100 nm, estimating ~60 nm. Nanotags are round 
shaped, most with the same size; only few smaller nanotags are present as well. 
(Picture provided by Dr R Stokes, University of Strathclyde), n=1. 189 
 
5.3 Linking proteins to nanoparticles 
My first task was to stably link proteins such as antibodies or cytokines to NPs. 
Difficulties can arise regard to stability, maintenance of SERRS signal ability, but 
also biological conservation of the protein itself. Linking the protein with its 
biologically active part to the NP would render the protein inactive (e.g. linking 
the antigen binding domain to the NPs instead of the Fc part). Even distant 
binding could modulate tertiary or quaternary structural properties of proteins 
to alter their precise binding properties e.g. affinities, on and off rates which 
may be of relevance in terms of future functional interpretation of receptor 
ligand binding in vivo. Figure 5.2 demonstrates the structure and process of 
protein linkage to the NP. Gold NPs are combined with a linker containing a 
surface seeking group (thiol group, which reacts with the gold surface), a SERRS 
active dye (SERRS tag) and a reactive acid group. This linker NP complex can 
then covalently bind a protein such as an antibody or, as illustrated in Figure 
5.2, Etanercept (ETA, recombinant TNF receptor construct with an IgG Fc 
component) using EDC/NHS chemistries. Nanotags contain reactive thiol groups 
protruding from the silica shell.  With use of a sulfo SMCC cross linker, its 
possible to conjugate antibodies and proteins to the surface. Thus functionalised 
NPs should retain their ability for SERRS imaging, but also should be able to bind 
TNF α and block the ability of TNF α to activate cells without being toxic to 
cells. Nanotags were functionalised using an alternative cross linker.   
The following sections will cover these key issues: 
-  5.3.1 Testing quantities of ETA on linked nanoparticles 
-  5.3.2 Biological binding properties of ETA linked nanoparticles to TNF 
-  5.3.3 Biological function of ETA linked nanoparticles in HeLa cells 
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Figure 5.2 Schematic linking of proteins to NPs. 
Gold nanoparticles (10 nm) bind a linker via its surface seeking group containing a SERRS 
tag and a reactive group. This linker can then covalently bind a protein, in this case 
Etanercept (ETA). 
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5.3.1 Testing quantities of ETA on linked nanoparticles 
Before moving into activity assays, it was important to determine how much ETA 
actually binds to NPs. Initial experiments done by Dr Stevenson showed that an 
estimated 10 HRP antibodies bind to one NP (data not included). Here, a 
Western blot approach was used to get a rough estimate as to whether ETA binds 
to NPs and if so, in what concentration.  
ETA was loaded with 100, 10 and 1 ng of total protein, and compared to 10  l 
solution of ETA NP or NP alone (NP = Au (for Aurum, latin: gold) Figure 5.3). 
Solutions were incubated in reducing loading buffer, heated for 5 min at 95°C to 
release proteins from NPs and then run on a gel. After blotting, membrane was 
blocked and probed with an anti Fc HRP which would detect the Fc region of 
ETA. 
Figure 5.3 demonstrates that ETA (from ETA NP) run faster than ETA protein (60 
kDa vs. 75 kDa), but also depicts a ball shaped band including variable migration 
speed in the middle. This might arise from altered properties of NPs themselves 
and could alter the running speed in the gel due to differences in charge. NP 
alone (Au) did not result in a band. 10  l of ETA NP solution contained a 
concentration between 1 and 10 ng of ETA (~ 0.1   1  g/ml ETA bound to NP). 
Similar results were obtained when using IgG bound to NP. 192 
 
 
Figure 5.3 Total protein on ETA linked nanoparticles 
Westernblot analysis of Au-ETA (ETA-NP) compared to different concentration of ETA 
(loaded 100, 10 and 1 ng of total protein). 10  l of Au-ETA loaded. Au = NP only with no 
protein linked. Y axis in kDa. Representative blot of n=2. 
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5.3.2 Biological binding properties of ETA linked nanoparticles to 
TNF-α 
Next we sought to determine if ETA linked to NPs can still bind to TNF α. Using a 
competition ELISA approach, a fixed concentration of recombinant TNF α (2000 
pg/ml) was incubated with different concentrations of ETA NPs or NPs linked 
with IgG as control. Samples were incubated at 37°C for 1 h, centrifuged and 
supernatant then tested by ELISA (procedure shown in Figure 5.4). Interestingly, 
incubation of TNF α only (without addition of NPs) reduced a starting 
concentration from 2000 to 50 pg/ml,  
Figure 5.5 A, black bar. Although ETA NP reduced levels of TNF α, this result has 
to be judged cautiously, due to the loss of TNF α in the control sample (Figure 
5.5A). 
To exclude possible plastic binding of TNF to the tube during the incubation 
period, the solution was spiked with 0.5% bovine serum albumin (BSA). Despite 
this, 50% of detectable TNF α was ‘lost’ in the control sample (due to possible 
binding, or degradation), 
Figure 5.5 B, black bar. Despite this, it was possible to now interprete the 
competitive properties of the NPs or ETA bound NPs.  Thus, Au IgG (Au = NP) or 
Au alone at different concentrations did not alter detectable TNF α,  
Figure 5.5 B, white bars. In contrast, Au ETA significantly reduced measurable 
TNF levels with approximately 50% reduction at 1:10 dilutions and approximately 
25% reduction at 1:100 dilutions. Reduction was not possible with further 
dilutions,  
Figure 5.5 B, grey bars.  
To test if nanotags with bigger size also are able to offer appropriate linkage to 
ETA the above experiments were repeated using NT440. Linked with IgG no 
reduction in TNF recovery was detected compared to media only (Figure 5.6 
white bars). In comparison, NT440 bound to ETA significantly reduced TNF α 
concentrations in dilutions of 1:10 and 1:100 (Figure 5.6 grey bars).  194 
 
Thus this demonstrates that ETA NP as well as ETA NT440 can specifically bind 
TNF α compared to IgG controls. 195 
 
 
Figure 5.4 Competition ELISA to test TNF-α binding to NPs. 
TNF-α was incubated with NPs at 37° C for 1 h. NP pellete d by centrifugation, and 
supernatant tested for the remaining TNF concentration by ELISA. Incubations either with 
uncoated Au, Au-ETA or Au-IgG. 
 
Figure 5.5 Biological binding properties of ETA-NPs. 
Preincubation of recombinant TNF-α with media only (none, black column), Au-IgG (Au = 
NP, white columns), Au only (B, 3
rd and 4
th white columns) or Au-ETA (grey columns) and 
analysis of subsequent TNF concentration by ELISA. A. TNF and NP incubated in media 
(without BSA). B. Incubation solution spiked with 0.5% BSA to prevent plastic adsorption. X 
axis show NP dilutions. Results are reported in means of triplicates +/- SEM, n=1. Unpaired t 
test, ** p<0.005; * p<0.05 
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Figure 5.6 Biological binding properties of ETA-NT440. 
Preincubation of 2000 pg/ml recombinant TNF-α with ETA-NT440 (NT = nanotag) particles. 
Solution contained 0.5% BSA to prevent plastic adsorption. Analysis done with TNF-α 
ELISA. Black bar: media only, white bars: NT440 linked to IgG, grey bars: NT440 linked to 
ETA. Results are reported in means of triplicates +/- SEM, n=1. Unpaired t test, *** p<0.0005 
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5.3.3 Biological function of ETA linked nanoparticles in HeLa cells 
After determining the biologic property of ETA linked NPs to bind TNF α, the 
next issue to address was their biologic inhibitory properties in a cell dependent 
model system. Therefore the following assay was established. HeLa cells (an 
adherent immortal cell line derived from ovarian cancer) was stimulated with 
TNF α and after 6 h incubation supernatant was assessed for IL 6 production by 
ELISA. ETA was then tested in this assay, to evaluate how it could influence IL 6 
production. 
HeLa cells stimulated with TNF, dose dependently released IL 6 (Figure 5.7, left 
graph, black bars). This was dose dependently reduced by ETA co incubation. 
Culturing HeLas with media containing 10% FCS stimulated cells to produce 
background levels of IL 6 (~ 200 pg/ml) which was not observed when cells were 
grown in media alone. This was therefore considered in estimating the inhibitory 
effects of ETA upon subsequent TNF stimulation (Figure 5.7 left graph compared 
to right graph). ETA was able to block TNF α induced IL 6 production. Thus I had 
generated a bio assay in which to test the capacity of NPs linked with ETA to 
inhibit TNF bioactivity in vitro. 
To test particles, a non SERRS active linker (1 mercaptoundec 11 yl) hexa 
(ethylene glycol) (MHA) was chosen which has the advantage of higher stability 
than SERRS linkers. ETA alone was again able to reduce IL 6 production induced 
by TNF (Figure 5.8 black bars). Similarly, Au ETA (Au = NP) significantly reduced 
IL 6 production induced by TNF at dilutions of 1:10 (Figure 5.8 grey bars).  
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Figure 5.7 Establishing TNF stimulation of Hela cells with ETA blockade. 
HeLa cells were stimulated with different doses of TNF-α (0, 10 and 100 ng/ml) incubated in 
media with (left panel) or without (right panel) 10% FCS for 6 h. Blockade of TNF was tested 
with different concentrations of Etanercept (black bar: 0, dark grey: 10, grey: 100, white: 
1000 ng/ml ETA). IL-6 production in the supernatant was assessed by ELISA. Shown are 
mean of triplicates and analysed by unpaired t test, n=1. ** p<0.005; *** p<0.0001 
 
 
Figure 5.8 IL-6 production by TNF stimulated HeLa cells blocked with Au-ETA 
Coincubation of HeLa cells with TNF (10 ng/ml) and different concentrations of Au-ETA 
(Etanercept (ETA) bound to nanoparticles with linker 1-(mercaptoundec-11-yl)hexa(ethylene 
glycol)(MHA)). Left part shows incubation without TNF, right part with TNF 100 ng/ml. White 
bar: media only, black bars: dose concentration with ETA in ng/ml. Grey bars: dose 
concentration with Au-ETA. Analysis of the supernatant for IL-6 secretion by ELISA. Shown 
are mean +/- SEM of triplicates, n=1, unpaired t test. ** p=0.0011, *** p<0.0005 199 
 
Next, NPs were tested that contained a SERRS active linker bound to ETA. 
Surprisingly, some batches aggregated in the tube (Figure 5.9, left tube, NPs 
aggregated to the plastic). Because this initially seemed to be random, linkage 
methods were altered to guarantee batch consistencies. Thus, after linkage 
different concentrations of BSA was added to the solution to prevent 
aggregation. Different batches were then tested in the “HeLa assay” (Figure 
5.10). Two types of NPs linkers were used: The SERRS active linker containing 
the dye Azo (Au Azo) and the MHA linker (Au MHA). After linker attachment to 
NPs these were incubated with ETA (final concentration 10  g/ml and for one 
batch with MHA 100  g/ml). At the end of incubation two different 
concentrations of BSA (1  g/ml or 10  g/ml) were added to prevent aggregation. 
The linking process was completed by multiple washes and then tested in the 
HeLa stimulation assay. In the absence of TNF none of the NPs stimulated HeLa 
cells to produce IL 6 (Figure 5.10 first eight bars). Stimulation with TNF induced 
IL 6 (white bar) which was inhibited by ETA (black bars). From the NPs solutions 
the most effective inhibitor was that containing an Azo linker (#2) which was 
incubated with 10  g/ml BSA (grey bar, #2). This was also the case for Au MHA 
(dark grey bar, #4). Using a higher concentration of ETA (100  g/ml instead of 10 
 g/ml) did not derive stronger IL 6 inhibition (compare MHA, dark grey bar #4 vs. 
#5). Results from this experiment were used to inform future linking processes 
an “anti aggregation” step with the addition of 1  g/ml BSA. 
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Figure 5.9 Nanoparticles aggregate over time. 
Left tube shows aggregation of Au-IgG nanoparticles to the plastic wall. Middle and right 
tube show unlinked nanoparticles in solution with different dilutions. 
 
 
Figure 5.10 Linkage and bioactivity of ETA-NP (Au) with BSA.  
HeLa cells were incubated with with or without 100ng/ml TNF-α and either ETA only or 1:10 
dilution of NPs solutions (numbered #1-5). NPs were linked with Azo dye or 1-
mercaptoundec-11-yl)hexa(ethylene glycol) (MHA). Then linked by incubation with ETA 
(different conc. #4 vs. #5) and addition of different conc. of BSA at end of incubation. 
Analysis of supernatant by IL-6 ELISA. white bar: media only, black bar: ETA, grey bars: #1-
3, Au-Azo, dark grey bars: #4-5, Au-MHA. Results are reported in means of triplicates +/- 
SEM, n=1. Unpaired t test, * p<0.05 
  201 
 
5.4 The detection of nanoparticles in vivo 
Future ideas as to the use of nanoparticles range from drug delivery with 
specific tags to targeting of drugs specifically to the site of action, e.g. a tumor 
cell or immune cells. A further possibility is to utilize this approach to image the 
occurrence, migration and tissue concentration of these cells. This can further 
be used as a follow up approach to monitor disease activity or tissue responses 
to therapeutics or injury. So far, nanoparticles have been used in humans only to 
stabilize drugs e.g. PEGylation of cytokines or antibody fragments. NP constructs 
for other purposes, in which nanoparticles are the main delivery component 
linked to a drug or antibody, have not been tested in humans. NP constructs 
have been studied mainly in vitro with few reports addressing in vivo utilization. 
Imaging and cancer treatment is at the forefront for the use of NPs. In regard to 
imaging, common caveats have been described to their general introduction 
include the limit of depth penetration or lack of resolution. Using SERRS active 
nanoparticles with a penetration of ~ 2mm I sought to overcome the issue of 
depth and to try to establish SERRS active NPs in vivo. Thereafter I explored the 
proof of concept of imaging NPs in vivo.  
5.4.1 SERRS profile of NP (Strathclyde) 
Imaging of tissue with fluorescence has the major disadvantage that laser wave 
length induces heat and therefore can damage the tissue. Here, gold NP (Au) 
were linked with a near infrared linker (NIR) which may be excited at 785 nm 
and does not induce strong heat transfer. Inelastic scattering from the Raman 
dye, enhanced by the metal surface accounts for a specific pattern with distinct 
Raman shifts/peaks compared to a fluorescent smooth curve (NIR Au, Figure 
5.11). Different linkers result in distinct individual patterns and therefore 
multiplexing without problems of compensation is possible.  202 
 
 
Figure 5.11 SERRS profile of NIR-Au-NP. 
As example for a SERRS profile Raman shifts of a NIR-Au-NP (near infrared linked gold NP) 
were measured. Distinct intensity peaks (e.g. at ~ 700 or ~950) are shown. 203 
 
5.4.2 Detection of NPs in tissue 
To address if NPs are detectable in tissue a mouse cadaver was injected with NIR 
linked NPs into the footpad (100  l) and the ear pinna (50  l). Before injection 
background values for SERRS signals were measured. A handheld laser was fixed 
in a stand to guarantee a standard distance with a focal length of ~ f = 7.5 mm 
(Figure 5.12A). Measurement was performed at 800 – 930 range (200 2000 cm 1) 
with an assumption of depth penetration of 2 mm. Signal was captured for 1 s. 
SERRS was detected in both tissues after injection (Figure 5.12B,C). For the 
footpad, ankle and popliteal areas were measured as control sites to determine 
leakage due to the pressure of injection. At the ankle, SERRS was also detected 
while the popliteal region derived only a very weak signal. Differences in 
intensity between footpad and ear pinna could be explained by reduced volume 
injected for the ear pinna.  In conclusion, SERRS active NPs can be detected in 
tissue after injection. Thus skin and other structures do not appear to 
significantly interfere with this methodology. 
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Figure 5.12 Detection of Nanoparticles in tissue 
NPs were injected into the footpad or intradermally into the ear and SERRS signals were 
detected using a handheld laser (n=1). A. measurement procedure as an example at the 
ankle with distance f laser exit to tissue. B. intensity of fluorescence, with background 
intensity, measurements at footpad, ankle and popliteal area. C. Measurement of SERRS at 
the ear pinna after NP injection. Injection volume: Footpad: 100  l, ear 50  l. Capture time 
1s. 205 
 
5.4.3 The detection of NPs in inflammation 
The next step involved the Raman detection of NPs in an inflammation model. 
Initial experiments comprised intravenous tail vain NP injection into a live 
mouse. Six hours later, the mouse was sacrificed and organs measured for SERRS 
activity. In agreement with the literature, signals were detectable in liver and 
spleen; however, no specific signals could be located in organs like heart, lung, 
muscle, kidney or lymph nodes (data not shown). This likely reflects 
accumulation of NPs in the reticulo endothelial system (RES) recently described 
by Qian et al. (223).  
To address if ETA linked NPs specifically track to the site of inflammation, the 
carragean induced arthritis model was used. With the hypothesis that high 
amounts of TNF are present in the arthritic joint ETA linked NP accumulate at 
the site of inflammation while IgG linked control NP do not. The right paw of 
n=3/group were injected with a carragean solution while the left paw as control 
was injected with PBS. Three groups were used with the following NP solutions 
injected 68 h after arthritis induction: Au IgG (1:100, control group), Au ETA 
(1:100) and Au ETA (1:1000). Paw thickness was measured before injection and 
at different time points after administration (Figure 5.13A). Already 4 h after 
administration severe swelling of the paw as well as the ankle (not shown) 
occurred in the right paw compared to the left demonstrating the acute model 
of action in this inflammation model. 68 hr after induction, NP solution was 
injected i.v. and 6 h later at the peak of inflammation (experiments performed 
with Dr Asquith, Glasgow University, who established the model in our group) 
mice were sacrificed and SERRS measured at both paws (Figure 5.13B). As 
expected significant difference in SERRS activity was measured in Au ETA 
administrated paws (Figure 5.13B, black and grey (filled and shaded) bars, p < 
0.05). Au IgG control injection showed no significant difference between paws, 
however, counts achieved in the control reached similar levels as Au ETA groups. 206 
 
 
Figure 5.13 Detection of NPs in the carragean footpad injection model. 
Inflammation of the footpad was induced by injection of carragean (100  l, right paw) or 
PBS (control, left paw). Paw swelling was monitored every day and is demonstrated in the 
difference of right to left paw (A). Six h before the peak of inflammation (68h post carragean 
injection) NP solutions were administered i.v. by tail vain injection (100  l) in different 
concentrations (see arrow in A). Six h post NP injection, mice were sacrificed and SERRS 
measured in paws (B). No difference is seen between left and right paw injected with Au-IgG 
(1:100 concentration, open and white dashed bar). Significant difference between right 
(black or grey bar) and left (black or grey dashed bar) paw in Au-ETA administered mice. 
Shown is mean +/-SEM analysed by unpaired t test. * p<0.05. n=3 per group.  207 
 
To further explore the effect of Au ETA, the experiment was repeated with two 
groups using an NP dilution of  1:100 and higher number of mice: Au IgG (n = 8) 
and Au ETA (n = 9). Paw thickness measurements indicated similar severity 
compared to the foregoing experiment with rapid onset of satisfactory incidence 
of swelling 4 h after induction (Figure 5.14A). 
Measurement of SERRS activity 6 h after injection resulted in no significant 
difference in both groups comparing left (PBS) and right (NP) paw (Figure 5.14B). 
Similar to the first carragean experiments, levels of SERRS were comparable 
between Au IgG and Au ETA. After normalising the intensity retrospectively no 
specific SERRS pattern was detected but an increase in tissue fluorescence 
enhanced by nanoparticles was observed (communication Dr Stevenson, 
University of Strathclyde). The gold nanoparticles used to this point could be 
considered a soft shell nanoparticle, i.e. the gold was encased in a soft PEG 
shell with the antibody attached.  As the linker is attached through the 
adsorption of a thiol group to the gold surface, the linker could possibly be 
leached from the surface by extreme salt or pH conditions.  In the case that the 
linker detaches from the surface, SERRS signal is lost. However, the fluorophore 
normally quenched by the close proximity of the nanoparticle surface regains its 
fluorescence. This could explain the loss of SERRS detection and an increase in 
fluorescence. The use of nanotags, i.e. nanoparticles with a ‘hard’ silica surface 
should provide a more stable platform for in vivo SERRS.   208 
 
 
Figure 5.14 Tracking of Nanoparticles to the site of inflammation. 
Mice injected with carragean into the footpad were injected i.v. with nanoparticles at the 
peak of inflammation. A. Same setup was used compared to Figure 5.13. Only one 
concentration was used (1:100) for each Au-IgG and Au-ETA (B). No difference in SERRS 
counts were observed between left and right paw for IgG and ETA. Shown is mean +/-SEM. 
n=8 for Au-IgG and n=9 for Au-ETA. 209 
 
5.4.4 Switch of detection laser and Nanoparticles to Nanotags 
The inconsistency of the carragean arthritis imaging could be accounted for by 
several issues which include technical and hypothetical biological reasons: these 
range from malfunction of the NP SERRS linker, reduced brightness of NP, 
subjective laser data capture, but also including to rejection of the hypothesis 
implying preferential accumulation of ETA NPs compared to IgG NP. In discussion 
with Prof. Graham (University of Strathcylde, Centre for Nanometrology), NP 
size with 10 20 nm do not emit a strong SERRS pattern.  
To address this a series of experiments were planned and performed as follows. 
Instead of using NP described above, silica shelled Nanotags (NT) were used. 
These NTs are NPs with a core gold nucleus (d=50 60 nm) wrapped in a SERRS 
active linker and further encapsulated with a silica shell (d total =90 nm). Figure 
5.1 shows a TEM of Nanotags with a size of ~ 60 nm. NTs also have the advantage 
of the availability of multiple different SERRS pattern NTs. This opens the 
possibility for multiplexing in future. Further the method of SERRS detection was 
changed. The laser used in the experiments above had the disadvantage that the 
distance from laser to tissue was changeable and therefore the focus and 
subsequently the intensity of SERRS output is variable. To overcome this problem 
a different laser was used with a cone head to standardize laser tissue distance 
(see methods Figure 2.4). 
5.4.5 SERRS profile of nanotags (NT) 
Figure 5.15 demonstrates the SERRS pattern of two different NTs. NT440 and 
NT420 exhibit different distinct peaks. Comparing the pattern of both NTs 
identifies a discrete peak for NT420 at ~1068 and ~1300 Raman shifts. On the 
other hand NT440 shows a discrete peak at ~1325 (Figure 5.15). 
Bioactivity of NTs linked to the protein ETA has been tested as well. This has 
been demonstrated in “Figure 5.6 Biological binding properties of ETA NT440.”. 
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Figure 5.15 SERRS profile of NT440 and NT420 
Solely the patterns for NT440 and NT420 are unique, however, for multiplexing experiments 
distinct peaks have been identified. SERRS profile Raman shifts of NT440 with a distinct 
peak at ~1325. Distinct intensity peaks for NT420 at ~ 1068 and ~1300. Representative 
measurement of n=2. 
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5.4.6 Detection of i.v. administered NT440 in vivo 
To test if NTs were also detectable in vivo, a solution of PBS containing NT440 
was injected i.v..  Six h later, mice were sacrificed and organ uptake was 
measured in situ with the cone laser head. Clear detection of SERRS output by 
NT440 was observed in organs of the RES (Figure 5.16A). Spleen showed highest 
intensity compared to liver. Control organs measured were lung, kidney, heart, 
muscle and lymph nodes and no signal was detected in these organs (only heart 
shown). Distinct peaks in liver and spleen are shown with for example the double 
peak at ~1600 Raman shifts. To compare intensity of NTs, Figure 5.16B 
demonstrates spleen, liver and heart signals in relation to NT440 (named in 
figure NP 1:10) measured in the tube. 
In conclusion, NTs are detectable in vivo with a distinct SERRS output, 
accumulating mainly in the RES (liver and spleen). 212 
 
 
Figure 5.16 SERRS signal of NT440 in tissue. 
Injection of 100  l NT440 (1:10 dilution) i.v. and detection 6 h later, n=2. With an 
accumulation time of 10 s clear NT440 Raman peaks are detectable in organs of the RES 
(liver and spleen) compared to no signal in the heart (A). B demonstrates the different 
intensity of NT440 in RES organs compared to NT440 (NP) measured directly in a tube. 213 
 
5.4.7 Ex vivo SERRS mapping analysis of spleen 
Figure 5.16 demonstrates the feasibility of SERRS detection in organs. However, 
high resolution for imaging was not achieved with a handheld laser set up and no 
cellular resolution could be utilized from this approach. To overcome this 
problem and to determine if NTs are detectable within an organ structure or at 
the cellular level, spleens were harvested, snap frozen and mounted in OCT. 
Cryosections were cut, tissue fixed and stained with haematoxylin for 
visualisation. Mounted slides were analysed on a fast mapping Raman detection 
system (Centre for Nanometrology). NTs accumulate in the spleen with specific 
Raman signals in distinct regions (Figure 5.17). Shown is a spleen section; the 
SERRS map was colored by integrating the area under single characteristic peaks 
(here 1600 peak). A single point at the cross section in the picture is reflected 
by the Raman curve below demonstrating the distinct double peak at ~1600. 
This experiment demonstrates the feasibility to use SERRS as a potential new 
method for imaging. 214 
 
 
Figure 5.17 SERRS image of a spleen section. 
Rensishaw InVia SERRS map of frozen spleen derived section. From the experiment above 
(Figure 5.16) spleens were harvested, snapfrozen and mounted in OCT. 8  m sections were 
cut, fixed, counterstained with haematoxylin and mounted. For analysis of the tissue the 
distinct NT440 Raman double peak at ~1600 (compare with Figure 5.16) was used (bottom 
panel). The tissue was scanned and Raman counts (intensity) are shown as a heat map (top 
panel). Raman counts of the cross-section point in the spleen section (top panel) are shown 
in the bottom panel.  215 
 
5.4.8 Multiplexing of NT in vivo and ex vivo 
To exploit the actual advantage of SERRS with distinct peak patterns to 
multiplex a combination of NTs were injected i.v. and examined ex vivo. 
NT440 and NT420 were injected either alone or as a mixture. Figure 5.18A shows 
the different Raman pattern for both NTs. Six h after injection mice were 
sacrificed and spleen and liver measured. NT440 showed a distinct pattern of 
expression in both organs with a 1 s capture time (Figure 5.18B, dark green: 
liver; bright green: spleen). NT420 had a weaker signature at 1 s capture time, 
but still a discrete peak at 1600 was detectable (Figure 5.18C). Increasing the 
capture time enhanced the pattern and produced a clearer graph (data not 
shown). To test, if the NT SERRS signal is influenced by linking proteins to NTs, 
NT420 linked with ETA was examined (Figure 5.18D). Liver measurement 
demonstrated again a weak but distinct signal at 1 s capture times, but when 
increased to 5 s, peaks were sharper with higher intensity and NT420 pattern 
clear visible (dark grey 1 s, bright grey 5 s). Finally, injection of NT420 and 
NT440 mixture revealed a detectable Raman fingerprint. All of the peaks can be 
assigned to the NT440 in the mixture; no clear peak of NT420 is distinguishable 
(Figure 5.18E). 216 
 
 
Figure 5.18 SERRS signals of liver and spleen in NT injected mice. 
SERRS active NTs (NT440 and NT420) were injected i.v. and 6 h later measured in liver and 
spleen for their expression and signal strength (1 mouse per injection, n=1). A. shows 
different Raman pattern of NT440 and NT420. B. Single injection of NT440 demonstrates 
clear detection in liver and spleen (capture time 1 s). C. Single injection of NT420 with low 
detection in liver (capture time 1 s). D. NT420 linked with ETA retains SERRS pattern in 
tissue (capture time 1 s and 5 s). E. Injection of NT440 / NT420 and measurement in liver. 
SERRS signal detectable, but no differentiation between NTs possible (similar result for 
spleen and longer capture times). 
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5.5 Conclusion and Discussion 
The aim of this chapter was to develop nanoparticle probes as a novel tool to 
image inflammation with use of SERRS. SERRS active probes provide a unique 
detection platform capable in theory of surpassing fluorescent alternatives.  
Owing to the loss of signal observed through tissue dampening effects 
(quenching) broad wavelength fluorescence analysis is not possible in vivo.  
There exists a window between 7XX nm  8XX nm where laser analysis can be 
optimised and SERRS probes allow multiplexed deep tissue imaging in this 
region. Not only is the specificity of SERRS probes an advantage but also the 
spectra used offer opportunities: this does not induce heat compared to lasers 
normally used for fluorescence which would cause heat damage to the tissue. 
This chapter arises from a unique collaboration between the Centre for 
Molecular Nanometrology and Division of Immunology addressing a fascinating 
subject translating novel chemical discoveries into biological applications. 
Joining two expertises together is mandatory for success; however, it also 
identifies limitations and learning opportunities on both sides.   
Two goals were addressed in this chapter: first, to determine the linking ability 
of SERRS active NPs with proteins, and second, to utilize SERRS active NPs to 
image inflammation in vivo. Here, I show that we can link proteins to NPs, and 
these constructs remain bioactive. Limitations were batch inconsistencies in 
protein concentrations but also in SERRS intensity. Also HeLa bioactivity assays 
lack a NP only or NP IgG control. Further NPs linked with proteins aggregated 
over time and therefore again led to reduced concentration. The SERRS active 
linker was attached to the gold NP by a thiol adsorption. The protein was then 
covalently attached to the SERRS active linker. Although unlikely, a potential 
detachment could occur at the disulfide bond releasing the protein. In a cell 
culture system, ETA linked NPs were able to prevent TNF stimulus on HeLa cells 
to produce IL 6.  
This indicates potential side effects of nanoparticles in vivo. Not only does 
induction of cell death in phagocytosing cells have to be considered, but also 
potential influences on the RES, potential accumulation in the lung, secretion by 
the kidneys, interaction with platelets and erythrocytes. Each factor is a 218 
 
probable site for side effects ranging from a low to severe potential. Incubation 
in 50 % FCS at 37°C for 1 h has been tested for SERRS activity loss with no 
difference detected (Dr Stevenson, data not shown); however, performance in 
100 % serum or equivalent incubations reflecting in vivo situation has not been 
studied in regard to accumulation, aggregation, protein loss, and changes in 
bioactivity and are rarely studied in other published reports.  Despite these 
issues manufacturing of SERRS active NPs linked to ETA was possible. In 
conclusion, these NPs studied in vitro were bioactive and retained their SERRS 
signaling capability. 
In vivo experiments performed in this thesis considerably advanced knowledge 
about the capability of NPs and their measurement. Thus the initial laser used 
was dependent on the distance and observer; a switch to a different system 
achieved a defined distance between tissue and laser exit which was less 
observer dependent. Further we could demonstrate that NPs are detectable in 
vivo with accumulation in the RES. These data are in concurrence with Qian et 
al. (223). Unfortunately, quantitative measurement of inflammation was not 
achievable. This could be due to the fact that the NPs used were too small to 
deliver a strong SERRS signal. Qian et al used 60 nm size NPs where NPs used 
here in the carragean inflammation model were ~15 nm. However, also other 
unknown factors could have influenced the experiment such as ETA as proper 
protein target choice, concentration of NP or ETA, time of administration or the 
model as the right selection could be questioned.  Future studies will be 
required to resolve these issues. 
To address the capability to image NPs and to potential multiplex in vivo we 
switched to NTs which are bigger in size and provide a set of different NTs with 
distinct SERRS patterns available. Here, we could demonstrate that NTs are 
measurable in vivo; however, multiplexing was not feasible with the current 
methods used. Gambhir and colleagues published multiplexing studies in nude 
mice (249). In our approach, SERRS imaging of tissue slices was measured by a 
Renishaw InVia Raman microscope. Conversely, NPs in tissue were measured 
with a handheld laser with restricted detection capabilities. Thus Gambhir 
demonstrated the feasibility of multiplexing; however, with our resources this 
was not reproducible as yet. 219 
 
Despite the problems addressed thus far, the method has a high potential for 
success. Currently, driven by nanoparticles imaged with MRI, different 
techniques will become accepted and the field of activity will grow addressing 
topics such as biodistribution, excretion and a rapid clearance from blood (250).  
NPs taken forward by the cancer field as therapeutics and cancer detection will 
lead to future knowledge and utilization in inflammation diagnostics. In 
summary, we demonstrated how NPs can be assembled to present bioactive 
molecules and how these NPs might be used for imaging of inflammation. 
Further we provided preliminary work which address solvable limitations in this 
method. 
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6  Discussion & conclusion 221 
 
Cytokines play a pivotal role in the cellular network by sending messages with a 
huge variation of content. This can range from simple production orders, to 
signals of danger and thus activation of cells or messages with the aim to 
tranquilize the responder or even to initiate self destruction. This tense 
framework of cytokines supports the body defence against intruders and is 
precisely balanced between immune activation and inhibition. Thus this 
guarantees a fast response to matters of immune defence in which the system 
has to react as quickly as possible. However, as fast as the system has been 
activated, scavenging mechanisms such as decoy receptors, regulatory proteins 
and cells can rebalance the system. Combined with host defence memory it can 
react even faster in similar future events. Although this system seems perfect 
for its purpose, the balance can tip over in the wrong context. Thus, in 
autoimmune diseases cytokines have been shown to play a critical role as 
mediators of autoimmunity. Twenty years after the introduction of TNF blockade 
in RA, now nearly every cytokine has been addressed in this context and have 
been chosen as therapeutic target. 
In this thesis three novel cytokines have been studied. IL 33 for its novelty being 
a recent described IL 1 family cytokine, IL 17 and IL 23 not for its timely novelty 
but its novelty in the knowledge in its crucial role of inflammation. Recent trials 
demonstrated that IL 17 or IL 23 blockade leads to brilliant outcome in 
autoimmune psoriasis. For IL 17/IL 23 aim was to address which cells are the 
source in RA, as data so far were scarce in regard to local tissue expression and 
despite clear evidence that Th17 cells are main producer of IL 17, more and 
more other cells have been described to add IL 17 to their cytokine portfolio. 
Unexpectedly, I have demonstrated that not Th17 cells but mast cells are the 
main source in RA synovium (239).  This contradicts various publications in which 
Th17 cells have been described to play a pivotal role in RA synovium (98, 251). 
Expression of IL 17 by mast cells, but also other cells like NKT cells, NK cells, 
macrophages, neutrophils, eosinophils  and CD4 positive lymphoid tissue inducer 
like cells have been described (229, 230, 239, 252). Origin in multiple sources 
demonstrates the ability of adaptive but also innate parts of the immune system 
to produce an important cytokine for host defence. A similar cytokine with high 
biologic potential is TNF α, expressed also by cells of the innate and adaptive 
immune system. Thus the fact that mast cells produce IL 17 strengthens the 222 
 
ambivalent role of pivotal cytokines by its production of multiple possible cells. 
Also these data rather reinforce than weaken the hypothesis of IL 17 blockade in 
autoimmune diseases.  
IL 33, a Th2 cytokine which induces IL 5 and IL 13 has been reported to play a 
role in autoimmune arthritis which is defined as Th1/Th17 disease (145, 146). 
This is another cytokine with multiple roles, supporting either a Th2 profile for 
parasite defence or Th1/Th17 profile studied in arthritis depending on the 
environment. In skin disease, a misbalance to Th2 can lead to atopic dermatitis, 
where a shift to Th1/Th17 can induce psoriasis. Interestingly, presentation of 
pathology is similar in regard to histological changes and cells involved; 
however, clinical features such as areas involved are different as is the cytokine 
profile. Similar to the ambivalent source of IL 17, this demonstrates production 
of two totally different disease associated cytokines by potentially the same 
cells. I studied IL 33 in psoriasis and detected high expression in human skin 
biopsies of psoriasis patients. Further, IL 33 epidermal injections led to psoriasis 
like dermatitis. Interestingly, cytokine profile in these experiments 
demonstrated a shift to Th2 with IL 33 signature cytokines such as IL 5 and IL 13. 
Pathology with epidermal thickening and infiltration of mast cells, macrophages 
and neutrophils could potentially account for an atopic Th2 disease. Despite this 
fact, the TPA model in ST2 deficient mice showed ameliorated skin inflammation 
allocates IL 33 more in the proinflammatory Th1/Th17 area. This cytokine with a 
crucial role as an alarmin seems to be able to tip the balance in the wrong 
context. It is surprising, how the normal protective effect of IL 33 is susceptible 
for these changes, although this would account for a high sensitivity in a system. 
Even more complex is the interplay with sST2/ST2. It could be that sST2 is 
released to limit the alarmin effect and thereby blocks the normal protective 
effect of IL 33. This would allow pathology and comorbidity to emerge in 
patients in whom IL 33 is involved in pathology such as asthma or RA. Evidence 
was shown by Dr Alves Filho with IL 33 attenuating sepsis (152). Individuals who 
did not recover from sepsis had significantly more soluble ST2 those who did 
recover demonstrating the protective role of IL 33 countered by sST2. 
Understanding the biology of the cytokine IL 33 is central to understanding its 
role in disease and how it can account for different types of diseases. Making it 
even more complex, IL 33 is expressed in the nucleus as a suppressor of 223 
 
transcription, it was surprising to address the role of IL 33 in the nucleus in 
which Girard and colleagues showed the conserved features with binding to the 
heterochromatin and how a herpes virus uses this binding site for maintenance 
of viral genomes (137). Giving the hints, that IL 33 also is expressed in the 
embryo, however, most likely by a different splice variant adds another feature 
to IL 33’s portfolio. This preliminary data and initial hypothesis needs to be 
further investigated.   
At last, I explored how nanoparticles can be utilized to image inflammation, to 
translate insights of cytokine biology and relevance in pathology, to early 
disease diagnosis. At a glance, despite being premature, it might be feasible to 
drive this technology to further levels. Undoubtedly, its potential has advantages 
compared to common techniques such as PET, MRI and other imaging modalities. 
However, also downsides which have to be addressed cautiously are present: 
toxicity (such as haematological alterations, immune system activation, and 
organ accumulation), long term effects but also clearance with kidney and lung 
involvement. With the cancer field pushing nanomedicines (nanoparticles linked 
with chemotherapeutics or proteins such as antibodies) forward, most of these 
queries will be answered in the future. Thus more work needs to be done to find 
the best possible target (or combination of multiple targets), setting and optimal 
technological realisation for early inflammation imaging. 
While medicine and especially rheumatology constantly advances in its 
knowledge about disease pathology, major questions still remain. This work 
demonstrated how complex even initial translations from mouse to human are, 
by discovering the source of IL 17 in synovium and thus complicating the Th1 
Th2 Th17 understanding. Further the ambivalent role of IL 33 supports the 
immense complexity of cytokine biology. Future studies must identify which 
mediators are responsible for certain diseases and should elucidate in which 
context certain cytokines play what kind of role. Finally, understanding the 
ambivalent role of cytokines is now a matter of paramount importance, 
representing a factor of unexpected outcome and is crucial for future targeted 
therapies. 
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